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ABSTRACT 
 
FROM DATA TO DECISION:  AN IMPLEMENTATION MODEL FOR THE USE OF 
EVIDENCE-BASED MEDICINE, DATA ANALYTICS, AND EDUCATION IN 
TRANSFUSION MEDICINE PRACTICE 
 
by 
Nazanin Tabesh 
The University of Wisconsin-Milwaukee, 2015  
Under the Supervision of Professor Timothy B. Patrick 
 
 
Healthcare in the United States is underperforming despite record increases in spending. The 
causes are as myriad and complex as the suggested solutions. It is increasingly important to 
carefully assess the appropriateness and cost-effectiveness of treatments especially the most 
resource-consuming clinical interventions.  Healthcare reimbursement models are evolving from 
fee-for-service to outcome-based payment. The Patient Protection and Affordable Care Act has 
added new incentives to address some of the cost, quality, and access issues related to healthcare, 
making the use of healthcare data and evidence-based decision-making  essential strategies. 
However, despite the great promise of these strategies, the transition to data-driven, evidence-
based medical practice is complex and faces many challenges.  
 
This study aims to bridge the gaps that exist between data, knowledge, and practice in a 
healthcare setting through the use of a comprehensive framework to address the administrative, 
cultural, clinical, and technical issues that make the implementation and sustainability of an 
evidence-based program and utilization of healthcare data so challenging. The study focuses on 
iii 
 
promoting evidence-based medical practice by leveraging a performance management system, 
targeted education, and data analytics to improve outcomes and control costs.  
 
The framework was implemented and validated in transfusion medicine practice. Transfusion is 
one of the top ten coded hospital procedures in the United States. Unfortunately, the costs of 
transfusion are underestimated and the benefits to patients are overestimated. The particular aim 
of this study was to reduce practice inconsistencies in red blood cell transfusion among 
hospitalists in a large urban hospital using evidence-based guidelines, a performance 
management system, recurrent reporting of practice-specific information, focused education, and 
data analytics in a continuous feedback mechanism to drive appropriate decision-making prior to 
the decision to transfuse and prior to issuing the blood component.  
 
The research in this dissertation provides the foundation for implementation of an integrated 
framework that proved to be effective in encouraging evidence-based best practices among 
hospitalists to improve quality and lower costs of care. What follows is a discussion of the 
essential components of the framework, the results that were achieved and observations relative 
to next steps a learning healthcare organization would consider. 
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Chapter 1:  Problem Statement   
1.1  Introduction 
Healthcare in the United States (U.S.) is underperforming despite record increases in spending. 
The causes are as myriad and complex as the suggested solutions. It is increasingly important to 
carefully assess the appropriateness and cost-effectiveness of treatments including the most 
resource-consuming clinical interventions 
1,2
.  One of the most promising solutions lies in a shift 
from authority-based medicine to evidence-based medicine (EBM). While there have been signs 
of a shift in this direction 
3,4
, very few healthcare organizations can point to tangible examples of 
improved outcomes and cost reduction that are directly the result of more informed decision 
making. The Patient Protection and Affordable Care Act, commonly referred to as the 
Affordable Care Act (ACA) has added new incentives to address some of the cost, quality, and 
access issues related to healthcare, making evidence-based decision-making an increasingly 
important strategy. 
  
Despite its great promise, the transition to evidence-based medical practice faces many 
challenges. It is commonly known that healthcare organizations are ―data rich and information 
poor‖ 5. This study demonstrates the effectiveness of a framework that bridges the gaps that exist 
between data, knowledge, and practice through the use of evidence-based guidelines, data 
analytics, enhanced contextualized data-driven practice information, education focused on the 
latest evidence, and feedback mechanism to assess the changes in practice. The American 
Hospital Association (AHA) has made a series of recommendations at this transformational 
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juncture in healthcare delivery. The AHA four priority strategies are incorporated into this 
study‘s process framework and include: alignment of hospitals, physicians and other healthcare 
providers across the care continuum; utilization of evidence-based practices to improve quality 
and patient safety; improvement of efficiency through productivity and financial management, 
and development of integrated information systems in a cohesive manner to operationalize the 
multiple components. 
 
Even though the basic principles behind evidence-based medicine (EBM) have been known for 
many years, the concept and the approach to integrating evidence-based decision making into 
day-to-day practice has only begun to evolve in the past twenty years 
6
. Different approaches to 
the development and implementation of evidence-based practice have been proposed and used, 
including: professional education and development, audit and feedback, evidence-based 
guidelines, total quality management, economic incentives, and organizational changes. A 
number of well-designed studies 
7-11
 have examined attempts to modify clinical practices using 
mostly one or infrequently more than one of the above approaches 
7
. However, an understanding 
of just which approaches are most effective in which settings remains unclear.  
 
Blood transfusion has been the focus of practice improvement efforts because it is among the top 
ten coded hospital procedures 
12,13
with significant cost and patient outcome implications. Patient 
Blood Management (PBM) is defined as ―an evidence-based, multidisciplinary approach to 
optimize the care of patients who might need transfusion‖ 14. Research findings in the areas of 
clinical evaluation of patients, transfusion outcomes, and decision-making processes have shown 
compelling evidence for the need for improvement of transfusion medicine practice. Blood is a 
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precious and a limited resource that carries inherent risks for patients when transfused 
15
. 
Extensive donor screening and infectious testing have made blood products much safer by 
drastically decreasing the rate of transfusion-transmitted infectious diseases. However, recent 
discoveries point to increased non-infectious transfusion hazards that have emerged as the 
leading complication of transfusion-associated morbidities 
16,17
 and even mortalities 
18-20
. 
Transfusion of allogeneic blood has long been suspected of consuming ―more healthcare 
resources than previously reported‖21. The underestimated cost and overestimated effectiveness 
of this long-standing and common clinical practice
1
 have contributed to higher associated 
expenditures which strain healthcare organization budgets.  
 
Lack of evidence for the need for practice improvement is not the issue. ―Transfusion medicine 
is currently adapting the principles and research methodologies that support EBM‖ 22. High level 
research has been undertaken at the same rate as in all other medical specialties in terms of 
numbers of randomized controlled trials and meta-analyses
22
. However, even today broad 
variation exists in transfusion medicine practice within and across hospitals and healthcare 
organizations. There is a demonstrated need to bring PBM evidence into the day-to-day practice 
of physicians and other healthcare providers. There are compelling motives and numerous 
incentives to introduce EBM practices into transfusion medicine as part of a PBM program. 
 
In this study, a comprehensive framework was developed and used to implement a data-driven, 
evidence-based patient blood management program at a large (385 bed), accredited, general 
medical hospital served by BloodCenter of Wisconsin in Milwaukee. The study demonstrates an 
approach that bridged the gaps that exist between data, knowledge, and practice through the use 
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of evidence-based guidelines, enhanced contextualized data-driven reports and focused education 
on the latest evidence. An analytics framework provided a feedback mechanism to evaluate 
changes directly impacted by the program, identified new areas for improvement, and helped 
avoid unintended consequences and outcomes. Focus on the tight integration of these elements 
successfully altered healthcare providers‘ inappropriate practices, increased adherence to the 
medical practices based on best scientific evidence (EBM), led to appropriate decision-making 
and interventions (EBP), and resulted in cost savings. The method, applicable in areas of 
healthcare beyond transfusion medicine, improved patient outcomes and reduced healthcare 
expenditures. 
 
1.2 Current Healthcare Landscape 
1.2.1. United States Healthcare System 
In 2011, total healthcare spending accounted for 10.1 percent of the world‘s gross domestic 
product (GDP) 
23,24
. At the same time, the United States spent 17.7 percent of its GDP on 
healthcare. This share roughly doubled from nine percent in 1980s 
25
. Health data released by the 
Organization for Economic Cooperation and Development (OECD) indicate that the United 
States compared to any other OECD country spends more on healthcare per capita 
24
. If 
healthcare expenditures continue to rise at historical rates, the Council of Economic Advisers 
projects the share to reach 34 percent of GDP by 2040 
26
. Despite the increase in healthcare 
spending, comparative analysis has shown that the United States underperforms in most 
dimensions of a high performance healthcare system (i.e. quality, access, efficiency, equity, and 
healthy lives) relative to other countries, such as Australia, Canada, Germany, the Netherlands, 
New Zealand, and the United Kingdom 
27
.   
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1.2.2. United States Healthcare Complexities 
The healthcare system in the U.S. is comprised of a vast array of complex interrelationships 
among patients, providers, payers, and insurers 
28
, in addition to the pharmaceutical and 
biomedical technology industries.  These interdependencies have created a multifaceted and 
complex care delivery model, which has been sustained for many decades by a set of mutually 
reinforcing elements. Some of the elements include: ―organization by specialty with independent 
private-practice physicians; measurement of ―quality‖ defined as process compliance; cost 
accounting driven not by costs but by charges; fee-for-service payments by specialty with 
rampant cross-subsidies; delivery systems with duplicative service lines and little integration; 
fragmentation of patient populations such that most providers do not have critical masses of 
patients with a given medical condition; siloed IT systems around medical specialties; and 
others‖29. The interlocking structure of the current healthcare system contributes to process 
inefficiencies, structural barriers, and system failures, which are significant impediments to 
quality care and prevent the delivery of effective, efficient, evidence-based health care 
29,30
. 
These factors highlight the complexity and explain resistance to change. 
 
1.2.3. Affordable Care Act  
The Affordable Care Act (ACA) was signed into law on March 23, 2010. It consisted of ten 
separate legislative Titles with several major aims. Passing ACA introduced a significant 
regulatory overhaul to the current healthcare system through mandates, subsidies, and health 
insurance exchanges 
31
. The provisions of ACA were designed to control increasing healthcare 
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costs, expand coverage, and improve patient access,  healthcare delivery, patient outcomes, and 
population health 
32
.  The enactment of ACA drastically shifted the operational landscape of 
healthcare organizations, insurers, payers, patients, and care providers, by moving away from a 
supply driven healthcare system organized around providers to a patient-centered system, 
focusing on patients‘ needs 29,33. The intent of the law was to lower overall healthcare costs by 
better aligning patient care with holistic approaches to treatment, with a significant focus on 
preventative medicine 
33
 and population health. One of the major aims of ACA was to ―improve 
health-care value, quality, and efficiency while reducing wasteful spending and making the 
health-care system more accountable to a diverse patient population‖ 34. Value may be defined as 
―health outcomes achieved that matter to patients relative to the cost of achieving those 
outcomes‖29. Value for healthcare organizations senior executives, providers, and stakeholders 
translates into improving one or more outcomes without increasing cost (in some cases even 
lowering cost) without compromising outcomes 
29
. Improving value is critical in the new 
healthcare environment.  Failure to improve value can decrease profitability and competitiveness 
of healthcare organizations and hospitals in the marketplace. To be better positioned for the road 
ahead, a fundamental departure from past practices is essential.  
 
1.2.4. Additional Healthcare Challenges 
Change is inevitable for healthcare systems and hospitals in order to drive transformation, 
operationalize care delivery, and move from volume to value as required by ACA. Healthcare 
organizations and hospitals are facing mounting pressure as they deal with: increasing cost of 
patient care, uncertainty surrounding healthcare reform, governmental mandates, cost 
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containment requirements, industry consolidation, challenges in enhancing patient outcome 
quality and safety, population health management, change in physician reimbursement models, 
physician hospital relations, caring for uninsured, improving patient satisfaction, conforming to 
new information technology, and creating accountable care organizations
35-37
. Healthcare 
systems and care providers must operate under new sets of outcome based demands and avail 
themselves of the latest research evidence and technological advancements. A paradigm shift is 
required of healthcare systems and care providers if they are to deliver quality patient care in the 
most effective and efficient manner, with outcome quality tracked, rewards granted based on 
evidence-based best-practice and quality metrics met as measured through an aggregation of hard 
data 
38
.  
 
At the industry level, the current culture of healthcare environment is characterized by 
―competition, misaligned incentives, and inherent distrust among stakeholders‖, which is 
exacerbated by tensions among ―consumers who ask for high service and low out-of-pocket 
costs, payers who select risk and limit cost, and purchasers demand more value at the lowest 
cost‖ 30. In addition, vast investments in biomedical research and technology, pharmaceutical, 
genetics and genomics research and discoveries have led to new and improved clinical 
approaches. Technological and scientific breakthroughs have led to a marked proliferation of 
new diagnostic and treatment technologies, which has led to a sharp increase in healthcare costs 
30
.  
 
Healthcare organizations in the United States have not fully leveraged clinical data to improve 
health outcomes. Siloed and diverse information technology systems within and across 
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healthcare organizations make cost and outcome measurement difficult and limit the value of 
these technologies. Three major impediments to the full use of health data include: limited 
integration capabilities in the design of various health information systems for health information 
technology (HIT) and other technologies (i.e. imaging systems, lab, pharmacy, transfusion 
service information systems and etc.); limited access to data, which is exacerbated by inadequate 
adoption of electronic health records (EHRs); and lack of data standards. These barriers and 
more have resulted in misuse or overuse of various systems and have hampered their ability to 
improve quality of care and delivery of services. The ―crush of information, plethora of new 
technologies, increased regulatory oversight, an aging population, and heightened consumer 
awareness and expectations have all contributed to the disorganization, fragmentation, and 
discontinuity of patient care‖30. 
 
1.2.5. American Hospital Association Recommendations 
To help healthcare systems and hospitals‘ senior leadership navigate the fluid environment, the 
American Hospital Association  (AHA) Committee on Performance Improvement has identified 
priority strategies and core organizational competencies to be considered by healthcare systems 
and hospitals in order to remain successful during  this transformational period 
39
. Among the 
following AHA strategies, the first four are considered major priorities:  
 Aligning hospitals, physicians and other providers across the care continuum 
 Utilizing evidence-based practices to improve quality and patient safety 
 Improving efficiency through productivity and financial management 
 Developing integrated information systems 
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 Joining and growing integrated provider networks and care systems 
 Educating and engaging employees and physicians to create leaders 
 Strengthening finances to facilitate reinvestment and innovation 
 Partnering with payers 
 Advancing through scenario-based strategic, financial and operational planning 
 Seeking population health improvement through pursuit of the ―triple aim 39 
The AHA recommendations highlight the need for today‘s healthcare systems and care providers 
to operate under a new set of outcome based demands. The paradigm shift requires healthcare 
systems and care providers to deliver quality patient care in the most effective and efficient 
manner, with quality of outcomes is tracked and rewarded based on evidence-based best practice 
measures, and meeting various quality metrics that can be measured through aggregation and 
analysis of hard data 
38
.  
 
1.2.6. Affordable Care Act Implementation Challenges 
The manner in which many healthcare systems have been implementing the different 
components of the new healthcare law has resulted in a succession of narrow piecemeal solutions 
some of which are designed to preserve existing roles 
29
. Some attempts to improve consumer 
access to care further fragment care delivery and add to the problem. Convenient care clinics 
improve access to primary care, but they are not designed to provide holistic and continuous care 
for healthy patients, or acute and preventative care for patients with complex chronic, or acute 
conditions
29
. Global capitation can strongly incentivize providers to reduce spending, without 
necessarily improving value or outcome for patients. Care coordination on top of a fragmented 
10 
 
healthcare system can produce very limited savings
29
. Information technology solutions are a 
critical component of an effective patient-centered healthcare system. However, misuse, and 
overuse of disparate, incompatible, and heterogeneous health information systems have 
intensified and further fostered siloed and fragmented care delivery models despite attempts to 
establish care-coordination and continuity of patient care.  
 
Practicing evidence-based medicine, for the purpose of improving quality and patient safety is 
appropriate but it is not without implementation challenges. Even though studies have shown that 
development and implementation of evidence-based clinical practice guidelines appear to be one 
of the most promising and effective tools for improving quality of care, many guideline are not 
used soon after dissemination 
40
. Evidence-based clinical practice guidelines become outdated 
quickly due to rapid advances in medical knowledge, clinical research, and technology.  Quality 
measures and metrics are high-level and limited. Many measures track and report only providers‘ 
compliance with certain guidelines, and dismiss outcomes achieved related to adherence with the 
guidelines. Measuring compliance with guidelines does not translate into practicing evidence-
based medicine, especially if improved patient outcomes are unquantifiable. Disappointing 
results from various attempted cost reduction strategies has fostered skepticism about whether 
value improvement in healthcare is possible with some concluding that the only solution to 
escalating cost of healthcare is rationing of services and shifting the cost to patients or taxpayers 
29
.   
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1.3.  Reshaping the Healthcare Ecosystem 
The healthcare ecosystem is being reshaped by two powerful and opposing economic forces: (1) 
to improve quality of care, and (2) to reduce cost. There is pressure to do more with less.  In 
order to achieve more with less, any healthcare organization with a vision of the future must face 
a fundamental question, how to best to use limited resources while better managing patient care? 
The answer to this question lies within healthcare organizations‘ data. Clinical, administrative, 
and other healthcare related data holds the key to transforming the healthcare system, by 
providing greater insight to patients, providers, and policy makers on the appropriate 
interventions, quality, and cost of care 
41
. As a result, the healthcare system model is changing 
into ―information driven‖, ―evidence-based‖, and ―outcome-driven‖ model 42.  Using technology 
effectively and managing the overwhelming quantity of data to derive new information are at the 
forefront of the change. 
 
1.3.1. Information Driven Healthcare 
Healthcare data offer the opportunity to accelerate progress on the six characteristics of quality 
care, in which a healthcare system must deliver. These characteristics include: 
1. Safe: Care should be as safe for patients in healthcare facilities as in their homes; 
2. Effective: Science and evidence behind healthcare should be applied and serve as the 
standard in the delivery of care; 
3. Efficient: Care and service should be cost effective and waste should be removed 
from the system; 
4. Timely: Patients should experience no waits or delays in receiving care and services; 
12 
 
5. Patient Centered: The system of care should revolve around the patient, respect 
patient preferences, and put the patient in control; 
6. Equitable: Unequal treatment should be a fact of the past; disparities in care should be 
eradicated 
43-45
. 
Addressing the above dimensions of quality care, necessitate an understanding of the scope of 
the potential and missed opportunity. This requires a sound knowledge of existing healthcare 
data (i.e. disparate data sources, types, accessibility, and use) 
41
. The combination of 
administrative and clinical data is a powerful and vital resource. Significant quantities of data 
permeate healthcare organizations and have the potential to transform healthcare delivery and 
performance 
46,47
. However, data alone is neither information nor knowledge. Data requires 
collection and processing (manipulation of items of data) to produce information 
47,48
. The 
combination of  a robust information technology infrastructure, technology expertise and 
informatics expertise are required to perform the data profiling, aggregation, analytics, 
visualization,  interpretation, and presentation in order to produce meaningful information and 
provide the knowledge that is required to contribute to informed decision-making in healthcare 
services and policies 
47
. However to date, many healthcare organizations have not fully embraced 
the expertise, technologies, and key business management processes or techniques (such as 
knowledge management, data mining, business intelligence, analytics, intuitive reporting 
systems, and etc.) required to maximize this invaluable resource 
46
.  
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1.3.2. Data Abundance and Information Scarcity in Healthcare 
Other industries (i.e. banking, retail, supermarkets, manufacturing, etc.) have been far more 
successful in harnessing the value from large-scale integration and analysis of their industry and 
organizational data 
5
. Healthcare is just getting its feet wet 
49. Although ―healthcare is inherently 
an information based endeavor‖50, it is commonly known that healthcare organizations are data 
rich and information poor 
51
. Only the fraction of available healthcare data is being used for 
analysis and reporting. Information rests at the core of healthcare. Meaningful, well managed, 
easily accessible, and timely information is fundamental to the future of medicine, cost 
containment, improvement of patient quality care and outcome 
50
.  One solution is the effective 
use of health information technology (HIT), which can be defined as the ―array of devices, 
procedures and processes for collecting, referencing and/or managing health information 
electronically 
50‖. HIT encompasses broad categories of technologies including: electronic and 
personal health records, e-prescribing, computerized physicians order entry, clinical decision 
support, telemedicine, advanced medical imaging, smart pumps, bar coding devices and etc. HIT 
offers improvement by augmenting decision-making for healthcare professionals and assisting 
healthcare staff in patient care. Healthcare professionals, particularly physicians, are struggling 
with information overload. It is beyond human capability to continuously learn, remember, and 
apply the mounting evidence and the knowledge that is being generated on a daily basis. HIT 
aims to compensate for human limitations, enhance decision-making, improve delivery of care, 
and offer value for patients.  The Health Information Technology for Economic and Clinical 
Health (HITECH) Act provided thirty billion dollars to promote ―meaningful use‖ of EHRs 
through the Medicare and Medicaid electronic health record incentive programs 
52-54
. The 
incentive program ―provides financial support for hospitals in the form of payments for the 
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meaningful use of health information technology through Medicare. Payments are made for 
adopting, implementing, or upgrading an existing EHR through the Medicaid program‖54. 
However, HIT is not without challenges. The implementation of HIT faces great challenges 
including: organizational, sociological, political, and technological. Fear of change, misaligned 
financial incentives, and performance limitations of the technologies themselves are among the 
challenges 
50,54-58
. 
 
1.3.3. Healthcare Digitization  
Digitization of healthcare data and information management has mirrored the transition to 
computerization in other industries. The initial digitization phase of an industry is designing and 
using systems that specifically support transaction-based workflow and data collection 
59
. The 
first wave of information technology in the 1950s was on the business and administrative side of 
healthcare using technology for the automation of repetitive tasks such as accounting and 
payroll, Healthcare payers and other industry stakeholders began to use information technology 
to process vast amounts of statistical data.   
 
Twenty years later, the second wave started with a focus on digitization patient‘s medical record, 
which began with the use of electronic medical record (EMR) systems in place of paper charts 
60
. 
EMRs contained the medical and treatment history of patients in a single practice. The EMR 
advantages over paper record were considerable and included the ability to track patients over 
time, to easily identify patients due for preventative screening, and to monitor patients on certain 
parameters (i.e. vaccination, blood sugar, etc.) 
61
. However, major drawbacks were associated 
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with EMR systems. Some disadvantages which emerged included: inability to maintain 
longitudinal medical records of patients being cared by multiple care provides
62
; limited ability 
to support coordination between clinicians and settings due to their design and lack of 
standardization of key data elements required for information exchange; difficulty in the 
management of information overflow; inability to adequately capture the medical decision 
making process and future care plans for care coordination; not designed for non-billable care 
coordination activities but rather for fee-for-service billable events (i.e. office visits, procedures, 
etc.) 
63,64
.  
 
Relatively recent changes in healthcare models (e.g. Pay-For-Performance, Patient Centered 
Medical Home, and Accountable Care Organization) highlight the need to embrace technologies 
that facilitate easier retrieval and tracking of patient data with a focus on the longitudinal health 
of patients and contribute to the urgency for conversion from paper records and EMR to EHR 
systems. EHR systems are defined as ―a longitudinal electronic record of patient health 
information generated by one or more encounters in any care delivery setting. Included in this 
information are patient demographics, progress notes, problems, medication, vital signs, past 
medical history, immunization, laboratory data, and radiology reports‖ 64. EHR is designed to go 
beyond the standard clinical data collection in a provider‘s office and is inclusive of a broader 
view of a patient‘s care. EHR has all the EMR capabilities in addition to the accessibility to 
computerized records and the ability to share information with other healthcare providers (i.e. 
laboratory, specialists, etc.).  EHR contains information from all clinicians involved in the 
patient‘s care.  EHR data ―can be created, managed, and consulted by authorized clinicians and 
staff across more than one healthcare organization‖ 61. EHR systems have many potential 
16 
 
capabilities, but three particular functionalities hold great promise in improving the quality of 
care and reducing cost. These include: clinical decision support (CDS) systems, computerized 
physician order entry (CPOE) systems, and health information exchange (HIE) 
65
.  EHR 
capabilities, in addition to the above particular functionalities, became the required criteria for 
―meaningful use‖ set forth by the Health Information Technology for Economic and Clinical 
Health Act (HITECH) of 2009 
53,65
. HITECH sought a means to address the alignment of 
economic incentives between payers and providers, to promote digitization, to strengthen 
healthcare delivery with seamless transfer of patient information, to provide transparency, and to 
improve the consumer experience. The enactment of HITECH led to  widespread EHR adoption 
for sharing data and health information among members of workflow teams 
59
. While digitization 
of patient and healthcare data is a necessary first step toward a data-driven care delivery, EHR 
alone is not enough. A platform that enables an enterprise-wide, consistent view of information 
that is aggregated from multitude of diverse and disparate data sources 
66
 is required. 
 
The third wave of digitization in healthcare focuses on the analysis of different aspects of data, 
information, and workflow that are reflected in the patterns of aggregated data 
59
 in order to 
provide value. This phase of information technology focuses on the utilization of data to improve 
care. Without a way of organizing the clinical, financial, administrative, other healthcare related 
data into a single source of truth, a healthcare system cannot extract value from their data. In 
order to gain actionable clinical, financial, and operational insights, data from EHR and other 
internal and external source systems must be captured, aggregated, analyzed, and presented in a 
meaningful manner
60
. This phase is characterized by the implementation and adoption of data 
repositories for aggregation of clinical data and building electronic data warehouses. To address 
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healthcare inefficiency and information deficiency, leading healthcare organizations have begun 
implementation of data repositories to aggregate clinical data and are building data warehouses 
to support the analytical needs  of various initiatives, mandates, and programs, such as evidence-
based practices, performance monitoring, quality improvement initiatives, outcome-based 
reimbursement models, and etc.  
 
Analytics is defined as ―systematic use of data and related business insights developed through 
applied analytical disciplines (e.g. statistical, contextual, quantitative, predictive, cognitive, other 
[including emerging] models) to drive fact-based decision making for planning, management, 
measurement and learning. Analytics may be descriptive, predictive or prescriptive 
67‖. It enables 
healthcare organizations or hospitals to analyze a set of structured, semi-structured, and 
unstructured patients and healthcare data in search of valuable business information and insight. 
However, healthcare organizations are struggling to successfully manage the myriad 
stakeholders, regulations, and privacy concerns required to build fully integrated information 
technology systems 
60
. 
 
1.3.4. Big Data and Healthcare  
The transition to the use of analytics unleashes the potential of ―big data‖. Big data in a 
healthcare setting would include data from the following sources: EHR; patient registries; CPOE 
systems, CDS systems, ambulatory and emergency care records; physicians‘ written notes; 
prescriptions; medical imaging results; laboratory values; pharmacy records; insurance 
information; administrative data; machine generated/sensor data. Raw data or data with no 
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context has no value on its own. Without context, it is nothing but a meaningless cluster of 
numbers, letters, or words 
68
. Transforming raw data into insightful information requires a team 
of experts with core skills of computer science, analytics and statistics, as well as domain 
knowledge, blended with strong communication skills 
69
.  Datasets must be identified, extracted, 
transformed, and linked together in order to be organized into a specific format, and be analyzed 
using techniques that provide answers to a specific set of questions. In healthcare, these basic 
steps alone pose a significant challenge. Often it is very difficult to identify and pin-point 
relevant and contextual data that can deliver value. One source characterized the process as 
finding ―insight among the chaos‖ 68. Other impediments to data management include: data 
volume, velocity, variety, variability, veracity 
70
. Healthcare complexity and lack or limited data 
governance across healthcare organizations contribute to the problem. Yet another challenge is 
inadequate accessibility to raw data for utilization in analytics because of vendor restrictions, 
proprietary databases, lack of data integration or lack of appropriate data stores. 
 
1.3.5. Healthcare Analytics Capabilities 
There are challenges associated with use of analytics, including insufficient resources, 
inadequate technological infrastructure and a lack or limited understanding of the application of 
analytics to business, quality issues, and performance goals across organizations and 
stakeholders. Even though the availability of data in data repositories, data warehouses, or data 
marts has been a great starting point, data often remains unanalyzed and unreported among 
stakeholders for actionable outcome. Technologies must be evaluated for interoperability and 
compatibility, and for measures that are necessary in data standardization for future data utilities 
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71
. Investments may be required to develop linkages across the source systems and data 
warehouses to leverage access to both administrative and clinical data. 
71
. Human capital is 
another facet of analytics that must be taken into account. There has been a limited supply of 
analytics talent. Analytics tools, technology, and infrastructure are necessary but the right people 
who understand the need, desired goals and objectives are critical for success. They deploy their 
knowledge, skills, and the appropriate tools to provide relevant and current information for 
information users, decision makers and other stakeholders at all levels in the organization. The 
lack of appreciation of the importance of an analytics team can be a problem. Many healthcare 
analytics teams become inundated by requests for a variety of reports, dashboards, and other 
analytics applications. The team becomes too involved in information development requests 
from users, rather than focusing on enhancing the analytics infrastructure and developing new 
tools of tactical and strategic significance 
72
. Furthermore, healthcare analytics is often impeded 
by regulatory concerns, resource constraints, and more importantly organizational cultures that 
are slow to trust and accept the role and importance of analytics 
73
. 
 
1.3.6. Evidence-Based Healthcare 
The philosophical origin of Evidence-Based Medicine (EBM) dates back to mid nineteenth 
century 
74. It is defined as ―conscientious, explicit, and judicious use of current best evidence in 
making decisions about the care of the individual patient‖ 74. It is the translation and integration 
of clinical expertise, with the best available external clinical evidence from systematic research, 
and patients values into the decision making process, for the purpose of medical intervention 
74,75
. Evidence-based practice is perceived by a majority as an important element in enhancing 
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patient quality of care by reducing unnecessary and inappropriate variations in medical practice 
76-78
. Practice of EBM aims to keep medicine current with the latest findings 
79
. This involves 
frequent updates to clinical knowledge base ( i.e., references that provide answers to clinical 
questions), dissemination of knowledge, and adherence to the latest acquired evidence 
77
. Such 
an approach faces significant and often justifiable barriers with regard to applicability, 
feasibility, implementation, and suitability of evidence-based practice 
80-82
. 
 
1.3.7. Authority-Based to Evidence-Based Medicine Shift 
EBM enhances a healthcare organization‘s ability to meet both its clinical and business needs. 
Challenges in the current healthcare environment, including the need to ―cope with information 
overload, cost-control, and the public‘s impatience for the best in diagnostics and treatment‖ 83 
make EBM a necessity. EBM employs clinical and financial logic to determine whether or not an 
action taken was beneficial 
83,84
. In the United States, the persistent increase in the cost of 
healthcare affects the cost of healthcare insurance. The cost of health insurance is rising faster 
than wages at a rate that is not sustainable 
85
. Cost-benefit analysis indicates that the quality of 
healthcare, measured in outcomes, safety, and service, has remained lower than expected 
85
. The 
value of healthcare delivered in the United States is lower than most developed nations in the 
world, when compared to relatively rich European countries such as France, Sweden, the United 
Kingdom, etc. Among individual states within the United States there is great variability in the 
value of healthcare delivered 
86
. On average only ten percent of the states provide high-value 
care, which has resulted in growing cost of care and poor outcome relative to developed 
countries on most dimensions of care 
27
. Ongoing cost-benefit analysis indicates increased 
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dissatisfaction with volume driven healthcare and authoritative-based medicine, which highlights 
the need for quality and cost control measures, and efforts to make the best use of finite 
resources.     
 
1.3.8. Challenges to Evidence-Based Medicine Implementation 
 There has been a shift from authority-based medicine to evidence-based medicine over the past 
decade. The shift has introduced fundamental changes in the business of healthcare, in clinical 
practice, in health research, and in medical education 
3,4
. Transition to the practice of EBM 
requires evaluation and acceptance of the possibility for improvement, and necessitates a process 
of life-long and self-directed learning. The shift to the practice of EBM has been highly praised 
but implementation of EBM has been very challenging and at times harmful 
4,87-89
. The 
foundation of EBM rests on two core principles: an empirical approach to optimal clinical 
decisions regardless of pathophysiology (i.e. Does the bottom line show a gain or loss?), and its 
quantitative expression (How big is that gain or loss?) 
90
.  These two core principles require 
some mastery of epidemiology and statistics, in addition to comprehensive domain knowledge.  
These requirements have been repelled and resisted by many physicians and even many medical 
students who view them as too mathematical and remote from clinical practice 
90
. Even though 
EBM has evolved to provide the skills needed to manage the potential information overload, it 
faces significant challenges. EBM challenges can be divided in four broad categories: volume of 
evidence,  availability of relevant evidence,  time and ability to interpret evidence appropriately, 
and translation of knowledge into clinical practice 
4
.  
 
22 
 
1.3.9. Volume of Basic Science and Clinical Research Evidence 
The volume of basic-science and clinical research evidence is growing at a high rate. ―Medicine 
must keep current with the research literature, and keeping current requires continuously 
updating the clinical knowledge-base‖, which is defined as references that provide answers to 
clinical questions that can lead to healthcare decisions for patients 
79
. A major barrier is the 
amount of clinical literature published in a variety of sources. The sheer volume of new articles 
published every day is growing exponentially, which makes it almost impossible for individual 
physician to remain up-to-date in their area of specialty, not even considering the latest evidence 
in related areas within their specialty. In 1992, around twenty English language clinical journals, 
with a focus on adult internal medicine published over 6,000 articles with abstracts. To keep up 
with the latest publications, an internal medicine physician would have had to read at least 
seventeen articles per day related to internal medicine alone to try to remain up-to-date 
91
.  A 
Medical Subject Heading (MeSH) study in 1994, estimated that over 30,000 biomedical journals 
and over 17,000 new medical text books were being published annually. In 2004, Alper and 
colleagues quantified the volume of published medical literature potentially relevant to primary 
care to be 7,287 articles in a month and estimated it would require 627.5 hours per month for 
trained physicians in medical epidemiology to evaluate these articles for updating a clinical 
knowledge-base 
79
. A 2005 study 
92
 on growth and decentralization of the medical literature 
examined data for all journal articles published from 1978 through 2001 which were available in 
2003 on MEDLINE which is maintained by the National Library of Medicine (NLM). The study 
reported publication of 8.1 million articles during the time period. The results indicate that 
―between 1978 to 1985 and 1994 to 2001, the annual number of MEDLINE articles increased by 
46 percent, from an average of 272,344 to 442,756 per year, and the total number of pages 
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increased from 1.88 million pages per year during 1978 to 1985 to 2.79 million pages per year 
between 1994 to 2001‖ 92. The study reported the growth to be particularly concentrated in 
clinical research with an increased proportion of studies with human subjects. Medical Subject 
Heading changes indicated a shift from basic science headings toward clinical care and public 
health related topics i.e. public health, quality of healthcare, epidemiology, etc. 
92
.  
 
1.3.10. Availability of Relevant Evidence 
To access the best available evidence it is essential to know:  how and where to search and 
retrieve the best research studies; which databases are rich and reliable; and how to conduct a 
systematic and purposeful search strategy. Limited knowledge of the best available evidence 
may be one of the reasons behind inappropriate, wasteful, or controversial medical interventions. 
Guidelines are important in the practice of evidence-based medicine. EBM guidelines are 
defined as ―systematically developed statements to assist the practitioner in making patient 
decisions for appropriate health care interventions for specific clinical circumstances 
11
. 
Evidence-based guidelines can be synthesized from numerous sources with the overall goal to 
aggregate the best available evidence and use the conclusions to assist in clinical decision 
making 
93-95
. There are challenges involved in the implementation of EBM in day-to-day 
practice. The volume of clinical research has been growing considerably, but optimal evidence is 
often not available for many physicians 
4
. Systematic literature reviews have demonstrated that 
large numbers of studies are grossly inadequate, and are thus potentially misleading 
83
. A study 
by Haynes 
91
 ―estimated over 95% of articles in medical journals do not meet the minimal 
standard of critical appraisal.‖ Critical appraisal is a ―systematic process used to identify the 
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strengths and weaknesses of a research article in order to assess the usefulness and validity of 
research findings‖ 96. The most important components of a critical appraisal are an evaluation of 
the appropriateness of the study design for the research question and a careful assessment of the 
key methodological features of this design. Other factors that must be considered include: 
suitability of the statistical methods used; interpretation of statistical methods;  potential conflicts 
of interest; relevance of the research to area of practice 
96
 and study biases. To assess clinically 
meaningful patient outcomes, physicians require well-designed, large-sale clinical studies that 
are reflective of approaches or interventions in their particular domain.   
 
1.3.11. Interpretation of Evidence  
―The limited or lack of time and training on the part of well-intentioned physicians to critically 
and independently evaluate evidence threatens the very basis of EBM 
4‖. Successful application 
of evidence-based practice depends on domain knowledge and the acquisition, appraisal, and 
applicability of clinical evidence 
97
. Physician and faculty clinicians often lack or have limited 
expertise in these key skills 
4,83,97
 thus are unable to demonstrate the processes for other 
physicians, residents, and medical students 
97,98
 in order to promote the practice of EBM.  Many 
physicians gain limited knowledge and training as medical students in statistics classes or 
residency journal club, a common venue to learn basis of EBM) 
97. ―These forums can leave the 
impression that EBM requires hours of study to answer a single patient care question, a difficult 
time commitment for clinically active physicians, who therefore lose appraisal skills over time‖ 
97
. Required skills are fundamental in distinguishing between poorly designed or high quality 
research studies, and interpreting information when studies of equally high quality are 
conflicting in their findings 
4
. In addition to a lack of the required skills, there is resistance within 
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a subset of clinicians who prefer to exclusively consult colleagues for less familiar diagnoses 
rather than do research frequently encountered patient problems. Additional obstacles include, 
aversion of physicians and medical students to learning and understanding statistics and 
epidemiology 
90
. There is a growing volume of evidence regarding the overall difficulty of 
translating the acquired EBM knowledge into behavioral change 
99
.  
 
1.3.12. Translation of Knowledge into Clinical Practice 
―Assuming the volume of published studies, availability of information, time, and ability to 
independently and critically evaluate evidence, translation of evidence to practice may still be 
challenging‖ 4. The preponderance of research evidence is in the form of clinical trials and 
observational studies which pose advantages and limitations for translation of the studies‘ 
outcomes 
4
. The designs of clinical trials are intently focused on specific patient populations who 
are subjected to strict monitoring parameters, which create a somewhat artificial environment. 
Consequently, translation of the outcome becomes difficult and may not be reflective of the 
majority of patients who would normally be seen in a clinical setting and be evaluated with the 
same stringent parameters 
4
. Observational studies answer many human health research questions 
and provide great contributions to medical knowledge. However, observational studies 
potentially have inherent selection bias based on age, socioeconomic status, information bias, 
measurement errors, confounders, etc. and have a limited level of clinical details, which makes 
the interpretation and translation of outcome difficult to answer relevant clinical questions 
4,100,101
. Given these challenges, it is naïve to assume that evidence is the only impediment to 
evidence-based clinical decision making. There are a multitude of other factors such as patient 
preferences, social circumstances, presence of disease, disease-drug and drug-drug interactions, 
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clinical conditions, etc. that influence clinical decision making 
4
. Besides the quality of the 
evidence itself, there are other barriers to surmount in order to provide the most consistent and 
best possible care to patients 
102
. 
 
1.3.13. Continuous Quality Improvement Barriers to Evidence-Based Practice 
Outside of clinical and patient specific issues there are many other factors that play a critical role 
in the translation of knowledge into informed clinical practice. The factors can be broadly 
categorized at the individual and the institutional levels 
4,102
. There are four major interrelated 
dimensions: strategic, cultural, technical, and structural with an effect both on individual and 
institutional levels 
102,103
. ―The strategic dimension includes the activities and processes that are 
most important to the organization and provide greatest opportunities for improvement, such as 
vision, budget, priorities, and long-term strategy. The cultural dimension represents the 
organization‘s beliefs, values, norms, and behavior. The technical dimension encompasses 
training and information infrastructure. The structural dimension refers to the ways that 
knowledge is acquired and dispersed throughout the organization‖ 102,103. An individual may 
practice EBM as a means to provide better care for patients or as a result of interest in a 
particular intervention or condition
102
. The institution may be inclined to practice EBM as means 
to maintain ―magnet accreditation, attract more payers, or to be eligible for incentives‖ 102. The 
challenge arises when ―individuals or institutions do not know about, nor see the value in 
practicing EBM‖ 102. 
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1.3.14. Outcome Driven Healthcare  
As part of the transformation of the healthcare system, the context in which physicians and other 
healthcare providers deliver care has also shifted 
104
. The reshaping of the healthcare landscape 
has led to the trend toward physician employment by healthcare institutions and consolidation of 
healthcare systems 
104-106
. Fee-for-service reimbursement models encouraged fragmented 
healthcare delivery systems.  Changes and reform in payment policies have encouraged a shift to 
a system that encourages integration and  care coordination that holds physicians and other 
healthcare providers accountable for patient outcomes and costs 
104
.  It is unclear whether the 
changes in incentives and payments will result in improved quality of care, enhanced health 
outcomes, and lower cost for patients and healthcare organizations because of the potential 
disconnects in organizational and individual physician incentives 
104
. Many payment reforms 
such as shared savings and various risk-based models are targeted at healthcare organizations. 
However, within these healthcare organizations, countless decisions are being made daily by 
physicians, nurses, and other healthcare provides who will predominantly determine 
organizational performance 
104
. Although bundled payment, shared savings, and other reform 
initiatives may have an effect on reducing the proportion of payments linked to volume at the 
organizational level, ―healthcare providers are still being paid to do more‖ 104.  ―The providers 
are often largely being compensated by their organizations based on productivity‖ 104. To achieve 
alignment, healthcare organizations, ACOs, and other healthcare delivery systems must redesign 
financial incentives to link payments to patient outcomes. The size and timing of the reward play 
a critical role in how individuals respond 
107
. Shortening the lag time between delivered care and 
rewards improves saliency 
108
. Strategies include decoupling outcome driven financial incentives 
from other usual compensation 
109
, and evaluating,  timing , frequency, size, and other 
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characteristics of incentives, including how to link them to a specific set of performance 
measures 
104
.  Non-financial incentives that appeal to intrinsic motivation also have an influence 
on behavior change
110,111
, including the desire to do a challenging task in order to positively 
impact the lives of others 
112
, peer comparison (i.e. quality report cards) 
113
, and putting 
individual healthcare providers‘ goals in writing 114. As the number of hospital and healthcare-
organization-―owned‖ physicians and practices increases, (significant increase was observed 
from16 percent in 2007 to 29 percent in 2012) 
115
, the need to align organizational and individual 
provider incentives will likely increase in the future 
104
.  Current evidence on the use of financial 
and non-financial incentives to drive ―quality improvement in healthcare has been mixed at best‖ 
116
 .   
1.3.15. Healthcare Organizations Improving the Value of Care Delivered  
In order to improve the effectiveness and value of care delivered, healthcare organizations  must 
build their capacities for ―ongoing study and monitoring of the relative effectiveness of clinical 
interventions and care processes through expanded trials and studies, systematic reviews, 
innovative research strategies, and clinical registries (They must also improve) system‘s ability 
to apply what is learned from such study through the translation and provision of information 
and decision support‖117. For a healthcare organization to thrive, it must a successfully 
implement a learning healthcare system. This is defined as a system that is designed to generate 
and apply the best evidence for the collaborative healthcare choices of each patient and provider, 
to derive a process of discovery as a natural outgrowth of patient care, and to ensure innovation, 
quality, safety, and value in healthcare 
118
. It must incorporate the best available scientific 
evidence as it seeks to improve the quality of patient care and outcomes, to quantify and report 
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on performance, and to design and implement a feedback mechanism to enable learning from 
various experiences and interventions. To achieve this high level of performance a higher level 
of organizational capacity is essential. This requires a robust information technology 
infrastructure and a new breed of skills such as informatics and performance management 
expertise, in order to achieve clinical integration 
119
. Such a high level capacity currently is not 
present in most healthcare settings 
119
.  Given the complexity of modern medicine, information 
technology plays a central role in the redesigning of the healthcare system if a substantial 
improvement in quality is to be achieved over the coming decade 
120
. Information is critical to a 
learning healthcare system; health informatics focuses on what, how, and why of managing 
information 
121
. The ultimate goals of health informatics approaches are to streamline the 
processes of patient care, provide clinicians with accurate information in a timely manner, 
educate providers, healthcare consumers and stakeholders, improve the quality of care, and 
provide the means to identify cost saving measures 
122,123
 
 
Healthcare organizations need to leverage their information technology infrastructure and 
informatics capability to: provide the best available evidence 
124
; use organizational culture to 
effectively foster the intrinsic motivation of physicians to ensure providers ―buy-in‖104; develop 
effective educational methods (i.e. systematic practice-based interventions as opposed to 
continuing medical education); effectively incorporate evidence-based knowledge into day-to-
day operations
125
; and align financial and non-financial incentives to promote environments that 
encourages effective professional behavior
104
. This will best encourage and alter the behavior 
and practice of their frontline healthcare providers in a way that enhances their performance and 
outcomes. While any single intervention may have relatively minor impact, over time the 
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combination of various incremental steps can lead to significant strides in improving quality of 
care and reducing cost for both patients and healthcare organizations 
104
.  
 
1.4. Application of Evidence-Based Medicine in Transfusion Medicine 
1.4.1. Rationale and Need 
To date, healthcare organizations in the United States have under-estimated and overlooked the 
cost of red blood cells (RBC) transfusion as part ―doing business‖ 21,126.  As a result, the true cost 
of transfusions, both to patients and to healthcare organizations, has been widely unappreciated 
21,127-129
. In a 2010 study, accurate measures were employed that revealed the cost of a 
transfusion ranging from $522 to $1,183 per unit depending on geographic location (these 
figures do not take morbidity into account) 
21
. Beyond the cost of transfusion, each unit of RBC 
has inherent risks, which are potentially associated with increased cost of care. In particular, 
liberal transfusion practices that occur at higher hemoglobin levels can increase the cost of care 
more than those given at lower hemoglobin levels 
126
.  
 
In transfusion medicine, as in other areas of medical practice, there is a gap between the latest 
knowledge and current physician practice. Transfusions of blood products, which include whole 
blood, RBC, platelets, plasma, and cryoprecipitate, are a critical component of clinical care. In 
the United States, RBC transfusion is one of the most frequent procedures performed in 
hospitals, with one in ten inpatients receiving one or more units of blood 
130
. In 2011, five 
million patients received RBC transfusions; 13.7 million RBC units were transfused 
131
. In the 
latest statistical reports (2010 and 2011) by Healthcare Cost and Utilization Project (H.CUP), 
blood transfusion is among the top ten prominent coded procedures in United States hospitals as 
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evidenced in discharge records. In the same report, the cost of transfusion accounted for ten to 
fifteen billion dollars annually 
12,13,132
. In a recent blood transfusion cost analysis study, the 
actual cost of RBC transfusion was determined to be 3.2 to 4.8 fold higher than previously 
estimated 
21
. The under- representation in the cost of blood transfusion is  a result of an 
incomplete accounting of the required resources and the associated activity-based costs 
21
. The 
factors not fully taken into account include, but are not limited to, patient testing, pre-transfusion 
preparation, transfusion administration, follow-up, and long-term tracking of patients 
133-135
. The 
actual cost of a blood product unit and transfusion related activities accounts for a significant 
portion of hospital spending. ranging from 1.6 – 6.0 million per hospital surveyed 136. Product 
acquisition costs contribute only 21 to 32 percent to transfusion related expenditure. Blood unit 
costs vary geographically with regional variation. Mandatory, transfusion-specific, informed 
consent in the United States accounts for 1.2 to 2.5 percent of total transfusion-related 
expenditures 
21
. Materials plus fixed and variable labor costs contribute approximately 18 
percent and indirect overhead (including equipment, utilities, nonprofessional personnel, and 
property) is estimated to contribute 46 percent to the total cost of cost of blood product 
transfusion 
21,137
. As a result, total expenditure and utilization varies by 2.3 fold across healthcare 
organizations. The spending variation cannot be explained entirely by hospital size, number of 
beds, or surgical volume 
21
. Hospitals‘ total cost of blood annually has been largely driven by the 
transfusion rate, which includes factors such as case-mix index; proportion of surgical patients 
transfused, number of RBC units per patient transfused, and practice differences 
21,138
. These 
factors have contributed to variation in transfusion rates among hospitals 
138
. Lower transfusion 
rate has not been associated with worse outcomes 
138
.  Reducing either of these factors has the 
potential to reducing costs dramatically 
21
.  
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1.4.2. Current Practices  
As commonly as transfusions occur in the United States, one may assume that physicians 
practice transfusion medicine based on strict standard guidelines. However, the efficacy of blood 
product transfusion is poorly understood among practicing physicians 
139-143
. A broad variation 
exists not only with regard to what type of blood components to transfuse and how much, but 
also with regard to whether to transfuse at all 
144-149
. ―For 100 years, we‘ve assumed blood 
transfusion is good for people, but most of these clinical practices grew before we had the 
research to support it 
150‖. ―The current transfusion triggers were established over sixty years ago 
at the time when transfusion medicine was still in its infancy‖ 150. Over the past fifteen years, 
scientific studies have highlighted the overuse of blood transfusion based on outdated transfusion 
triggers and guidelines of practice 
151-155
 . A recent systematic review of 494 studies on the 
appropriateness of allogeneic RBC transfusion has illustrated that up to 59 percent of 
transfusions are unnecessary 
142
, providing either no benefit, or heightened risk of complications 
for patients, and increased cost of care 
142,156
. Additionally, published studies have associated 
blood transfusions with negative outcomes including longer length of stay, increased rate of 
infection, postoperative complications, myocardial infarction, pulmonary edema, and mortality 
131,157
. Transfusion reaction is defined as any adverse event or complication that occurs in 
relation to the transfusion of a blood component 
152,158
. Historically, infections were considered 
the main risk, but because of the abundant donor testing and thorough donor screening, the risk 
of acquired infectious diseases through transfusion has declined drastically 
159,160
. The infectious 
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complications and the current infectious risks of blood transfusion are represented in Table 1 
161-
178
. 
Table 1 - Infectious complications and risks of blood transfusion, 2007 to 2012. 
With the decrease in rate of transfusion-transmitted infectious diseases, non-infectious serious 
hazards of transfusions have emerged as the leading complication of transfusion 
16
. Research has 
shown, a patient is 1000 fold more likely to experience non-infectious complications than an 
infectious complication of transfusion 
179
. Some of the more common non-infectious serious 
hazards of transfusions include transfusion reactions such as hemolytic, febrile, septic, allergic, 
urticarial, and anaphylactic. Transfusion of the incorrect product to the incorrect recipient is 
another potential hazard. Other problems include transfusion-related acute lung injury (TRALI), 
transfusion associated circulatory overload, post-transfusion purpura, transfusion-associated graft 
versus host disease, microchimerism, transfusion-related immunomodulation, alloimmunization, 
metabolic derangements, massive coagulopathic transfusion complications, red cell storage 
lesion complications, over or under transfusing complications, and iron overload 
16
. Table 2 lists 
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the non-infectious complications and the current non-infectious risks of blood transfusion with 
associated clinical signs and symptoms 
161-178
. An analysis by the Food and Drug Administration 
(FDA) showed hemolytic transfusion reaction alone has accounted for more than twice of 
transfusion-associated fatalities compared to all infectious hazards combined 
180
. Meta-analysis 
from risk-adjusted observational studies has shown RBC transfusions are associated with a 69 
percent increase in mortality and 88 percent increase in morbidity 
181
.  The major concern now is 
the non-infectious hazards of blood transfusion. 
 
Table 2 - Non-infectious complications and risks of blood transfusion, 2007 to 2012. 
 
1.4.3. Need for Change in Transfusion Medicine Practice 
It has been more than a decade since the publication of the landmark study ―Transfusion 
Requirements in Critical Care (TRICC) trial‖ 148 and many others studies 140,142,149,155,182-184 
supporting the restriction of RBC transfusions for patients 
185
. Since then, there have been some 
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reports indicating improvements in transfusion practices, mostly with regard to reduced 
hemoglobin thresholds at which patients are transfused 
186-188
). Nonetheless, the overall use of 
allogeneic RBC transfusions in clinical practice remains relatively high and still varies widely 
among many centers and practitioners 
185,189-191
. One underlying issue is that many physicians 
were trained before transfusion research and evidence were available regarding transfusions. For 
example ―the leading risk factor for perioperative transfusion is preoperative anemia‖. 
Preoperative anemia can be feasibly corrected with advanced testing and preoperative 
interventions such as vitamin B12, folic acid, erythropoietin 
154,192,193
. Historically, some 
physicians have been taught liberal transfusion practice and to follow the maxim ―if you are 
going to transfuse, why not give two‖ 15,194,195. Now, however, numerous research studies have 
examined RBC 
148,149,155,162,182,183,196,197
 and platelet use 
27,198-202
. This has led the American 
Association of Blood Banks (AABB), the Joint Commission, the World Health Organization, 
and other groups, to publish guidelines to help guide evidence-based practice in transfusion 
medicine 
15,162,203,204
. Nonetheless, many clinicians are slow to change 
15
, and some are even 
skeptical without seeing hard evidence, such as individualized data driven reports, information 
on latest research evidence in practice, reports on their individual practice and the practice of 
their peers. 
 
1.4.4. Scrutiny of Transfusion Efficacy      
Over the past two decades, the efficacy of transfusion, particularly RBC, has been challenged. 
Recent clinical studies have indicated that transfusion of critically ill patients with traditional 
hemoglobin level triggers i.e. to maintain hemoglobin levels in the range of 10.0-12.0 g/dL, may 
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not improve patient outcomes 
153,205-208
. Restrictive RBC transfusion practices, in which RBC 
transfusions are given at lower than ―traditional‖ hemoglobin levels i.e. to maintain hemoglobin 
levels in the range of 7.0-9.0 g/dL, have been proven safe in multiple randomized controlled 
trials 
139,140,158,209
. Given that RBC transfusion is one of the top five overused procedures 
210
 with 
its increased risks and costs, there is a growing recognition of the need to implement strategies to 
reduce transfusions. The concept of Patient Blood Management (PBM) has evolved as a strategy 
to promote a proactive rather than reactive approach.  
 
Even though, over the past twenty years, ―high-level research in transfusion medicine has been 
undertaken at the same rate as in all other medical specialties in terms of numbers of randomized 
controlled trials and meta-analyses‖ 211,  there is a considerable variability that exists in 
transfusion practices within different groups of patients 
142,149,212-217
, including critically ill 
205,218-
220
 and acutely ill 
182,221-223
 hospitalized patients, obstetric patients
224,225
, and patients undergoing 
various surgical procedures (i.e. cardiac 
146,226-228
, hip and knee 
229-232
, neck and spine 
188,233-235
 
surgeries.  Variation in transfusion practices has been observed nationally among physicians 
practicing in the same geographic region or even in the same healthcare institution performing 
the same procedures on patients but producing different rates of transfusion and, consequently, 
varying outcomes. The decision on whether or not a patient receives a blood transfusion depends 
on each physician‘s training on the clinical indication of anemia, the tolerance level of anemia, 
the patient‘s physiological condition and the level of need for correction of the anemia 217,236. In 
addition, since it is known that untreated anemia can have adverse effects, physicians are often 
prompted to transfuse even if the benefits of transfusion are not entirely certain 
237
. Another 
significant contributing factor is inadequate formal training of clinicians on the clinical 
37 
 
indications for blood transfusion therapies during their time at medical school 
238-240
. Audits and 
review of clinical transfusion practices have consistently demonstrated deficiencies in knowledge 
and practice of blood product transfusion, which impact patient safety and outcomes. Studies 
241-
243
 on the effect of formal educational programs on transfusion safety have identified deficiencies 
in the practice of transfusion medicine, including inappropriate transfusion prescribing, improper 
administration of blood products, improper documentation, and inadequate identification of 
potential transfusion recipients.   
 
1.4.5. Patient Blood Management 
Patient Blood Management (PBM) is defined as ―timely application of evidence-based medical 
and surgical concepts designed to maintain hemoglobin concentration, optimize hemostasis, and 
minimize blood loss in an effort to improve patient outcome‖ 204. Further it is defined as ―an 
evidence-based, multidisciplinary approach to optimize the care of patients who might need 
transfusion.‖ It encompasses all aspects of ―patient evaluation and clinical management 
surrounding the transfusion decision-making process, including the application of appropriate 
indications, as well as minimization of blood loss and optimization of patient red cell mass‖ 244. 
The concept of PBM promotes a proactive rather than reactive approach to the practice of 
transfusion medicine addressing anemia, coagulation conditions, and blood conservation, with a 
focus on the practice of restrictive approaches in order to ―reduce or eliminate transfusions when 
applied as a multimodality approach‖127. The goal of PBM is to reduce unnecessary or 
inappropriate resource utilization and improve patient outcomes 
245,246
. PBM is rooted in an 
evidence-based approach to medicine. 
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1.4.6. U.S. Department of Health and Human Services Recommendations 
The United States Department of Health and Human Services (HHS) Advisory Committee on 
Blood and Tissue Safety and Availability has recognized the significant risks associated with 
transfusions, the wide variability and deficiencies in transfusion practices, the changing patterns 
of demand for blood, and the documented success of PBM programs. Therefore, the Advisory 
Committee on Blood and Tissue Safety and Availability has made the following 
recommendations: 
 Identify mechanisms to obtain data on PBM, utilization of transfusion and clinical 
outcomes. 
 Support, develop, and circulate national standards for blood use recognizing the value of 
patient management, blood conservation, and conservative blood use. 
 Establish transfusion expertise integral to transfusion practices in hospitals and other 
patient care settings. 
 Establish metrics for good practices of blood use and PBM. 
 Advise the Office of the National Coordinator for Health Information Technology on the 
need to integrate PBM and blood utilization into electronic health records. 
 Promote education of medical students and practitioners on optimizing PBM and the use 
of transfusion, and elevate awareness of the essential role of PBM in the quality and cost-
efficiency of clinical care. 
 Promote patient education about the risks, benefits and alternatives of transfusion to 
promote informed transfusion decision-making. 
 Support demonstration projects on PBM. 
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 Support research on non-invasive clinical measures to define indications for transfusion, 
e.g., ischemia, hemostasis, platelet function, and patients‘ functional status247. 
 
1.4.7. Recommendations of Health Organizations 
The World Health Organization (WHO) followed the HHS recommendations with the adoption 
of declaration 63.12 ―addressing the global importance of incorporating PBM into clinical 
practice as a patient safety measure 
247‖. In conjunction with these activities, the American 
Medical Association (AMA) and the Joint Commission have introduced Patient Blood 
Management Performance Measures to help evaluate the appropriateness of transfusions as a 
continuous quality indicator 
210
. Establishing an evidence-based approach to blood utilization has 
the potential to encourage appropriate transfusion practice and simultaneously reduce blood 
utilization, while improving patient outcomes and substantially lowering healthcare organization 
expenditures 
142,164,246,248-251
. Such an approach conserves a precious resource and permits the 
same blood products to be re-directed to other patients who are in true need of the supply within 
or outside the hospital 
251,252
.  
1.4.9. Implementation of a Patient Blood Management Program 
To date, practice of transfusion medicine has followed the approach of traditional medicine, 
where the decision-making relied more on physicians‘ background knowledge, clinical 
experiences, consultation with senior physicians and textbooks 
93
. Even though some of the basic 
principles behind evidence-based medicine have been known for many years, the concept and 
approach to integrating evidenced-based decision making into clinical practice on a day-to-day 
basis have only evolved over the past twenty or more years 
6
. The emergence of compelling 
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evidence of the benefit and the need to change has begun to change the landscape of transfusion 
medicine. The shift is to base decision making on evidence-based practice, and to promote a 
convergence of both individual clinical expertise and the best available evidence 
6,93,253
.  
 
1.4.8. The Need to Promote EBP in Transfusion Medicine through PBM 
A 2011 editorial on blood transfusion practices stated, ―Possibly the major obstacle to making 
transfusion practice more consistent and in line with published guidelines and evidence-based 
medicine is the overall lack of knowledge regarding transfusion medicine shared by clinicians 
across specialties as evidenced by published data. This evidence would seem to indicate that 
medical education in transfusion medicine continues to lag behind. Thus, no matter what the 
conclusions of future studies on transfusion efficacy turn out to be, there will be little impact on 
blood utilization overall if we continue to fail to educate the end users 
217‖. Transfusion triggers 
cannot be precisely defined and there are questions as to whether a non-bleeding patient will 
benefit from blood transfusion, particularly a patient whose hemoglobin concentration is in the 
middle range of published guidelines, i.e. between 7.0 and 10.0 g/dL [257]. This has led to 
inconsistent transfusion practices and often inappropriate transfusions. There is a particular need 
to bridge the gap between evidence and transfusion medicine practice. 
 
1.4.10. Patient Blood Management Implementation Requirements 
Organizational Structure and Engagement 
There is mounting physiological, medical, ethical and financial evidence that a change in 
physician transfusion practices is essential to ensure patients‘ improved quality of care and 
41 
 
outcomes. Implementation requires a top-down approach.  PBM challenges the training of 
clinicians, which makes the effort difficult to embrace 
254
. Endorsement from top senior 
executives is essential to prioritize, determine urgency, and allocate resources (i.e. human, 
financial, and information technology services) in order for the program to successfully roll-out 
across different hospitals 
255
. The level of support and engagement provided by hospital 
executives can greatly impact the success of the program both positively or negatively. In order 
to engage physicians and other clinical providers, it is essential for executives to be educated on 
the evidence supporting PBM, so they can speak knowledgably to the initiative. Implementation 
of PBM involves and requires diverse groups of stakeholders including: administrative (C-suite 
executives, senior vice presidents, vice presidents, department heads, and quality teams), clinical 
(multispecialty [i.e. surgery, anesthesiology, intensive care, etc.], multidisciplinary [medical, 
nursing, perfusion, etc.], laboratory [pathology, blood bank, and transfusion service]), and 
information technology and informatics. Healthcare organizations or hospitals have to overcome 
significant practical and political challenges to effectively implement PBM programs at their 
facilities. 
 
At its core, PBM aims to re-educate healthcare providers on the latest evidence-based research in 
order to promote the change to best-practices. Re-education of physicians with ingrained 
transfusion practices is difficult. PBM principles apply to many different medical disciplines and 
affect many patients‘ clinical care and treatment plans which makes implementation of a robust 
and scalable PBM program healthcare system-wide or hospital-wide very challenging. The 
program requires a Transfusion Medicine Medical Director who is knowledgeable of the 
intricacies of transfusion medicine and a PBM Committee whose members are tasked with 
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driving implementation of the program in their area of discipline. The Committee should consist 
of respected stakeholders and physician champions from different medical disciplines to 
illustrate the legitimacy of the initiative within a hospital 
255,256
. The committee must be 
convinced of the value of the program, believe in the principles of PBM and trained in their 
roles, responsibilities and the vision for the program. It is essential for senior executives to work 
closely with the PBM Committee as well as with quality and IT personnel to assess the hospital 
areas in greatest need of improvement from a PBM approach and to ensure that the planned 
initiatives are relevant for surgical and non-surgical physicians within each discipline 
256
.  
 
Prior to implementation, assessment and base line analysis must be conducted to evaluate current 
practice and to identify areas of focus that should be communicated to all stakeholders. Current 
state and continuous analysis of transfusion medicine practice requires: a deep knowledge of 
transfusion medicine; familiarity with the context and type of data and information that is 
required for assessment; knowledge of the various health information systems in play; and a 
mechanism for bringing fragmented data and information together for coherent reporting and 
evaluation. The significant challenge associated with this analysis will be discussed in depth. 
PBM requires transfusion medicine expertise to routinely evaluate and examine the latest 
transfusion medicine evidence and guidelines for different disciplines, in order to synthesize and 
communicate educational materials to relevant medical disciplines. Reports must be developed 
based on hard data and evidence to provide physicians and other clinical professionals with 
information about their practice relative to current evidence-based best-practice guidelines. 
Evaluation and analysis of transfusion medicine practice and communication of the progress in 
outcomes are the key factors in the success and sustainability of PBM program.  
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Data, Analytics, and Reporting 
Identification, extraction, aggregation, and analysis of contextual data are critical in providing 
the meaningful information needed to raise awareness and empower informed decision making. 
Transfusion related data is captured in different formats and in several diverse and disparate 
source systems both on the administrative and the clinical side. This impedes the aggregation of 
the minimum data sets required to feed the measures and indicators, thus hinders reporting and 
analysis. In transfusion medicine, in order to provide a comprehensive view on performance of a 
healthcare organization and individual physician practice, data from both clinical (clinical 
service lines, laboratory, pharmacy, transfusion service, etc.) and administrative (billing, finance, 
information services, credentialing, etc.) departments are required. Healthcare organizations have 
always generated a multitude of data including: administrative information, clinical indicators, 
procedural indicators, provider and staff measurements and interpretations and equipment 
readings. However, most of the generated data is stored in hard copy form, outdated legacy 
platforms, or siloed information systems. Even though the aim of digitization of healthcare is to 
transition from fragmented healthcare delivery systems to integrated healthcare models, 
challenges remain. Even as EHRs are becoming the norm as a way to provide fast and easy ways 
to share data and make information accessible  to more members of patients‘ care delivery teams, 
many components of healthcare organizations and hospitals still operate on diverse and disparate 
departmental information systems with inefficient and ineffective data and information gathering 
and reporting systems 
257
. While each department and branch of operations has unique needs, 
siloed technical and information ecosystems compromise cross departmental data aggregation, 
reporting, and analysis and foster fragmented clinical and administrative decision-making. 
Transfusion practice reporting and performance tracking is often not available. If it is available, 
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it may not contain the detailed level of information necessary to highlight trends in an individual 
physician‘s practice. Manual data collection and analysis is not feasible or sustainable. It requires 
alignment of staff and resources in order to accomplish an arduous process on an ongoing basis. 
The process is time consuming, challenging, inefficient, and costly 
258
. 
 
Presentation of Actionable Information 
The meaningful presentation of actionable information must be provided on a routine basis to 
guide transfusion practice and encourage sustainable behavior change. The information should 
provide a baseline of current practice against which to measure progress in future improvement 
initiatives. Many healthcare organizations lack the reporting mechanisms. The lack of necessary 
information negatively impacts the work of the PBM Committee, the Transfusion Medical 
Director, and the physicians because they are unable to adequately monitor the manner in which 
transfusion medicine is being practiced. To date, monitoring physicians‘ transfusion practice has 
been primarily achieved through individual chart reviews by a transfusion committee to ensure 
appropriateness of transfusions as determined by the hospital‘s medical staff 238,259.  However, 
the common practice of individual chart review frequently fails to recognize the forty to sixty 
percent 
142,260
 of inappropriate and non-beneficial transfusions that occur in almost every hospital 
259
. There are many reasons that individual chart review is not as effective as it is intended to be 
259
, including:  
 the underlying complexities surrounding transfusion medicine;  
 lack of or limited subject matter expertise;  
 limited knowledge of the intricacies of transfusion practice;  
 lack of awareness of the latest evidence and best practices;  
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 outdated and inappropriate transfusion criteria and guidelines for evaluation of 
transfusions, e.g. using a single lab value as a reference point for determination of 
appropriateness, in contrast to a comprehensive evaluation of the patient‘s condition; 
 limited or lack of a ―big-picture‖ view of hospital and provider transfusion practice; 
 uncompensated physicians‘ review time;  
 organizational culture and disciplines;  
 reviewer bias, particularly when physicians review the work of other physicians with 
whom they may have work, economic, political, social, and referral relationships. 
259
.  
1.5. Current Approaches 
Data gathering from diverse and disparate systems within a healthcare organization is a major 
impediment to implementation of an evidence-based PBM programs.  Some forward-looking 
healthcare organizations have been relying on manual processes to capture transfusion data and 
report information 
258
. This approach is highly redundant and time-consuming and introduces 
great potential for human error. It is important to note that manual analysis and review are taking 
place in healthcare settings with diverse health information ecosystems, where interoperability 
and data integration is very limited or non-existent. In such environments, data is stored in 
multiple disparate systems, with limited or lacking interface capabilities with other systems. As a 
result, one must work with fragmented data which can create an incomplete view of a clinical 
event. This method of monitoring can create conflicting perspectives on the type of data 
necessary to capture and report
258
. Such an approach may also introduce tension between 
colleagues, which can negatively impact the benefits of monitoring efforts and affect both quality 
and compliance measures. Traditional manual processes are resource intensive and most likely 
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require multiple full-time equivalents to handle the laborious task. Therefore, this approach is not 
feasible and sustainable on an ongoing basis
258
. To date there is no framework for efficiently 
accessing relevant data and information in a coherent, contextual manner, in order to learn about 
and evaluate transfusion practices and monitor providers‘ transfusion behavior in an 
organization.  Bringing together data from diverse and disparate systems remains a major 
impediment to the practice of evidence based transfusion medicine practice. 
 
1.6. Conclusion: Application of an Evidence-Based Data Analytics Framework 
Healthcare is undergoing a paradigm shift from authority-based to evidence-based medical 
practice in response to current clinical, financial and regulatory challenges. Significant hurdles 
face organizations as they struggle to implement successful, scalable evidence-based programs 
4,93,261-263
. A great deal of attention is being paid to evidence-based practice in the area of 
transfusion medicine with the implementation of Patient Blood Management programs. Despite 
the fact that blood transfusion is among the top ten most prominent coded procedures according 
to U.S. hospital discharge records 
12,13
, the efficacy of blood product transfusion is poorly 
understood among practicing physicians
18,152,181,222,228,264,265
 making transfusion medicine an area 
ripe for improvement through evidence-based approaches. 
 
This study demonstrates the effectiveness of an evidence-based approach to transfusion medicine 
practice that can be applied to many areas of medical practice. It takes into account the clinical, 
administrative, cultural and technical issues that make the implementation of an evidence-based 
program so challenging. The study focuses on reducing the inappropriate practices in transfusion 
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medicine, particularly in the transfusion of allogenic RBC in healthcare institutions.  A 
framework was developed that promotes the use of evidence-based guidelines by: 
 Obtaining broad organizational engagement; 
 Obtaining physician engagement and attain accountability; 
 Incorporating latest evidence and best practices into medical practice;  
 Identifying, extracting, and aggregating contextual data from diverse and disparate source 
systems; 
 Identifying measures and indicators to track transfusion behavior in accordance with the 
latest evidence; 
 Developing a performance management system;  
 Transforming physician specific data into meaningful information; 
 Providing current targeted information to physicians and administrators; 
 Enhancing awareness and education; 
 Developing a feedback mechanism; 
This study demonstrates the importance and the effectiveness of the tight integration of these 
elements to promote evidence-based decision-making at the point of care. The approach bridges 
the gaps that exist between the latest medical knowledge and current physician practice and has 
the potential to improve the quality of patient care, improve outcomes and decrease the cost of 
care.  
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Chapter 2:  Literature Review  
2.1. Healthcare Industry and Transformation of Clinical Practice  
2.1.1. Evidence-Based Practice as a Way to Improve Quality of Care 
Healthcare organizations are being pushed in the direction of evidence-based practice as a way to 
improve quality and patient safety. Research has constantly shown clinical decisions are rarely 
based on the most current and best available evidence. Rosenberg states in a 1995 article that 
―For decades people have been aware of the gaps between research evidence and clinical 
practice, and the consequences in terms of expensive, ineffective, or even harmful decision 
making‖ 266-268. The current magnum opus of evidence-based practice is the book published by 
Sackett and colleagues in 2000 titled Evidence-Based Medicine: How to Practice and Teach 
EBM 
84
 . The book defines EBM as ―the integration of best research evidence with clinical 
expertise and patient unique values and circumstances.‖ It also provides definitions for:  (i) best 
research evidence as ―clinically relevant research, sometimes from basic sciences of medicine, 
but especially from patient-centered clinical research into the accuracy and precision of 
diagnostic tests, the power of prognostic markers, and the efficacy and safety of therapeutics, 
rehabilitative, and preventative strategies‖; (ii) clinical expertise as ―the ability to use clinical 
skills and past experiences to rapidly identify each patients‘ unique health state and diagnosis, 
their individual risk benefits of potential interventions, and their personal values and 
expectations‖; (iii) patient values as ―unique preferences, concerns, and expectations each patient 
brings to clinical encounter and which must be integrated into clinical decision if they are to 
serve the patients‖; and (iv) patient circumstances as ―their individual clinical state and the 
clinical setting‖84. Once ―the four elements are integrated clinicians and patients form a 
diagnostic and therapeutic alliance, which optimizes clinical outcomes and quality of life‖84. 
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Sackett and colleagues explicitly note that evidence-based practice is not a static state of 
knowledge but rather represents a constantly evolving state of information. Healthcare 
practitioners have the obligation to continually stay abreast of clinical developments in research 
and to incorporate such developments into daily care   
84,269
. To practice EBM the following 
steps must be followed 
84
: 
 Convert one‘s need for information into an answerable question. 
 Track down the best clinical evidence to answer that question. 
 Critically appraise the evidence in terms of its validity, clinical significance, and 
usefulness. 
 Integrate this critical appraisal of research evidence with one‘s clinical expertise and the 
patient‘s values and circumstances. 
 Evaluate one‘s effectiveness and efficacy in undertaking the four previous steps, and 
strive for self-improvement.  
Evidence-based practice offers healthcare providers both the opportunity and the challenge to 
―avail themselves of the emerging knowledge-base and of the developing philosophy and 
approach to service delivery known as evidence-based practice‖, which is ―scientifically tenable 
and ethically incumbent‖ 269. Evidence-based practice presents significant complexities and 
opportunities not only for those in academics in charge of developing and maintaining the state-
of-the-science, and the state-of-the-art clinical training programs, but also to those providing 
clinical supervision to physicians and other healthcare providers 
269
. 
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2.1.2. Knowledge Translation 
In 2000, the term knowledge translation was defined by the Canadian Institute of Health 
Research 
270
   as ―the exchange, synthesis and ethically-sound application of knowledge— within 
a complex system of interactions among researchers and users—to accelerate the capture of the 
benefits of research for Canadians through improved health, more effective services and 
products, and a strengthened health care system‖271. The World Health Organization (WHO) 
defined knowledge translation as ― the synthesis, exchange, and application of knowledge by 
relevant stakeholders to accelerate the benefits of global and local innovation in strengthening 
health systems and improving people‘s health‖ 272. In other words,  ―any activity or process that 
facilitates the transfer of high-quality evidence from research into effective changes in health 
policy, clinical practice, or products 
273‖. The Canadian Institute of Health Research 274 has 
defined the steps for knowledge translation, to include: dissemination, communication, 
technology transfer, ethical context, knowledge management, knowledge utilization, two-way 
exchange between researches and those who apply knowledge, implementation research, 
technology assessment, synthesis of results with the global context, and development of 
consensus guidelines. The steps encompass  elements previously implicated in the application of 
knowledge
270
. Sudsawad characterizes knowledge transfer as:  
 Including all steps between the creation of new knowledge and its application, 
 Needing multidirectional communications, 
 An interactive process, 
 Requiring ongoing collaboration among relevant parties, 
 Including multiple activities,  
 A nonlinear process. 
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 Emphasizing the use of research-generated knowledge that may be used in conjunction 
with other types of knowledge, 
 Involving diverse knowledge-user groups, 
 User and context specific, 
 Impact oriented,  
 An interdisciplinary process.  
 Knowledge translation has been increasingly valued in healthcare as it ―represents the 
process of moving what is learned in research to actual application of such knowledge in 
variety of practice setting and circumstances‖ 270.   
 
2.1.3. Translation of Knowledge in Evidence-Based Practice 
The growing interest in evidence-based practice which integrates research evidence into clinical 
decision-making coincides with an increased emphasis on knowledge translation
74,270
. Evidence-
based practice makes knowledge translation an increasingly imperative discipline 
273
. It aims to 
―conceptually combine elements of research, education, quality improvement, and electronic 
systems development to create a seamless linkage between interventions that improve patient 
care and their routine implementation in daily clinical practice 
273‖. Despite the strong 
endorsement for evidence-based practice, the translation of research findings (knowledge) to 
clinical practice is a well-recognized challenge in healthcare 
270,275-279
. Common hurdles include: 
the sheer volume of research evidence; time required to gather findings; skills needed to interpret 
research evidence; conflicting evidence, irrelevant evidence; limited access and cost of 
continuing education; lack of supervisory support; lack of or limited access to scholarly articles; 
physician attitudes towards evidence-based practice; inadequate organizational leadership; 
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inadequate responsiveness to program participants; failure to include stakeholders from multiple 
disciplines; lack of transparency to foster trust; and difficulty in evaluation of efficacy of final 
program on patient health 
96,99,262,279-282
.  As a result of the challenges associated with the 
translation of knowledge into practice, gaps exist between research and clinical practice, which 
present a real barrier to clinical implementation of innovative research findings 
283
. The 
consistent failure to translate evidence into practice, has contributed to three major shortcomings 
in healthcare system 
280
 which include: preventing patients from benefiting from latest 
discoveries and advances in treatments and interventions;  exposing patients to unnecessary risks 
of iatrogenic harms; and exposing healthcare systems to unnecessary expenditures at significant 
cost 
280
.  Both the knowledge and the application of the knowledge are essential in all areas of 
medical practice. It is imperative to bridge the gap that exists between research evidence and 
practice.  
 
2.1.4. Technology in Healthcare 
Technology is the engine of change that has set the stage for an unprecedented transformation in 
healthcare 
284
.  Digitization of data has been one of the key underlying factors in the rapid 
transformation of healthcare as and in other industries.  Digitization refers to the conversion of 
an analog signal to a digital one 
285
, where analog data are measured as continuous variables and 
digital data are measured as simple discrete variables 
285,286
. Digitization of patient care has been 
driven by wireless sensors and devices, imaging, health information systems, and genomics 
287
.  
Each of the digital medical technologies is propelling healthcare forward at an unprecedented 
pace, focusing on human biology, physiology, and anatomy to illuminate what Topol refers to as 
the ―high definition man‖287.  Use of technology in healthcare has been focused on digitization of 
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various processes, which has led to the accumulation of large amount of diverse and siloed 
electronic data related to admissions, billing, health records, finances, imaging scans, pharmacy, 
lab, transfusion service, insurance claims, scheduling, and etc., in disparate health information 
systems. Various reform efforts like the ACA‘s meaningful use requirement, accountable care 
organizations, health information exchanges, public health exchanges, and other initiatives seek 
to place patients at the center of care 
288
 with the use of various technologies. The aim of the 
healthcare initiatives is to improve patient care and lower the cost through meaningful use of 
patient data and information in order to enhance appropriate decision-making and interventions. 
―Health information systems serve as an indispensable foundation for improved delivery of 
routine health services in an evidence-based manner‖289.  Development of information systems 
has provided a way to reduce medical errors, improve patient outcomes, and increase 
collaboration among care providers 
290
. Although these approaches  have the potential to 
dramatically improve the delivery and quality of healthcare, they are contingent upon data 
exchanges and interoperability of the various information systems which to date have been a 
great hurdle and ―largely an unreached goal 290‖.  
 
2.1.5. Uniqueness of Healthcare Data and Complexity of Reporting 
Healthcare data are unique both in complexity and diversity. Healthcare data have characteristics 
that vary from any other industry. In a healthcare setting data reside in multiple source systems 
(i.e. from EHRs, medical credentialing systems, claims processing systems to specific 
department systems such as lab, transfusion service, pharmacy, radiology, etc.). Data also occur 
in different formats (e.g. text, numeric, paper, digital, pictures, video, multimedia, etc.). It is the 
norm for the data to exist in different systems and in different formats 
291
.  For example, in the 
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case of a patient with a broken arm, the medical records show an image of a broken arm. 
However, the broken arm appears as ICD-9 code 813.8 in claims data. Additionally, contrary to 
common belief, data have been anything but consistent. For years, clinical data have been 
captured on paper in however way is most convenient for the healthcare provider with little 
regard for how the data could eventually be aggregated and analyzed 
291
. EMR and EHR systems 
have attempted to standardize the data capture process, but physicians and other healthcare 
providers have been reluctant to adapt to a ―one-size-fits-all‖ approach. As a result, most of the 
data have been captured in both a structured and an unstructured manner, which makes it 
difficult to aggregate and analyze 
291
. Another problem has been the variability and 
inconsistencies of healthcare data.  Variability exists in the length of the same data element (e.g. 
patient last name 50, 25, 16 characters), and in the values for the same elements (e.g. Gender: M, 
F, or U; or Male, Female, or Other). Inconsistencies exist in naming conventions (e.g. Date of 
Admission, Admission Date, Admit Date, etc.), and in definitions of terms (e.g. patient access 
modules defined date of admission as the date   inpatient or day surgery visit occurs; trauma 
registry defined the date on which the trauma patient enters the operating room, and etc.) 
292
.  
Addressing the complexity surrounding the development of standard processes to improve 
quality is one of the main goals of recent changes in healthcare system. However, aggregation of 
administrative data (e.g. admissions, insurance, billing) with clinical data (e.g. EHR, pharmacy, 
radiology, transfusion service, lab) to create a more complete picture of the patient‘s story is very 
challenging. There is no finite number of identical parts to create identical outcomes. Rather 
there is an amalgam of individual systems each with its own complexity designed to capture 
different information about an individual. Managing data from disparate systems and turning 
them into meaningful information requires a sophisticated set of tools, approaches, and a broad 
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range of expertise 
291
. As research advances and knowledge is enriched, new best practices arise 
with new definitions of terms, new criteria, and different approaches. Best practice is 
continuously being redefined in an unpredictable manner contributing to the complexity of 
aggregating contextual data. Furthermore, as medicine and healthcare technology evolve, 
regulatory and reporting requirements change (i.e. CMS quality requirements such as 
readmissions) adding to the burden of aggregating and reporting of data.  
 
2.1.6. Diverse Health Information Systems  
Integration and interoperability of different health information systems is a fundamental 
requirement for achieving continuity of care and a comprehensive view of patients‘ health. 
Currently, health information systems used in each department (i.e. admissions, billing, 
laboratory, pharmacy, transfusion service, etc.) within hospitals and across healthcare 
organizations have been developed independently with diverse sets of approaches in methods, 
processes, and procedures for capturing data and presenting the information 
293
. Additionally, 
lack of specificity in healthcare standards and information sharing protocols,  has resulted  in a 
―large number of heterogeneous and distributed proprietary models for recording and 
representing patients‘ data and information‖290.  Diverse and disparate health information 
systems pose  great challenges for the exchange of patient data causing duplication of data, a 
considerable amount of transcription (i.e. transfer of data from one system to another such as 
transfer of patient diagnosis data from patient records to an order entry form) and maintenance of 
referential integrity when data is replicated or duplicated 
293
. Other challenges include the cost of 
uncontrolled redundancy, maintenance, and updating. Much of the difficulty pertains to the 
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proprietary nature of each system and the syntactic and semantic differences across them. These 
challenges are ―exacerbated by the lack of standardization between health information systems 
and the costs associated with software upgrades and data restructuring‖ 294.  As a result of the 
disparity that exists among health information systems, gaining user acceptance is another major 
challenge due to the learning curves associated with the use of each system resulting from 
different user interfaces, overlapping features, separate user identification procedures, and many 
more issues.   
 
2.1.7. Data Integration Challenges  
―A key attribute of a learning health care system is the ability to collect and analyze routinely 
collected clinical data in order to quickly generate new clinical evidence, and to monitor the 
quality of the care provided. To achieve this vision, clinical data must be easy to extract and 
stored in computer readable formats‖ 295. Clinical data provide the health context directly related 
to an individual patient. Clinical data include patient vital signs, laboratory tests, scans, medical 
history, immunization record, family history, life-style information, physical exams, diagnoses, 
progress notes, operative reports, ambulatory care reports, care plans, medication reports, and 
etc. Integration of clinical data ―facilitates the coordination of patient care across conditions, 
providers, settings, and time in order to achieve care that is safe, timely, effective, efficient, 
equitable, and patient-focused‖ 296. Integrated data can greatly assist care providers in making 
accurate assessments and interventions, administering proper treatments, and optimizing 
operations among peers in the department and across organizations. However, achieving clinical 
integration faces significant challenges due to heterogeneity of healthcare ecosystems in which: 
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data tend to reside in multiple different sources; data collection occurs in different formats (i.e. 
text, numeric, hand written paper, digital, pictures, videos, and etc.), and the same data exists in 
different formats in multiple systems. Structured and unstructured data is another issue 
297
.  EHR 
systems attempt to standardize the data capture process. However, providers are disinclined to 
adapt to a one-size-fits- all approach to documentation and unstructured data capture has been 
put in place to allow autonomy and leniency in this process 
290
. This approach introduces 
inconsistency in data capture and makes data aggregation and analysis very cumbersome.  
Complexity of medical data is another factor. Although construction of workflows and 
standardized processes for data capture does improve quality, the number of variables that exist 
in medicine makes the effort far more challenging, particularly when the variables are being 
captured in disparate applications 
291
 and are subject to change as new evidence emerges. The 
variability that exists in healthcare terminology and definition is also problematic 
290
. Much of 
the data are not available in easily extractable and structured formats. While textual and 
unstructured data are convenient for both entering and reviewing of patient history and progress 
by care providers, they present significant obstacles for graphic presentation, searching, 
summarization, and statistical analysis 
295
.  
 
―The principles of evidence-based health care posit that clinical and public health decisions 
should be made using, among other elements, the best available clinical evidence‖75,295,298. 
Evidence-based practice focuses on incorporation of the latest scientific and clinical evidence 
into practice 
75
. It is gaining ground in the current healthcare environment as a means to improve 
quality and productivity of healthcare services by reducing variation in care 
75
. As great as 
evidence-based practice is, it also contributes to the challenges of data integration. The 
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continuous advancement in the understanding of the functions of the human body, adds new 
variables, changes what is considered important, adds new variables, changes the how, what and 
when of measurements, and alters how to determine goals and reach targets. As a result of our 
advanced understanding we routinely add inconsistencies to ways we aggregate and manage 
data.  Changing and increasing regulatory and reporting requirements also affect data integration. 
The Center for Medicare and Medicaid Services requires various types of reports such as clinical 
quality measures, outcome based measures, readmission rate, and etc. to provide transparency in 
quality and pricing information to public 
291
.  
  
2.1.8. Issues of Interoperability 
It is widely accepted that medicine requires complex and highly specialized information 
technology systems 
299
. This complexity has led to the development and use of a variety of 
diverse health information systems that often address the needs of small units within a larger 
organization.  The concept of seamless interoperability rests at the center of all this.  
―Interoperability is a fundamental requirement for ensuring that widespread EMR adoption will 
give us the social and economic benefits that we want‖300. There are three dimensions to 
interoperability, which include:  
 Business Interoperability focuses on organizational context such as policies, agreed upon 
organizational communication practices. Business Interoperability is independent of 
existing technologies.  
 Technical Interoperability tolerates heterogeneity in hardware and software but allows 
them to coexist in harmony, in addition to ―Plug-and-play‖ of new devices.  
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 Information Interoperability focuses on the ability to interchange data in a meaningful 
manner through establishment of common semantics 
301
.  
An interoperable healthcare technology system facilitates the ―right information at the right time 
and place‖ and depends on ―systems being able to exchange information in a way that is safe, 
secure, and reliable‖ 302. The concept of interoperability is multifaceted and means something 
different for different individuals. HIMSS Dictionary of Health Information Technology Terms, 
Acronyms, and Organizations lists seventeen different definitions from purely technical to 
definitions that include all the various aspects of interoperability such as technical, social, 
political, and organizational. A widely used definition has defined interoperability  as the ―ability 
of two or more systems or components to exchange information and to use the information that 
has been exchanged‖303. There are three main components to this definition: (i) the exchange of 
information (technical interpretability), (ii) the ability of recipient to use that information 
(semantic interoperability), and (iii) the actual use of the information (process interoperability).  
Each of the three types carries a same weight as the other two. Because of the interdependency 
among them, all the dimensions must be present to deliver significant business benefits
304
.  
 
Although significant funds have been allocated to address problems of interoperability, the 
efforts have been largely unsuccessful 
293
. Interoperability is beneficial, but certainly not easy to 
achieve. This is because patient health records contain an extensive set of diverse data and 
information types, ranging from family history, social habits, diagnostic tests, clinician 
assessments, medical history, care interventions and treatment plans. As hospitals introduce new 
workflows and technology capabilities to support increasing numbers of clinical quality 
measures, they face numerous challenges around discrete data capture, data quality and 
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standardization, including accuracy, integrity, searchability, completeness, quality, redundancy 
and consistency, and misaligned, or non-existent incentives 
305,306
.  
 
Some of the high-level barriers that slow down attempts to achieve interoperability include:  
 Limited syntactic interoperability, different systems represent the same data in different 
ways 
307
; 
 Limited ability to capture clinical notes, discharge summaries, administrative 
information, etc. in an structured format 
308
; 
 Poor quality of data, which includes redundancy, duplication and incompleteness of data, 
as well as multiple listings of the same data. Poor data quality hinders analyses and 
creates lack of trust in users.  In addition, correcting for poor quality data is both time- 
and resource-intensive undertake, which puts further pressure on already strained 
healthcare intuitions 
309
;  
 Difficulty in employment of standards in health information technology. There is a 
significant need for consensus in the use of standards in the healthcare industry. Types of 
standards include: 
o  Standards for data exchange and messaging (to allow transactions to flow 
consistently between systems or organization using instructions for structure, 
format, and data elements); 
o  Clinical terminology standards (use of ontologies to provide specific codes for 
clinical concepts); 
o  Document standards (define for every documents what information must be 
included and where they must be found);  
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o Conceptual standards (allow data to be transported from one system to another 
without losing meaning or context); 
o Application standards (the manner in which business rules are implemented and 
various software systems interact); 
o Architecture standards (to define processes in data storage and distributions). 
Although, there have been various initiatives and efforts to develop standards, there has been a 
lack of effort and buy-in for deployment and effective use of those standards
310
. The issue of 
standards on its own greatly hinders attempts for interoperability.  
Other factors hamper interoperability efforts including: 
 Lack of cooperation between health information system vendors, as vendors may feel 
siloed solutions are more beneficial to their bottom line 
311
. Vendors have not been 
incentivized to enable sharing of health information across vendor boundaries. As an 
example, EHR vendors have been focused on promotion of information sharing only 
through their monolithic systems as opposed to supporting interoperability standards 
306
.   
 Failure among providers and across organizations to share their data with each other, or 
share the connection burden and costs 
312
. 
 Vendor resistance to initiatives, as the experts question the effectiveness of meaningful 
use incentives in spurring efforts to achieve interoperability. This has led to speculation 
that EHR and other solution vendors are purposefully stalling because it is not in their 
best interest to achieve interoperability yet 
311
. Such speculation bolsters the idea that 
interoperability is not just a technical issue, but also a political, economic and even social 
one.  
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Other complexities of interoperability pertain to the dynamic nature of patient health records, the 
rapid accumulation of patient data, and the limited or lack of availability of information in a 
meaningful manner at the critical point of care for decision making.  
 
The Affordable Care Act‘s meaningful use incentives are still  in the ―carrot‖ phase, which 
encourages and simultaneously forces health care organizations to potentially over-commit and 
invest multi-million dollars on the implementation of a single EHR system to achieve the 
mandated criteria, with the knowledge that interoperability remains a chief concern 
313
.  As a 
result of the lack of interoperability, widespread adoption of EHR systems has exacerbated the 
problems of information silos and the fragmentation of patient data and care delivery which exist 
today. The ―stick‖ phase begins after 2015 and will affect healthcare organizations if they are 
unable to generate and report complete patient quality measure outcomes, due to the 
heterogeneity of the healthcare environment, disparate health information systems, and 
fragmented patient data. This will potentially result in a significant financial impact 
313
 for 
healthcare institutions. The push for healthcare organizations, hospitals, clinics, and physicians 
to collaborate more closely to form an accountable care organizations may have unintentionally 
created an atmosphere for slowing down cross-vendor interoperability efforts, as vendors use 
these initiatives to further strengthen their sales pitch and push healthcare organization to buy-in 
to monolithic systems 
313
. Until healthcare reform initiatives properly incentivize vendors, 
healthcare institutions, and providers, and until vendors and providers are willing to extend their 
boundaries and share the responsibility of interoperability, health information exchange will 
likely continue to progress slowly and will negatively impact continuity of care, quality of 
patient care, and cost of healthcare 
313
. These unintended consequences have potentially slowed 
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down interoperability efforts. Without a complete and seamless interoperable environment, the 
great promise of seamless patient health records will not be achieved.  
 
2.1.9. Healthcare Silos 
―Healthcare is not a system but a set of independent actions and activities that often have little or 
no continuity. One reason for this lack of continuity is the silos that exist within the healthcare 
environment‖314. The information silos are part of organizational culture and a way of thinking. 
In a siloed organizational structure, departments generally do not share the same priorities, goals, 
and even the same tools and information technology solutions 
315
. Each department operates as 
an individual unit or entity within a healthcare enterprise, with different priorities, 
responsibilities and vision 
316
. For many years this model worked well, as there was limited need 
to communicate with other departments, with healthcare providers within the hospital, or across 
healthcare institutions 
316
. As a result of siloed organizational structures, information gathering, 
processing, communication, and management have also been operating in an insular manner 
317
. 
Although health information systems have been essential to health care delivery, they have been 
incapable of reciprocal operations with other related information systems 
317
.  As a result of this 
culture, ―the health care sector as a whole has historically trailed far behind most other industries 
in investments in information and communications technologies‖ 317,318. Most healthcare related 
information technologies and communication investments have been concentrated on the 
administrative and business side of the healthcare, rather than on the clinical side. Until recently 
because of this ―prolonged under-investment, little overall progress has been made toward 
meeting the information needs of patients, providers, hospitals, clinics, and the broad regulatory, 
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financial, and research environment in which they operate‖ 317. Healthcare systems are comprises 
of a variety of databases that have been designed and built separately for different applications 
with no common data model constructs. This makes communications across databases very 
cumbersome. ―Communication between people using databases is not the same as 
communication among people, which is adequately handled by natural language and 
mathematics. Nor is it the same as communication between people and computers which is 
adequately handled by computer programming language.  Communication across databases 
requires a very different type of language, one that addresses data meaning using functional data 
classification and a finite number of relations. Without the use of a data language, 
comprehensive person to person communication via databases is extremely limited and true 
system integration is virtually impossible‖319. Organizational structures, disparate health 
information systems, data integration barriers, and lack of or limited health information systems 
interoperability create silos at many different levels within and across healthcare institutions 
resulting in fragmented care delivery systems. 
 
2.1.10. Central Role of Analytics in Healthcare 
Data analytics and continuous audits are not new concepts. Their appeal and vitality are on the 
rise in the healthcare industry as it transitions from volume-based business to a value-based 
business. ―With increasing demands from consumers for enhanced healthcare quality and 
increased value, healthcare providers and payers are under pressure to deliver better outcomes‖ 
67
. Clinical and healthcare organizational data have a vast potential and broad range of uses, from 
service line profitability, patient quality of care, and outcome analysis, to claims and revenue 
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cycle management and utilization. Building analytics competencies can help organizations 
harness ―big data‖ providing critical insights in order to make assessments, meet organizational 
goals and achieve competitive advantage 
320
. Analytics will be central in demonstrating value 
and achieving better outcomes by using new treatments and technologies, and refining outdated 
practices.  Analytics can improve effectiveness and efficiency in numerous ways by managing 
small details as well as large processes, aiding in exploration and discovery, helping policy and 
program design and planning, improving healthcare service delivery and operations, enhancing 
sustainability, mitigating risk; and providing a means for measuring and evaluating critical 
organizational data 
67
. Healthcare organizations increasingly use analytics to consume, unlock 
and apply new insights gained from their information.  
 
According to a survey report by HIMSS
321
, healthcare organizations choose to report on the 
following types of information: 
 Data that they are required to track by the government or other external organizations 
 Data that has the potential to significantly reduce costs and enhance their ability to reduce 
the inventory of high-cost products;  
 Information that is required for recertification of professional staff.  
Although healthcare institutions reside in a rich data environment, the healthcare industry lags 
far behind in analytical capabilities because of the diversity and disparity among health 
information systems and the challenges associated with interoperability and integration of the 
various systems, lack and/or limited use of standards, and the use of different data types, data 
models, and information. Performing analytics on data that is collected and aggregated using a 
single health information system may not be as cumbersome. The difficulty comes with analytics 
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that aim to examine heterogeneous data from multiple diverse source systems. This type of 
analytics requires aggregation of patient data from multiple health information systems, data 
such as admission and discharge records, patients‘ vitals, laboratory tests, patient medical 
history, immunizations, family history, life style, physical exams, diagnoses, progress notes, 
operative reports, ambulatory care, care plan, medication report, etc. in conjunction with 
administrative data.  
 
A 2010 report by Healthcare Information and Management Systems Society (HIMSS) has 
identified a number of barriers and challenges that impact efforts to effectively perform analytics 
on clinical and administrative data across multiple source systems and data warehouses 
322
. The 
following issues are in addition to interoperability and integration challenges indicated in 
previous sections and they include
322
:  
 Static reporting of data and information, which is mostly done in a paper format. These 
types of reports do not allow the recipient to manipulate data and the information.  
Analysis of paper reports requires extensive data re-entry for manipulation purposes in 
order to yield a satisfactory layout.  
 The assumption that electronically housed data is analysis ready. Data storage, 
transformation, and governance are required prior to any analysis.  
 Limited or lack of access to data elements thatare required for analysis. These types of  
data elements may be  captured in an alternate format that is not streamlined into the 
main data collection tool (e.g. lab values captured at a different site), which requires data 
to be either entered manually or omitted from the overall analysis.  
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 Unstructured or free-form of data capture. These types of data require human curation 
and conversion to a discrete or structured field, in order to be used for analysis.  
 Required expertise. Apple-to-apple results that include many different variables are 
challenging and requires skills and expertise to understand what is being measured and 
why. Additionally, it is also important to understand the clinical context of a particular 
data point, and how the different clinical scenarios can impact that data point. There are 
also issues with nomenclature, and ensuring that data is captured using the same 
terminology (e.g. data normalization and semantic interoperability).  
 Limited and/or lack of skilled personal with combination of technical, statistical, and 
clinical background to analyze the data that is required for evaluation. There are further 
constraints not only because healthcare organizations lack the financial resources to hire 
additional personnel, but also because it can be difficult to find individuals who possess 
the right skills for the job. As a result, some organizations are turning to external 
resources to meet these needs
321
. Many healthcare institutions rely on different 
technological solutions to meet their analytics need with dependence on limited 
information technology resources and solutions vendors to develop reports and tools in 
order to effectively analyze clinical data. Others are turning to niche vendors that 
specialize in the development of data warehouses or data mining to assist in different 
types of analysis 
321
.  To date, the  majority of the specialized reports are in a form of 
managed static reports, which prevent the end user from manipulating the information for 
better understanding or further analysis 
67
. Every question or a small change to the reports 
requires involvement of technical personal and waiting for extended periods of time.  
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2.1.11. Current Use and Challenges of Clinical Analytics 
A research report by the MIT Sloan Management Review, in partnership with the IBM Institute 
for Business Value defined three specific analytics capability segments among healthcare 
organizations including: aspirational, experienced, and transformed 
323
. Each of the three 
segments has its own set of challenges and opportunities: 
 Aspirational: ―These organizations are the farthest from achieving their desired analytical 
goals. Often they are focusing on efficiency or automation of existing processes, and 
searching for ways to cut costs. Aspirational organizations currently have few of the 
necessary building blocks – people, processes or tools – to collect, understand, 
incorporate or act on analytic insights 
323‖. 
 Experienced: ―Having gained some analytic experience – often through successes with 
efficiencies at the Aspirational phase – these organizations are looking to go beyond cost 
management. Experienced organizations are developing better ways to effectively collect 
incorporate and act on analytics so they can begin to optimize their organizations 
323‖. 
 Transformed: ―These organizations have substantial experience using analytics across a 
broad range of functions. They use analytics as a competitive differentiator and are 
already adept at organizing people, processes and tools to optimize and differentiate. 
Transformed organizations are less focused on cutting costs than aspirational and 
experienced organizations, possibly having already automated their operations through 
effective use of insights. They are most focused on driving customer profitability and 
making targeted investments in niche analytics as they keep pushing the organizational 
envelope ― 323. 
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On the analytics sophistication spectrum, the study showed 35 percent of 116 healthcare 
organizations in the United States are in the aspirational segment (with the following 
characteristics: new or limited users of analytics, focused on analytics at point-of-need, and turn 
to analytics for ways to cut costs), 45 percent are in the experienced segment (established users 
of analytics, seek to grow revenue with focus on cost efficiencies, and seek to expand ability 
share information and insights), and only 16 percent are in the transformed segment (use of 
analytics is the cultural norm, highest levels of analytics prowess and experience, seek to target 
revenue growth, and feel the most pressure to do more with analytics) 
323
. The future demands 
that healthcare organizations focus on the biggest and highest value opportunities and within 
each opportunity, to start with questions, not data, and embed insights to drive actions and 
deliver value, and keeping existing capabilities while adding new ones 
67,323
.  
2.1.12. Physician Performance Measure and Reporting  
In 2001, a report by the Institute of Medicine encouraged healthcare organizations and 
purchasers to implement policies to increase the likelihood for delivery of ―safe, effective, 
patient-centered, timely, efficient, and equitable‖ care 324. In 2010, the enactment of ACA has 
changed the practice of the healthcare industry from volume-based to value-based healthcare 
delivery, and with it changed the physician reimbursement model
325
. The recent changes are 
transforming the context in which physicians and other healthcare providers deliver care 
104. ―A 
key strategy on the policy agenda is advancing performance measurement at all levels of the 
healthcare system, and in particular, at the physician level where there is substantial unexplained 
variation in practice that leads to poor quality, inefficient delivery of care, and wasteful spending 
on care. Physician performance measurement, including both quality and cost-efficiency, is an 
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important vehicle stimulating improvements in quality and costs of delivering care‖ 326. In order 
to move the physician measurement and reporting initiative forward, continued development of 
evidence-based quality assessment measures must be developed in a broader and deeper array of 
clinical conditions, medical specialties and medical procedures. Efforts are underway nationally, 
by CMS, as well as regionally by many private payers to develop reporting and payment systems 
that support and reward quality and the efficient delivery of care 
326
. Measurement of physician 
quality performance has become increasingly important for health plans as the basis for quality 
improvement, network design, and financial incentives 
327,328
.  
 
2.1.13. Need for Data Integration and Analytics to Assess Physician Performance  
The shift to reimbursement based on performance is spurring new ways to assess physician 
practices and performance. The shift requires use of data analytics capabilities to generate 
meaningful insights about physician performance. Analytics capabilities provide a feedback 
mechanism to evaluate changes in practice and to provide a deeper understanding of physicians‘ 
decisions through quantification and assessment of trends. Reporting on compliance to best-
practice guidelines and high level metrics alone is insufficient.  An analytics framework is 
essential in evaluating changes directly impacted by various initiatives (i.e. best-practice 
guidelines, education, incentives, etc.), identifying new areas for improvement, and avoiding 
unintended consequences and outcomes. 
 
A key component of analytics capability is data integration, which is the capture, cleansing, 
storage, and linkage of data from clinical and financial sources 
329
. A complete data integration 
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solution encompasses discovery, cleansing, monitoring, transforming, and delivery of data from 
variety of sources 
330
. Data integration is the combination of technical and business processes 
used to combine data from disparate sources into meaningful and valuable information
330
. There 
are significant barriers to achieving data integration and conducting analytics on quality 
improvement and patient outcomes. Some of the barriers are:  
 The variation that exists in the study of clinical data. There is variation depending on the 
complexity of the protocol, the design of an individual study and the method of data 
collection. This prevents standardization of approaches to data integration from multiple 
disparate source systems. 
 Difficulty in meaningful integration of clinical data because of the variance of semantics 
for different contexts. 
 Lack of standardization and the unstructured nature of the significant portion of clinical 
data which necessitate complex transformations at different phases. This poses a hurdle 
for auditability of data for regulatory and compliance purposes. 
 Interfacing disparate systems requires extensive integration exercises that turn into large 
projects and require significant resources. 
 Diverse systems are used at different phases of clinical data life-cycles because individual 
systems are usually put in place to fulfill a specific business need 
296,305,331-333
. Individual 
systems are combinations of home grown and commercial products from multiple 
vendors, which significantly adds to the complexity of the integration process. 
A 2013 report by the Health Initiative and the College of Healthcare Information Management 
Executives focused on the state of health analytics in the area of improving quality and lowering 
cost. The survey group included 102 organizations and was comprised of hospitals (37%), 
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integrated delivery networks (33%), academic medical centers (13%), and others (11%). The 
study examined attitudes toward data use, trends in business use cases for data and analytics, 
technological solutions employed by organizations, and  associated challenges and barriers 
334
. 
―Respondents‘ attitudes toward data and analytics reflect a common understanding of the 
potential impact and benefits of using data and analytics to help drive organizational decision-
making and action. A large majority (82%) indicated that bi-directional sharing of clinical and/or 
patient data with local healthcare organizations is important or very important to their 
organization. It is likely that increased pressure to meet data sharing requirements under the 
federal EHR Incentive Program has contributed to this belief. Additionally, nearly 80 percent of 
respondents felt that leveraging big data and predictive analytics is important to their 
organization‘s strategic plans and priorities. However, the reality on the ground may not match 
the desires of respondents. Eighty-four percent believe that the application of big data and 
predictive analytics is a significant challenge for their organization‖334 due to ―uniqueness and 
complexity of healthcare data‖ 335. ―Only 45 percent of respondents feel that their organization 
has implemented a flexible and scalable plan to adapt to the growing volume, liquidity, and 
availability of electronic health data‖334.  
 
The report 
334,336
 highlighted some of the key analytics applications that were reported by the 
participants, which included: 
 Revenue Cycle Management which focuses on cost reduction. Healthcare institutions are 
closely managing and monitoring their revenue cycle to ensure profitability.  Analytics 
have been utilized to determine patient eligibility, validate coverage, authorize services, 
assess payment risk, manage submissions, and track performance. 
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 Resource Utilization which focuses on ways to concurrently improve patient outcomes 
and reduce costs using finite resources. Analytics have been used to track and manage 
workforce, patient volumes, services, and supply chain.  
 Prevention of Fraud and Abuse which accounts for between 3 and 15 percent of annual 
healthcare expenditures. ―Fraud refers to a calculated misrepresentation of facts aimed at 
convincing payers to process a false claim for financial gain. Similarly, abuse refers to 
neglect of accepted business or medical practices resulting in higher reimbursements. 
While fraud is a willful act, abuse is unintentional. Common forms of fraud and abuse 
include improper coding, billing for services not actually provided, and providing 
unnecessary medical services given the patient‘s condition‖334,337. Analyses of billing and 
claims data assist in identification of ―fraud and abuse by predicting expected service 
utilization and comparing it to actual billing information. Trends and patterns in claims 
data can help organizations create a baseline for behaviors indicative of fraud and abuse 
and further investigate as necessary‖334. 
 
Population Health Management which is one of the important components of new healthcare 
initiatives and the basis for new healthcare delivery models (i.e. ACOs) focused on improving 
outcome for the entire population, rather one individual seeking help. It requires ―organizations 
to define a population, identify gaps in care, stratify risks, engage patients, manage care, and 
measure outcomes‖334,338. Analytics plays a significant role ―given the vast amount of important 
health-related data to consider when caring for an entire population. Data analysis can assist 
healthcare organizations in recognizing populations consuming the most resources or at greatest 
risk for hospital readmissions, enabling them to target high-risk groups to reduce costs and 
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improve outcomes. Analytics can also help identify trends in disease prevalence, determine the 
comparative effectiveness of treatment options, and derive best practices‖334. 
Quality Improvement which focuses on ―broad categories of variations in services, underuse of 
services, overuse of services, misuse of services, and disparities in quality‖334,339. Analytics 
facilitates quality improvement efforts such as utilization and outcome analyses, patient adverse 
outcome reports. Quality improvement has been identified by 88 percent of respondent
334
 as a 
key area of focus.  
 
The key analytics applications reported by the survey highlight the gap that exists in the ability to 
perform analytics on different types of data from disparate health information systems. The 
analytics functions represented in the survey do not require data from various health information 
systems. The reported applications of analytics are mostly focused on extracting data from either 
one or two systems. Revenue Cycle Management, Prevention of Fraud and Abuse, and 
Population Health Management mostly use claims data. Claims data in the healthcare industry is 
known for their cleanliness and completeness. These strengths perfectly counter the limitations 
of clinical data. Some of the characteristics of claims data include: use of diagnosis and 
procedure codes that are standardized nationwide (i.e. ICD-9 and ICD-10 in October 2014); 
incorporation of multiple security levels into coding and claims processes; and automation of 
data cleansing to ensure accuracy. In addition, since healthcare institutions‘ workforce has a 
stake in successful submission of claims, everyone goes to great lengths to continually improve 
accuracy and comprehensiveness of claims before submission. Other robust characteristics of 
claims data is in its shareability, partly due to its structured and standardized format, and partly 
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because of the powerful incentive behind efficient transmission and exchange of the information. 
After all, this is how providers are paid 
340
.  
 
Data integration and analytics challenges are not unique to healthcare and have been encountered 
in other industries. The difference is that the healthcare industry operates in a more 
heterogeneous data ecosystem with different levels of regulations, standardization, and clinical 
intricacy that add to the complexity of matter. Healthcare institutions are tasked to gain greater 
performance and operational efficiencies to unify fragmented clinical processes, quality 
performance, people, projects, and siloed systems in order to drive evidence-based decision 
making. Meanwhile, healthcare payers are demanding evidence of efficacy of treatments before 
authorization of payments. Data and availability of information on the efficacy of various 
interventions is at the heart of evidence-based decision making, and quality of patient outcomes.   
 
2.1.14. Performance Management System  
Performance measures have been described as ―quantifying the efficiency and effectiveness of 
past actions‖ 341. The process involves ―regular collection of data to assess whether the correct 
processes are being performed and desired results are being achieved ―342. Performance measures 
are a significant part of any organizational strategy, planning, and reporting.  They can assist 
healthcare institution executives and heads of hospital departments in reviewing trends in various 
areas, making decisions on how to improve departments based on a broader scope, and refining 
organizational performance. There are many reasons why any healthcare institution must 
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measure performance including: quality improvement, transparency, accreditation and 
participation in financial incentive programs.  
 
Performance Management System (PMS) encompasses multiple components; measure, metric, 
indicator, and key performance indicators. In many organizations, these separate phrases are 
used interchangeably, and/or are merged into a single concept. It is important to highlight the 
fact that each component represents a different notion.  
 Measurement is defined as the act or a process of measuring; a figure, extent, or amount 
obtained by measuring
343
. A result of measuring would be a figure expressing the extent 
or value that was obtained by measuring against a standard. An example of a 
measurement may be ―10 centimeters‖, the centimeter is the standard, and 10 identify 
how many multiples or fractions of the standard are being appraised.  
 Metric is a quantitative measure of the degree to which a system, component, or process 
possesses a given attribute
344
. Metric is a calculated or composite indicator based on two 
or more measures. It presents a trend. As an example recording hourly body temperature 
provides a trend on whether the temperature is remaining constant, increasing, or 
decreasing. Metric is a comparison of two or more measures.  
 Indicator is an entity that provides insight on process improvement activities concerning 
goal attainments. An example is body temperature of 99.1 degrees Fahrenheit as 
compared to normal body temperature of 98.6 degree Fahrenheit. Indicator is a device or 
variable that can be set to a prescribed state based on the results of a process or the 
occurrence of a specified condition
344
. An indicator generally compares a metric with a 
baseline or expected result.  
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 Key performance indicators are indicators that are very specific. They are measureable 
values that demonstrate the effectiveness of a process that is contributing to the 
attainment of a single organizational key objective. Performance measures are used in a 
type of analytical approach that provides information about key aspects of activities, e.g. 
in transfusion medicine, the appropriateness of transfusion. They drive the results of the 
key activities in an evidence-based program. Analytical processes must be applied to the 
measures. Clinical analytics can be classified into two categories of retrospective 
(looking back) and prospective (looking forward) measures. ―Performance measures are 
typically considered retrospective analyses; it requires aggregation and analysis of data 
and information on a performed task over an extended period of time‖345. Performance 
measures are categorized based on whether they analyze an input or am output of a care 
process. Types of performance measures include 
345
: 
 Resource and Efficiency Measures: track specific resources used, such as red 
blood cell, platelet, plasma etc.  
 Process Measures: track the level of compliance with specific guideline or 
standards, for example order of red blood cell transfusion based on a pre-
transfusion lab value (i.e. hemoglobin level). 
 Structural Measures: track information about how a care delivery system operates 
for example number of transfusions performed by a physician. 
 Outcome Measures: track the impact of a particular intervention, such as 
transfusion on patient‘s health (e.g. review of patient days – ―a unit in the system 
of accounting used by healthcare facilities and healthcare planners. Each day 
represents a unit of time during which the services of the institution or facility are 
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used by a patient 
346‖; meaning 100 patients in a hospital for 1 day would be 
represented as 100 patient days.  
 Patient Experience Measures: are based on surveys conducted from patients to 
track perception and satisfaction for the level of care received.  
 
Characteristics of a robust PMS include: strategic support; holistic view of progress through 
quantitative and qualitative perspectives; incorporation of the needs and activities of decision-
makers; mechanism for routine and timely reports on progress; detailed attention to accuracy of 
data; calculation of measure in reporting the information; and consistency and feasibility in 
visual presentation of information back to stakeholders
347
. To implement an evidence-based 
PMS, identification of metrics, indicators, and key performance indicators is required in order to 
qualitatively or quantitatively measure the past, and conduct historical analysis to forecast 
potential future outcomes 
348
. The various measures can portray a snapshot of pre-defined 
standards established according to the evidence. Through utilization of the PMS, the success of a 
project, program, department, or an organization can be defined and evaluated. Metrics provide a 
way for trend analyses. Key performance indicators provide actionable metrics that can be used 
to increase the effectiveness and efficiency of operations 
348
, directly associating organizational 
strategic plans with performance. Key performance indicators differ from other measures. They 
are very specific measures that highlight aspects of performance that directly tie strategic 
objectives to operational routine (i.e. physicians practice). Therefore, they are integral in 
providing insights on the level of performance and progress and in determining whether 
improvements are necessary.  
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2.2. Application of New Strategies to Transfusion Medicine Practice 
Human error is a nearly constant component of human involvement in any complicated task 
349
. 
Patient safety is defined as ―freedom from accidental or preventable harm due to events 
occurring in the healthcare setting‖350. Healthcare industry and healthcare providers aim to 
reduce, if not prevent, medical errors and adverse outcomes. However, studies 
180,351-353
 
performed from various perspective has shown medical errors are a serious problem 
350
, which 
involves multiple areas including human factors and systems engineering 
354
. In clinical and 
laboratory medicine, considerable time and expense is invested in institution of policies and 
procedures, to include detailed and often redundant patient and specimen identification and test 
result verification, with the specific purpose of minimizing human error 
349
. However, despite 
such intensive measures, ―human errors continue to occur at a seemingly irreducibly small rate in 
medical practices, sometimes with catastrophic results‖349. Transfusion medicine, with its 
intricacies is unique among clinical laboratory services in that the end result is the delivery of a 
biologic product that may be both lifesaving and capable of causing death 
349
. The production 
and delivery of blood products involves many people in several different areas of the hospital. 
Error prevention and patient safety in transfusion medicine have been a serious concern 
355
. 
There are numerous steps involved in transfusion of a blood product, including physician orders, 
patient identification for specimen collection by nursing or phlebotomy staff, blood bank work-
up, product selection and issue, patient identification for transfusion, and, ultimately, the 
administration of the blood products to the patient by nursing or physician staff 
349
.  Thus, errors 
can and do occur at any step in transfusion and any point along the way 
355
. Haemovigilance 
systems have emerged in the global transfusion community with the ultimate goal of improving 
the patient experience and outcome in blood transfusion 
356
. Haemovigilance is required to 
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―identify and prevent occurrence or recurrence of transfusion related unwanted events, to 
increase the safety, efficacy and efficiency of blood transfusion, covering all activities of the 
transfusion chain from donor to recipient‖ 357. To incorporate haemovigilance into practice, it is 
necessary to incorporate information gained from the investigations and analyses to facilitate 
corrective and preventive actions in order to minimize the potential risks associated with safety 
and quality in transfusion of blood products. Such information is key to introducing required 
changes in the applicable policies, improving standards, systems and processes, assisting in the 
formulation of guidelines, and increasing the safety and quality of the entire process from 
donation to transfusion 
357
. 
2.2.1. Economics of Transfusion  
Transfusion of blood products, which includes whole blood, red blood cells, platelets, plasma 
and cryoprecipitate, is a critical part of clinical care. In the United States, an estimated five 
million patients receive transfusion of blood products annually, which results in 14.5 million 
transfusions per year 
159,160,358
.  In a 2010 statistical report by Agency for Healthcare and Quality 
(AHRQ), blood transfusion is among the top ten prominent coded procedures in the United 
States hospital discharge records. The cost of transfusion accounts for ten to fifteen billion 
dollars annually 
132
.   According to a recent study 
21
 on the cost analysis of blood transfusion, the 
actual cost of red blood cell transfusion is 37 percent higher than previously estimated. The 
under-representation in the cost of red blood cell transfusion is a result of an incomplete 
accounting of required healthcare resources and associated activity-based costs
21
. These factors 
include but are not limited to, donor recruitment and qualification, blood collection, processing, 
laboratory testing, transportation, storage, pre-transfusion preparation, transfusion administration 
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and follow-up, and long-term tracking of patient outcome 
133-135
. The underestimation in cost of 
red blood cell transfusion has the potential to misdirect program-based and strategic decision 
making. In addition, it has the potential to negatively affect allocation of monitory resources and 
cost of care calculation.  A study by Goodman et al 
359
 states that ―nearly half of transfusion 
recipients in the United States are Medicare beneficiaries, and Medicare's prospective payment 
system is said to substantially under-reimburse hospitals for the costs associated with 
transfusions.‖ The ability of Medicare Prospective Payment System (MPPS) to accurately 
reimburse hospitals is dependent on the quality of cost and charge data that are reported to 
Medicare by the hospitals 
133,359-361
. Lack of consensus on the underlying complexity around 
factors associated with blood transfusion has resulted in insufficient reporting of data by the 
hospitals 
362
. Consequently, the insufficiency in reported data propagates inadequate accounting 
for the cost, resulting in under-representation of the accurate cost of blood transfusion, which in 
turn results in insufficient reimbursement of hospitals for the provided care. 
 
2.2.2. Current View Points on Transfusion of Blood Products 
Transfusion of blood and blood components has been a routine practice for more than half a 
century. The rationale behind transfusion of blood products assumes that the replacement of 
blood loss should be beneficial for the patient 
363
. This assumption has constituted the 
underpinning of transfusion medicine for many decades 
363
. Although transfusion blood and 
blood components has been a lifesaving procedure and a routine practice for more than half a 
century, it is not without risks 
364
.  It has been only over the past 20 years that we have seen a 
more concerted effort to answer very basic questions regarding the value of transfusion therapy. 
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As commonly transfusions occur in the United States, one may assume physicians practice 
transfusion medicine based on strict standard guidelines. However, broad variation exists 
regarding what type of blood components to transfuse, how much to transfuse and whether to 
administer transfusion at all 
152
.  There has been a debate in medical literature concerning the 
appropriate use of blood components and indications for transfusion of blood and blood products 
364
. In a statement by Dr. Jeffrey McCullough, American Red Cross Transfusion Medicine Chair, 
author of Transfusion Medicine, ―If red blood cells were a new drug today, it would be very 
difficult to get it licensed.‖ In a different statement by the Director of Transfusion Medicine at 
the University of Rochester Medical Center ―For 100 years we‘ve assumed blood transfusion are 
good for people, but most of these clinical practices grew before we had the research to support 
it. The current transfusion triggers were established over sixty years ago at the time when 
transfusion medicine was still in its infancy.‖ Over the past ten years scientific studies have 
highlighted the overuse of blood transfusion based on outdated transfusion triggers and practice 
guidelines 
140,141,365
. Over the past twenty years, a growing number of single center and 
multicenter randomized controlled clinical trial investigations have been published to ―answer 
very basic questions regarding the value of transfusion therapy‖363. The studies are designed in 
an effort to optimize transfusion practices, determine appropriate transfusion indications and 
develop the necessary knowledge base to assess the impact of transfusion practice on patient 
outcomes. 
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2.2.3. Complexities Surrounding Blood Transfusion 
Blood transfusion is a medical treatment for replacement of blood lost during surgeries, in 
serious injuries, and with critically and chronically ill patients 
140
. Blood transfusion is performed 
with the intention of increasing arterial oxygen content in order to sustain oxygen delivery to the 
tissues. Blood transfusion has ―undoubtedly been proven effective in many medical and surgical 
conditions, thereby particularly improving the survival of patients with critical impairment of 
tissue oxygenation‖ 366. Although blood transfusion is a common and a life-saving procedure, 
there are serious risks associated with it 
158
. Transfusion reaction is defined as any adverse event 
or complication that occurs in relation to the transfusion of a blood component 
152
. Historically, 
infections were considered the main risk but because of the abundant donor testing and thorough 
donor screening, the risk of acquired infectious diseases through blood transfusion has been 
extremely low 
171,367
. The major concern now is the non-infectious complications of blood 
transfusion which significantly contribute to adverse patient outcomes, many of which are a 
result of human errors and thus may be preventable or reduced 
16,179,368
. In the field of transfusion 
medicine, controversy exists relative to when to transfuse, what blood or blood product to 
transfuse, and how much to transfuse.   
 
2.2.4. Infectious Complications 
Transfusion-transmitted infections may occur through countless numbers of agents that are 
transmitted to the recipient though transfusion of donated blood. These include bacteria, viruses, 
and parasites. A study by Maxwell and Wilson showed 
369
 ―Bacterial contamination of blood 
components is an infrequent complication of transfusion. However, if it does occur, the potential 
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for fulminant sepsis in the recipient is associated with high mortality.‖ This can result from 
contamination during venipuncture or if an asymptomatic donor was bacteraemic at the time of 
donation. Symptoms can occur during or shortly after transfusion of the contaminated unit 
369,370
. 
Red blood cells are stored at 4
o
C. At this temperature, contamination of Gram-negative bacteria, 
such are Yersinia enterocolitica and Pseudomonas species are more likely as they proliferate 
rapidly in this environment. Gram-negative bacteria cause infections such as pneumonia, 
bloodstream infections, wound or surgical site infection, and meningitis 
371
. At room temperature 
Gram-positive bacteria such as Staphylococcus epidermidis, Staphylococcus aureus and 
Bacillus species proliferate rapidly. These are the most common bacterial contaminants of blood 
products. Gram-positive bacteria exist on skin flora and are transmitted to collected blood 
through collection needles
371
. Platelets are stored at 25
o
C, thus Gram-positive contaminations are 
more commonly observed in platelets 
369,370
. Another bacterial infection is Anaplasmosis which 
is caused by Anaplasma phagocytophilum which is transmitted to humans by tick bites
371
.  
 
Transfusion related viral infections have been greatly reduced since the mid-1980s, as result of 
the implementation of pre-donation questionnaires to identify high risk behaviors and pre-
transfusion testing of donated blood. Examples of viral diseases that may be transmitted through 
transfusion include: Human Immunodeficiency Virus (HIV), Hepatitis A, B, and C, Human T—
Lymphotropic Virus (HTLV I/II), Cytomegalovirus (CMV), West Nile virus, and Dengue Fever 
371. The transmission of these diseases may occur in the ―window period‖, which is defined as 
―the time after infection when the donor is infectious, but screening tests are negative‖ 369,372.  
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Transmission of parasitic diseases transmitted through blood donations is rare 
373
. To determine 
the existence of these parasitic infections, donors are asked a series of questions about recent 
travel to areas where infections are more common. Examples of parasitic disease include: 
Babesiosis, Chagas Disease, Leshmaniasis, and Malaria. Prion diseases that are transmitted 
through blood transfusion include Transmissible Spongiform Encephalopathies, ―a family of rare 
progressive neurodegenerative disorders that affect both humans and animals‖ 371 and variant 
Creutzfeldt-Jakob Disease, a rare ―rapidly progressing neurological disease that causes dementia 
and death‖371.  
 
Studies 
374-376
 have shown transfusion reactions are under-diagnosed and under-reported in the 
United States. Even though the blood supply in the United States is relatively safe because the 
Food and Drug Administration Center (FDA) for Biologics Evaluation and Research regulates 
and safeguards the collection of blood and blood components against the infections, 
complications of transfusion remain a threat. 
 
2.2.5. Non-Infectious Complications 
According to Goodnough and Shander 
158
, allogenic transfusion may have both a suppressive and 
stimulatory effect on the immune system. These effects have been referred to as 
―immunomodulation‖.  Recently immunomodulatory effects have been a major concern and the 
common cause of transfusion related non-infectious complications. Leukocyte mediated 
transfusion-related immunomodulation has been correlated an with increased rate of cancer 
recurrence and post-operative infections. Transfusion errors have been estimated to occur with a 
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ratio of 1:30,000 units transfused 
377
. Hemolytic reaction remains a leading cause of fatal 
transfusion reaction which occurs as a result of ABO-incompatible blood transfusion.  Another 
transfusion error is caused by the ―issue of donor blood to patients from whom autologous blood 
is available‖ 378. Alloimmunization is more common in patients who receive multiple 
transfusions e.g. Sickle Cell Disease patients. The multiple transfusions result in the introduction 
of new antigen variants into the body. The new antigens may stimulate the immune system to 
produce alloantibodies against minor blood 
158
. Alloimmunization to platelets may be caused by 
a large number of heterogeneous antigens, thus ―transfusion of patient with preformed 
alloantibodies against that antigen (due to sensitization in previous transfusions) may result in 
delayed hemolytic reaction which has been estimated in a range of 1:1000 to 1:9000 
transfusions‖ 158,379. Transfusion associated graft versus host disease (TA-GVHD) is another 
complication. In ‗TA-GVHD, immune-competent HLA-incompatible donor lymphocytes are 
transfused to a recipient who is immunologically incapable of eliminating them‖ 158,380. The 
donor lymphocytes then generate an immune response against the host cells. Transfusion Related 
Acute Lung Injury (TRALI) occurs within six hours of transfusion. It is ―characterized by the 
acute onset of respiratory distress, bilateral pulmonary edema, fever, tachycardia, and 
hypotension in the presence of normal cardiac function‖ 158,381 as a result of increased vascular 
permeability. Transfusion Associated Circulatory Overload (TACO) is also characterized by 
pulmonary edema and respiratory distress. This is caused by increased central venous pressure 
and pulmonary blood volume, resulting in fluid extravasation into alveolar space. TACO is 
estimated to occur from 1:3000 to as many as 1:10 transfusions 
158,381
. Febrile Non-Haemolytic 
Transfusion Reactions (FNHTR) are the ―most common cause of transfusion-associated fever 
which occurs in 0.1 to 1 percent of red blood cell transfusions. Other causes of transfusion 
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associated fevers include: allergic reactions, hemolytic reactions, bacterial contamination, 
cytokine-medicated, TRALI, and HLA alloimmunization‖158 in febrile patients. Stored blood 
undergoes morphologic changes, which results in the cells becoming more rigid and less pliable. 
Although scientific evidence remains contradictory in this area, retrospective studies have 
reported an increased rate of adverse clinical outcomes and a reduction in survival with 
transfusion of older blood units (greater than 14 days) 
158,382-388
.   
 
2.2.6. Transfusion of Blood Products: Reactions and Fatalities  
In a report by the American Association of Blood Banks and the Department of Health and 
Human Services in the United States, 14.65 million whole blood and red blood cells, 4.0 million 
fresh frozen plasma, and 1.7 million platelet doses are transfused annually 
389
. Although 
transfusion-related fatalities have been significantly reduced, both transfusion reactions and 
fatalities still do occur and laboratories are required to report them directly to regulatory 
agencies
390
. Transfusion-related adverse events, both short- and long-term, are among the 
costliest contributors to health care expenditures 
391
. Costs associated with the long-term 
consequences of the adverse effects of transfusion are among the hardest to quantify 
135,392-397
. 
―Despite the increasing cost of blood, transfusion practices remain quite liberal135‖ , varies  
widely in a single institution among individual physicians 
398
 and from institution to institution 
144
,  and are often inappropriate
185
 
399-401
 
 
In the 2011 report by the Nationwide Blood Collection and Utilization Survey 
375
,  267 
transfusion-related fatalities were reported to FDA between fiscal year 2005 and 2009 
376
. 
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Additionally, from October 1, 2010 through September 30, 2011, FDA received a total of 79 
fatality reports 
159
. Of these, 69 were determined to be transfusion recipient fatalities and 10 were 
deemed to be post-donation fatalities
402,403
. The percent breakdown of the 69 transfusion 
recipient fatalities include: 43 percent were transfusion related; 41 percent were cases in which 
transfusion could not be ruled out as the cause of death, and 16 percent were unrelated to the 
transfusion 
402
.  An FDA report showed, Transfusion Related Acute Lung Injury (TRALI) was 
the leading cause of reported transfusion fatalities (43%) in recent years, followed by acute 
hemolytic transfusion reactions (23%) 
402,403
. Both of these reactions typically occur as a result of 
human error 
397,404,405
. Complications of Transfusion Associated Circulatory Overload (TACO), 
microbial infection, and anaphylactic reactions each accounted for a smaller number of the 
reported fatalities
159,160
. Most adverse transfusion outcomes are the result of human error 
135,350
. 
Reactions due to human errors are often misdiagnosed or under-reported 
135
. Statistical studies 
indicate in the cases of non-infectious transfusion related reactions, specifically in minor or 
delayed onset of reactions, adverse transfusion outcomes are more likely to be underreported 
406,407
. The misdiagnosis and under-reporting of adverse events is alarming and has the potential 
to increase the number of negative transfusion related outcomes and death on an annual basis. 
Many of these events are potentially preventable.  The estimated percentage of costs attributable 
to inappropriate blood transfusion has been reported to range between 9% and 44% 
220,400
.  
Frequent transfusions have been linked to poorer patient outcomes, including increased patient 
mortality 
220,408
, a higher incidence of nosocomial infections 
409
, multi-organ failure 
410,411
, and 
increased length of hospital and ICU stays 
408,412,413
. Even though the number of reported 
transfusion fatalities in the United States remains small  in comparison to the total number of 
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transfusions 
135
, the medical and legal cost of transfusion related adverse outcomes further 
burdens the fragile healthcare system 
135
. 
 
2.2.7. Scrutiny of Transfusion Indications   
RBC transfusion should be based on the patient‘s clinical condition, hemorrhage treatment need 
and need for improvement of oxygen delivery to tissues 
414
. In a 2011 study, Sharma and a 
colleague defined indications for blood transfusion as acute sickle cell crisis (for stroke 
prevention), acute blood loss of greater than 1,500 milliliter or 30 percent of blood volume, and 
symptomatic anemia 
379
. A restrictive strategy has been defined as transfusion when the 
hemoglobin level falls below 7 g/dL. The aim for conservative or restrictive transfusion practice 
is to achieve a hemoglobin target level of 8-10 g/dL (low transfusion threshold: 7-10 g/dL) 
149,209,415
. Conversely, a liberal strategy has been characterized by transfusion for hemoglobin 
levels below 9 g/dL. The liberal transfusion practice aims to achieve a hemoglobin target level of 
9-12 g/dL (high transfusion threshold: 9-11 g/dL) 
149,183,209
. For more than five decades, a 
hemoglobin level of less than or equal to 10 g/dL(100 gram per deciliter) and a hematocrit level 
less than or equal to 30 percent was accepted as minimum level, and considered a trigger for 
transfusion particularly in surgical settings, regardless of patient's clinical presentation 
244,379,414
 . 
The transfusion trigger, known as ―10/30‖ rule, was first proposed in 1942 and was practiced 
until the 1980‘s 416,417.  Physicians have been practicing the ―10/30‖ rule based on faith and 
tradition rather than on scientific data 
418. Even though ―transfusion at a hemoglobin level of 10 
g/dL is much less common today‖, according to Corwin et al. 218, only 25 percent of red blood 
cell transfusions occur in the range of 7.0 g/dL or less in order to maintain the hemoglobin 
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concentration level between 7.0 and 9.0 g/dL 
205
. The red blood cell transfusion itself is an 
additional independent predictor for adverse outcomes and therefore, has been referred to as the 
―second hit‖ for the recipient 192,419.  The two-hit hypotheses involves two separate components. 
The ―first hit‖ is defined as the underlying patient characteristics 420, which may include ―recent 
surgery, hypoxia, infection, trauma, malignancy, massive transfusion, cardiopulmonary disease, 
or bypass‖ 421,422. These underlying conditions are believed to ―activate the vascular endothelium 
and ultimately result in pulmonary neutrophil priming‖ 421,422. The ―second hit‖ is the 
―transfusion of blood products containing lipids, antibodies, or cytokines that stimulate 
previously primed neutrophils. The result is endothelial cell damage and non-cardiogenic 
pulmonary edema‖ 421,422. Among general complications, blood transfusion leads to higher 
mortality, increased rate of ischemic complications, organ dysfunction, infections, delayed 
wound healing, non-Hodgkin lymphoma, and increased length of hospital stay 
21,126,152,423,424
. 
Numerous transfusions are not required for these adverse outcomes to occur. Studies 
21,126,152,423-
428
  have shown that complications were observed after administration of minimal (i.e. one or 
two) units of blood. The ―decision to transfuse is often made without understanding  the risk and 
benefits of transfusion‖ 429, as a result of the underlying complexities associated with blood 
transfusion for a particular patient. This leads to transfusion practices that vary widely.  
 
Over the past two decades, blood transfusion triggers and utilization have been under 
considerable scrutiny as studies on the efficacy of blood transfusion show poor patient outcomes 
have been correlated with blood transfusion 
181,218,265,430
 .  Recent studies have associated blood 
transfusion with a two to four-fold increased risk of postoperative infections when transfused 
patients are compared with non-transfused cohorts 
18,21,181,245,428,431-434
. A dose-response 
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relationship study by Boucher and Hannon 
435
 showed ―blood transfusions lead to increased 
postoperative infection, higher rates of multisystem organ failure, increased mortality, increased 
mechanical ventilator time, and increased length of stay‖. Other studies 382-388 have highlighted 
decreased immune function – known as transfusion-related immunomodulation effect – in 
patients who have received transfusion although the intensity of the immune response varies 
from person to person.  
 
2.2.8. Evidence-Based Indications for Optimization of RBC Transfusion  
In 1999, a landmark randomized, controlled clinical trial study of stable adults in multicenter 
intensive care units (ICU) by Hébert et al. 
205
 compared hemoglobin levels of patients with 7 
g/dL versus 10 g/dL; and found a ―restrictive strategy of red-cell transfusion and a liberal 
strategy produced equivalent results in critically ill patients‖. The study showed restrictive 
transfusion practices were as effective as the liberal transfusion strategy and demonstrated that 
patients were able to tolerate lower levels of hemoglobin without an increased rate of morbidity 
or mortality. In 2001, Wu and colleagues 
213
 in a retrospective cohort study evaluated the effect 
of blood transfusion in 78,974 Medicare beneficiaries 65 years old or older hospitalized with 
acute myocardial infarction. They determined ―patients with lower hematocrit values on 
admission had higher 30-day mortality rates. Blood transfusion was associated with a reduction 
in 30-day mortality among patients whose hematocrit on admission fell into the categories 
ranging from 5.0 to 24.0 percent (adjusted odds ratio, 0.22; 95 percent confidence interval, 0.11 
to 0.45) to 30.1 to 33.0 percent (adjusted odds ratio, 0.69; 95 percent confidence interval, 0.53 to 
0.89)‖. In 2004, Corwin et al 218 designed a multiple center, observational cohort study of ICU 
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patients in the United States to quantify the incidence of anemia and red blood cell transfusion 
practice in critically ill patients and to examine the relationship of anemia and red blood cell 
transfusions to clinical outcomes. The result showed the ―number of red blood cell transfusions a 
patient received during the study was independently associated with longer ICU and hospital 
lengths of stay and an increase in mortality. Patients who received transfusions also had more 
total complications and were more likely to experience a complication‖ 412. In the same year, an 
international study by Rao and colleagues 
436
 was designed to determine the association 
between blood transfusion and mortality among 24,112 patients (in 3 large international 
trials) with acute coronary syndromes who developed bleeding, anemia, or both during their 
hospital course. The result indicated that ―of the patients included, 2401 (10.0%) underwent at 
least one blood transfusion during their hospitalization. Patients who underwent transfusion were 
older, had more comorbid illness at presentation and had a significantly higher unadjusted rate of 
30-day death (8.00% vs 3.08%; P<.001), myocardial infarction (MI) (25.16% vs 8.16%; P<.001), 
and death/MI (29.24% vs 10.02%; P<.001) compared with patients who did not 
undergo transfusion. In the landmark analysis that included procedures and bleeding 
events, transfusion was associated with a trend toward increased mortality. The predicted 
probability of 30-day death was higher with transfusion at nadir hematocrit values above 25%.‖ 
They concluded ―blood transfusion in the setting of acute coronary syndromes is associated with 
higher mortality, and this relationship persists after adjustment for other predictive factors and 
timing of events‖436. In 2008, Marik and Corwin 181 conducted a systematic review of the 
literature using meta-analysis of observational studies (45 studies, 272,596 patients) to determine 
the association between red blood cell transfusion, and morbidity and mortality in high-risk 
hospitalized patients. Their multivariate analysis of data which corrected for age and illness 
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severity showed, ―in 42 of the 45 studies the risks of RBC transfusion outweighed the benefits. 
The risk was neutral in two studies with the benefits outweighing the risks in a subgroup of a 
single study (elderly patients with an acute myocardial infarction and a hematocrit <30%). 
Seventeen of 18 studies, demonstrated that RBC transfusions were an independent predictor of 
death; the pooled odds ratio (12 studies) was 1.7 (95% confidence interval, 1.4-1.9). Twenty-two 
studies examined the association between RBC transfusion and nosocomial infection. In all these 
studies, blood transfusion was an independent risk factor for infection. The pooled odds ratio 
(nine studies) for developing an infectious complication was 1.8 (95% confidence interval, 1.5-
2.2). RBC transfusions similarly increased the risk of developing multi-organ dysfunction 
syndrome (three studies) and acute respiratory distress syndrome (six studies). The pooled odds 
ratio for developing acute respiratory distress syndrome was 2.5 (95% confidence interval, 1.6-
3.3)‖. Marik and Corwin 181 concluded that ―in adult, intensive care unit, trauma, and surgical 
patients, RBC transfusions are associated with increased morbidity and mortality and therefore, 
current transfusion practices may require reevaluation‖.  
 
In 2010, Hajjar and colleagues 
182
 conducted a prospective, randomized, controlled clinical non-
inferiority trial on patients (n = 502) who underwent cardiac surgery with cardiopulmonary 
bypass in an ICU at a university hospital cardiac surgery referral center in Brazil in order to 
define whether a restrictive perioperative red blood cell transfusion strategy is as safe as a liberal 
strategy in patients undergoing elective cardiac surgery.  The result, ―hemoglobin concentrations 
were maintained at a mean of 10.5 g/dL (95% confidence interval [CI], 10.4-10.6) in the liberal-
strategy group and 9.1 g/dL (95% CI, 9.0-9.2) in the restrictive-strategy group (P < .001). A total 
of 198 of 253 patients (78%) in the liberal-strategy group and 118 of 249 (47%) in the 
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restrictive-strategy group received a blood transfusion (P < .001). Occurrence of the primary end 
point was similar between groups (10% liberal vs 11% restrictive; between-group difference, 1% 
[95% CI, -6% to 4%]; P = .85). Independent of transfusion strategy, the number of transfused 
red blood cell units was an independent risk factor for clinical complications or death at 30 days 
(hazard ratio for each additional unit transfused, 1.2 [95% CI, 1.1-1.4]; P = .002). They 
concluded that the use of a restrictive perioperative transfusion strategy compared with a more 
liberal strategy resulted in non-inferior rates of the combined outcome of 30-day all-cause 
mortality and severe morbidity
182
. In 2013, Villanueva et al 
222
  studied transfusion strategies for 
patients with acute upper gastrointestinal bleeding.  They compared the efficacy and safety of a 
restrictive transfusion strategy with those of a liberal transfusion strategy in 921 patients with 
severe acute upper gastrointestinal bleeding.  Out of a ―total of 225 patients assigned to the 
restrictive strategy (51%), as compared with 61 assigned to the liberal strategy (14%), did not 
receive transfusions (P<0.001). The probability of survival at 6 weeks was higher in the 
restrictive-strategy group than in the liberal-strategy group (95% vs. 91%; hazard ratio for death 
with restrictive strategy, 0.55; 95% confidence interval [CI], 0.33 to 0.92; P=0.02). Bleeding 
occurred in 10% of the patients in the restrictive-strategy group as compared with 16% of the 
patients in the liberal-strategy group (P=0.01), and adverse events occurred in 40% as compared 
with 48% (P=0.02). The probability of survival was slightly higher with the restrictive strategy 
than with the liberal strategy in the subgroup of patients who had bleeding associated with a 
peptic ulcer (hazard ratio, 0.70; 95% CI, 0.26 to 1.25) and was significantly higher in the 
subgroup of patients with cirrhosis and Child–Pugh class A or B disease (hazard ratio, 0.30; 95% 
CI, 0.11 to 0.85), but not in those with cirrhosis and Child–Pugh class C disease (hazard ratio, 
1.04; 95% CI, 0.45 to 2.37). Within the first 5 days, the portal-pressure gradient increased 
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significantly in patients assigned to the liberal strategy (P=0.03) but not in those assigned to the 
restrictive strategy‖. In a 45 day survival comparison with a liberal transfusion strategy, a 
restrictive strategy significantly improved outcomes in patients with acute upper gastrointestinal 
bleeding.  
 
Evidence and the growing number of studies in the area of transfusion practice have contributed 
to a better understanding of the risks associated with transfusion of blood and blood components. 
It has ―transformed transfusion medicine through the accelerated development of more 
sophisticated donor testing (i.e. ever-improving infectious disease tests), pre-transfusion testing, 
recipient identification, and multiple improvements in blood component characteristics and 
quality (i.e. leukoreduction, irradiation, pathogen inactivation). These developments have 
resulted in improved safety profiles for transfused components and a perception of minimal 
risk‖363.  
 
2.2.9. Pillars of Patient Blood Management  
Patient Blood Management (PBM) programs have been introduced to ensure that every 
transfusion is optimized. The Society for the Advancement of Blood Management 
437
 defines 
PBM as ―timely application of evidence-based medical and surgical concepts designed to 
maintain hemoglobin concentration, optimize hemostasis and minimize blood loss in an effort to 
improve patient outcome‖. Further it is defined as ―an evidence-based, multidisciplinary 
approach to optimizing the care of patients who might need transfusion.‖ It encompasses all 
aspects of ―patient evaluation and clinical management surrounding the transfusion decision-
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making process, including the application of appropriate indications, as well as minimization of 
blood loss and optimization of patient red cell mass‖ 438. Based on the accumulating scientific 
evidence on the overuse of blood, liberal transfusion practices, and adverse outcomes of blood 
transfusion, the American Society of Anesthesiologists Committee of Blood Management 
250
  
and the Joint Commission
439
 have emphasized the importance of a standardized transfusion 
practice
142,439
. In 2010, World Health Organization (WHO) adopted patient blood management 
principles to improve transfusion safety 
440
; and in 2012 implemented a resolution (WHA63.12) 
in favor of patient blood management, with a ―focus on the availability, safety and quality of 
blood products, and their safe and rational use‖441. The concept of PBM has been developed to 
address known and unknown risks of blood transfusion, preservation of national blood inventory, 
and constraints from escalating costs 
245
.  PBM aims to achieve improved patient outcomes by 
avoiding unnecessary exposure to blood products through effective conservation and 
management of a patient‘s own blood.  
 
PBM views patients‘ physiological reserves as a natural valuable resource that should be 
conserved and appropriately managed. The concept of PBM is still evolving. According to 
Shander
251
 and Gombotz 
2, ―an earlier definition of PBM involved the appropriate provision and 
use of blood, its components and derivatives, and strategies to reduce or avoid the need for 
transfusion, with the ultimate goal of improved patient outcome.‖  The recent concept has been 
focused on ―preventative measures that will obviate the need for transfusion‖251. The goal is to 
employ a patient-centered pre-operative approach to optimize, conserve, and manage patient‘s 
own blood. It aims to identify the patients who are at risk of blood transfusion and provide them 
with a managed plan aimed to reduce or eliminate transfusion with an acceptable risk of 
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anemia
442
. Studies have shown low pre-operative hemoglobin levels, excessive surgical blood 
loss, and inappropriate transfusion practices are the underlying factors in majority of surgical 
patients which result in the therapeutic decision to transfuse
2,251
. According to Isbister
443
, 
―allogeneic blood transfusion should be considered only when there are no options available.‖  
Based on the above findings, Shander
251
 has defined the three aspects of PBM as ―optimization 
of hematopoiesis, minimization of bleeding and blood loss, harnessing and optimizing 
physiological tolerance of anemia‖, commonly known as the ―pillars‖ of PBM; more specifically 
(i) detection and treatment of pre-operative anemia, (ii) reduction in peri-operative RBC loss, 
and (iii) harnessing and optimizing the patient-specific physiological reserve of anemia 
(including restrictive hemoglobin transfusion triggers)
155,209,245,264,444
. In Table 1, Isbister 
445
 
summarized the evidence-based components of the three pillars of PBM in a perioperative 
setting.   
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Table 3 - Three pillars of patient blood management. 
 
 
This matrix provides an evidence-based checklist for the decision making process to improve 
clinical outcomes. As various approaches to PBM continue to evolve, currently the ―low hanging 
fruit‖ has been elective surgeries, where the greatest benefits can be demonstrated in 
improvement of patient outcomes through utilization of the above best-practice evidence in 
conjunction with customized clinical and personal management of individual patient cases.   
 
Shander and colleagues 
251,446
 recommended that ―all treatments should be evaluated to 
determine their effect on improving patient outcomes as this is the ultimate objective of any 
intervention. Despite widespread use, allogeneic blood products have not undergone such 
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scrutiny, and the balance between their established risks and questionable benefits is often 
obscured by a quest to meet and surpass arbitrary laboratory thresholds. The result is a 
transfusion practice that is highly variable, costly, and likely to do more harm than good to the 
patients.‖ PBM emphasizes the appropriate use of blood and blood products with the aim of 
improving patient outcomes by using a multimodal approach. According to recent evidence, 
strategies involved in PBM are often considered a restrictive approach when compared to 
common or ―cultural‖ practice. In order to be most effective, PBM requires a multidisciplinary 
teamwork approach in the context of an established hospital-wide program 
251
.   
 
2.2.10. The Joint Commission Recommendation for Effective PBM Programs 
The Joint Commission aims to ―continuously improve health care for the public in collaboration 
with other stakeholders by evaluating health care organizations and inspiring them to excel in 
providing safe and effective care of the highest quality and value‖ 447. The Joint Commission 
accredits over 19,000 health care organizations and programs in the United States and more than 
400 programs internationally. The Centers for Medicare Services (CMS) recognizes Joint 
Commission accreditation as a condition of licensure and the receipt of Medicaid and Medicare 
reimbursement. Advisers to HHS Secretary Kathleen Sebelius observed that as a result of the 
variability that exists in transfusion practices, the Joint Commission has recognized "there is both 
excessive and inappropriate use of blood transfusions in the U.S. Improvements in rational use of 
blood have lagged."
448
.  
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In order to reduce the inappropriate use of blood transfusion, in a report by Knowles 
449
, ―the 
2012 Joint Commission and the American Medical Association have gathered a Physician 
Consortium for Performance Improvement National Summit on Overuse which focused on 
overuse as a patient safety and quality concern, and advocated PBM programs that include: 
 A tool kit of clinical educational materials for physicians throughout the learning 
continuum, providing information on risks and benefits of transfusion and disseminating 
best practices and guidelines supported by evidence; 
 Education on transfusion avoidance and appropriate alternatives to transfusion; 
 Identification of subject matter experts to provide guidance; 
 Advocacy for scheduled periodic assessments of prescriber competency and for 
accountability to organizational standards; 
 Standardization of performance metrics, data collection and vocabulary to allow valid 
benchmarking within organizations; 
 Measurement of individual physician transfusion practice as part of ongoing professional 
practice evaluation; 
 Development of a separate informed consent process for transfusion that communicates 
risks and benefits consistent with current evidence; 
 Identification of research priorities to close evidence gaps in what constitutes optimal 
transfusion practice‖. 
 
The metrics of the Joint Commission‘s PBM performance Measures from 2011 include 450: 
PBM-01: Transfusion Consent 
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Patients with a signed consent who received information about the risks, benefits and alternatives 
prior to the initial blood transfusion or the initial transfusion was deemed a medical emergency.  
Numerator: Patients with a signed consent who received information about the risks, benefits and 
alternatives prior to the initial blood transfusion or the initial transfusion was deemed a medical 
emergency. 
Denominator: Patients of all ages who received red blood cell, plasma or platelet transfusions. 
 
PBM-02: RBC Transfusion Indication 
RBC units transfused with pre-transfusion hemoglobin or hematocrit result and clinical 
indication documented.  
Numerator: Number of RBC transfusion units with pre-transfusion hemoglobin or hematocrit 
and clinical indication documented.  
Denominator: Number of red blood cell transfusion units evaluated. 
 
PBM-03: Plasma Transfusion Indication 
Plasma units with pre-transfusion laboratory testing and clinical indication documented.  
Numerator: Number of plasma transfusion units with pre-transfusion laboratory value AND 
clinical indication documented  
Denominator: Number of plasma units evaluated 
Trauma patients excluded 
 
PBM-04: Platelet Transfusion Indication 
Platelet doses transfused with pre-transfusion platelet testing and clinical indication documented.  
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Numerator: Number of platelet transfusion units with pre-transfusion platelet testing AND 
clinical indication documented.  
Denominator: Number of platelet units evaluated 
Trauma patients excluded. 
 
PBM-05: Blood Administration Documentation 
Transfusions of blood units with documentation for all of the following: 
Patient identification, transfusion order and blood ID number confirmed prior to the initiation of 
transfusion. 
Date and time of transfusion. 
Blood pressure, pulse and temperature recorded pre, during and post transfusion. 
Numerator: Number of transfusion units (bags) or doses with documentation for all of the 
following: patient identification and transfusion order (or Blood ID) confirmed prior to the 
initiation of transfusion date and time of transfusion blood pressure, (pulse) and temperature 
recorded pre, during and post transfusion.  
Denominator: Number of red blood cells, plasma and platelet units or doses evaluated. 
 
PBM-06: Preoperative Anemia Screening 
Patients have documentation of preoperative anemia screening 14-45 days before Anesthesia 
Start Date.  
Numerator: Patients with preoperative anemia screening 14 - 45 days before Anesthesia Start 
Date 
Denominator: Selected elective surgical patients 
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Cardiac patients removed.  
 
PBM-07: Preoperative Blood Type and Antibody Testing 
Patients with documentation of preoperative type and screen or type and crossmatch completed 
prior to Anesthesia Start Time.  
Numerator: Patients with preoperative type and screen or type and crossmatch completed prior to 
Surgery Start Time Anesthesia Start Time.  
Denominator: Selected elective surgical patients.  
 
The seven blood measures have been added to the measure reserve library.  The Joint 
Commission encourages use of the above PBM measures. In addition, the department of Health 
and Human Services is organizing further data collection efforts.  
 
2.2.11. Challenges in Establishment of Effective PBM Program  
Establishment of an evidence-based approach to blood utilization has the potential to reduce 
blood usage which can substantially lower hospitals expenditures and improve patient outcomes. 
The same blood products may be re-directed to other patients who are in need of the supply 
within or outside the hospital 
252
. In order for hospitals or healthcare systems to gain a 
competitive advantage from PBM, a robust multidisciplinary, patient-centric, data driven 
approach is imperative to optimize the utilization of blood products in patients who may require 
transfusion and to simultaneously reduce preventable complications. Establishment of true 
metrics to track good practices of blood use and adherence to PBM guidelines are essential 
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elements of the program 
245
. The cornerstone of an effective PBM program is identification, 
collection, and analysis of relevant data that are captured in disparate hospital information 
systems 
451. To effectively monitor the program‘s performance, a performance management 
system consisting of measures, metrics, and Key Performance Indicators (KPIs) is required to 
quantitatively and qualitatively measure and track the hospital‘s and/or healthcare organization‘s 
progress against its goals, and to inform the stakeholders at different levels (operational, 
management, and executive level) in the organization of the extent of the progress 
439
. 
Establishment of such a program faces many different challenges. The  practice of transfusion 
medicine extends across multiple specialties, covers diverse clinical and laboratory services, and 
requires data from many different departments and systems (i.e. admission, billing, laboratory, 
pharmacy, transfusion service, etc.) in order to provide a comprehensive view of the hospital and 
healthcare organization‘s practice452.  
 
Hospitals are not required to have a PBM program, but they are required to review blood use to 
ensure their transfusions meet appropriateness criteria established by medical staff (commonly 
by a transfusion committee) based on the hospital‘s blood utilization protocols and guidelines. 
However, transfusion committees in hospitals are not as effective as they have been intended to 
be 
239
. The transfusion committees often conduct cursory chart reviews of the transfusion cases 
and frequently fail to recognize the forty to sixty percent of inappropriate transfusions that occur 
in almost every hospital 
239,453
. The ineffectiveness of chart reviews may be explained by the 
following reasons: 
 Underlying complexities of transfusion medicine 152,158; 
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 Lack of or limited subject matter expertise; inability to understand the intricacy of 
transfusion practice and the latest evidence 
217,239
; 
 Lack of proper knowledge and training  to identify relevant metrics, and key performance 
indicators 
239,435,453
; 
 Outdated and inappropriate transfusion criteria and guidelines, such as a single lab value 
as a reference point for appropriate use of blood (i.e. hemoglobin level) 
435,453
; 
 Ineffectiveness of single chart reviews  without holistic view of hospital‘s transfusion 
practice at multiple granular levels 
453
; 
 Uncompensated physicians‘ review time 453; 
 Organizational culture 239;  
 Reviewers‘ bias (when physicians review the work of physicians they know, and with 
whom they may have economic, political, social, referral relationships 
239,453
;    
Another significant impediment pertains to the aggregation of many different critical data 
elements residing in disparate hospital information systems making data management and 
analysis a significant hurdle 
452
. Manual data collection and analysis is not feasible and 
sustainable. It requires alignment of staff and resources in order to accomplish an arduous 
process on an ongoing basis. The process is time consuming, challenging, inefficient, and costly 
258
. A further challenge is the regular provision of the meaningful, actionable information needed 
to guide transfusion practice and promote a sustainable behavioral change 
452
. The meaningful 
presentation of information is critical for informed decision-making in order to provide a 
baseline for current practice, to support future improvement initiatives, and to permanently 
change behavior. Many healthcare organizations lack such a reporting mechanism.  
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2.3. Implementation Challenges of EBP in Current Health Information Ecosystem 
After years of underinvestment in information systems, large-scale health infrastructure 
initiatives have emerged and with it have brought dramatic change to healthcare. The use of 
internet and health information technologies have empowered providers and patients to have a 
wealth of information literally at their fingertips 
454
. It is believed harnessing the power of 
information technology and incorporating it into clinical medicine will improve the delivery and 
outcomes of health services. This stems from the belief that changes in knowledge must trigger 
changes in health practices, and, as a result, altered practices must improve outcomes. In other 
words, ―better information begets better health through the medium of better choice‖ 454.     
 
The national healthcare reform initiatives in the United States have placed evidence-based health 
information systems and practice among the top deliverables for this decade. 
455
. Historically, 
care of the patient was influenced by the experiences and opinions of those involved in providing 
treatment 
77,456
. Evidence-based practice marks a shift among healthcare professionals from a 
traditional emphasis on authoritative opinions to an emphasis on data extracted from prior 
research and studies 
77,84,457
. However, evidence-based decision making and practice face a 
multitude of challenges. Evidence-based practice requires that the healthcare decision maker 
discern better from worse information, use that knowledge to trigger a change in clinical 
practice, and evaluate the outcome. To make the shift, it is integral for the individual (physicians 
and other healthcare providers) to embrace critical thinking values of 
458
: 
 Courage: Critically appraise claims regardless of negative reactions; 
 Curiosity: An interest in deep understanding and learning; 
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 Intellectual empathy: Accurately understanding and presenting the views of others; 
 Humility: Awareness of the limits of knowledge including our own; lack of arrogance 
(e.g. promoting false claims of effectiveness); 
 Integrity: Honoring the same standards of evidence to which we hold others; 
 Persistence: Willingness to struggle with confusion and unsettled questions. 
On the organizational level, in order for the decision maker to make the better choice they must 
be supported with evidence convenience (all the right information available in the right place at 
the right time), discrimination  (the relevant and important information filtered by the unique 
needs of community, group, and individual), and integration  (evidence embedded in work flow 
with its use monitored and effective evidence behaviors correlated with health outcomes) 
455
. In 
order to provide evidence convenience, discrimination, and integration at the point of decision 
making, a variety of health information technologies and approaches are necessary to facilitate: 
(i) simplicity with uncluttered, straightforward, and consistent presentation of information using 
an intuitive interface that requires a minimum effort to use without training; (ii) accessibility 
with rapid access wherever healthcare decisions are made; (iii) sensitivity to individual and 
group information preferences; and (iv) efficiency in the organization of information resources to 
reduce the healthcare professional‘s burden of information management 455.  
 
Information systems are the key to evidence-based practice 
459
. Information systems can capture, 
transform and maintain data at three levels: raw data, processed data, and knowledge 
460. ―If the 
raw data is valid, then the processed data, or "information‖, can be considered as equivalent to 
evidence. Knowledge is information (evidence) in context‖459. Information and knowledge 
management is at the heart of physician and other healthcare providers‘ intellectual and practical 
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activities. The applicability of all the available ―best evidence‖ in a particular care management 
setting requires other information as well, which may be of a contextual, local, or organizational 
nature. ―The integration and exchange of clinical and administrative best practice information 
among health professionals outside the restricted scope of the technical and scientific literature 
has been shown to be a significant factor in appropriate decision-making‖ 461.  
 
To embed evidence into practice, an iterative approach must be developed to empower the 
decision-makers to ―know what to do (best evidence on best practices must be available to 
inform decision making), do what is known (recognize problems, formulate questions, select 
resources, and apply knowledge appropriately), and understand what is done (health choices and 
outcomes must be iteratively validated)‖ 455.  There are six major categories of information 
systems and technology that contribute to evidence-based practice they include: reference 
databases (biomedical literature, clinical trials review, current research, etc.); contextual and 
case-specific information (individual patient medical records); contextual information 
(environment, anthropology, epidemiology, socioeconomic, etc.); clinical data repositories 
(clinical databases from different units or departments); administrative data repositories (claims, 
billing, finance, etc.); and clinical decision support systems (web-based interactive health 
information). 
459
. According to a WHO 2015 report on health evidence networks by Michelsen 
and colleagues, 
462
 the process from data provision to dissemination of information (from data to 
information and knowledge) should be integrated. Integration has to take place at each step of the 
process. Data have to be collected and integrated in datasets. Datasets have to be consistent (both 
operationally and conceptually) and comparable. Different types of data, even across 
jurisdictions, have to be collected in a well-coordinated manner to minimize overlaps and allow 
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datasets to be combined in order to compare different populations or health service providers, to 
monitor developments over time, or to analyze correlations, and to determine the social 
determinants of health and the health status of patient or population groups. The approach to the 
utilization of clinical and management health information is still a complex, chaotic, and 
controversial subject 
459
. It is not surprising that many expectations with regard to the 
―contribution of health information systems to clinical practice have not been fulfilled‖ 459. 
 
2.4. Implementation of Evidence-Based Patient Blood Management Program  
Patient Blood Management is defined as ―a multidisciplinary, evidence-based approach to 
optimizing the care of patients who might need blood transfusion‖463. Recent studies point to a 
risk profile associated with the use of blood products 
142,164,245,251,364
.  There is increasing 
evidence that inappropriate blood transfusions may contribute to increased risk of morbidity and 
mortality 
142,197,218,464
.  There is, therefore, a need to review transfusion practice in order to 
identify opportunities for improved patient outcomes and to reduce costs. The key component of 
PBM program is a successful employment of a performance measurement system to track blood 
product utilization, transfusion appropriateness, providers‘ performance, and patient outcomes. 
Effective data integration, data management, and analytics play a critical role in the evaluation of 
best-practice evidence, the improvement of performances, and the assessment of quality 
outcomes. Aggregation and analysis of data, presentation and interpretation of information 
through different measures and indicators allow healthcare professional and healthcare system 
identify and recognize the shortcomings of the system, target areas for improvement, and make 
corrective adjustments to address the shortfalls.  
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However, the diversity of data and disparity of sources in the healthcare information ecosystem 
pose a significant challenge for implementation of an evidence-based program. Cross-
disciplinary evidence-based programs such as PBMs span multiple specialties (i.e. across 
departments), cover diverse clinical and laboratory services, and require data both from multiple 
departments in the business side and the clinical side. The types of data sets that are required for 
PBMs reside in disparate systems (e.g. admissions, billing, laboratory, pharmacy, transfusion 
service, surgical scheduling, etc.) and are not linked. These systems have their own databases, 
data architecture, and applications that are different from one another and at times incompatible. 
As a result, the limited data exchange between disparate information systems creates barriers to 
tapping into all the required information that has been captured relative to physicians and other 
healthcare providers practicing transfusion medicine and the patients who receive various blood 
products. This makes it very difficult to evaluate physicians‘ transfusion practices, patients‘ 
quality of outcome, and total costs.  
 
In order to optimize and sustain transfusion medicine best-practice and change providers‘ 
behavior, there is a need to aggregate clinical, financial, and operational data into a common 
platform, develop an evidence-based performance measurement system to track practices against 
best-practice guidelines, and evaluate the observed changes using analytics to address the 
variability that exists in the practice of transfusion medicine. Such an effort requires an approach, 
that (i) brings together targeted data from disparate information systems, (ii) uses methods to 
measure performance, track patient‘s outcomes, and evaluate level of adherence to evidence-
based best practice guidelines; (iii) provides a meaningful presentation of processed information 
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back to stakeholders; (iv) uses targeted education to inform healthcare providers of their 
practices; (v) supports program oversight; and (v) employs an analytics framework to evaluate 
changes in transfusion medicine practice resulting directly from the program, to fine tune areas 
for improvement, to evaluate patient quality of care, and to avoid unintended consequences and 
outcomes. In addition, it is important to keep the process collaborative and constructive as the 
healthcare institutions and the providers work toward the common goal of eliminating 
unnecessary transfusions 
465
. 
Chapter 3:  Methods 
3.1. Rationale  
The shift toward evidence-based practice (EBP) empowers healthcare practitioners to move from 
a culture of delivering care based on tradition, intuition, and authority, to a system in which 
decisions are guided and justified through the best available evidence 
466
. The concept of EBP 
emerged in the early 1970s as a means to improve clinical practice
74,298
. Despite the great 
advantages of EBP, many healthcare professionals remain cautious about embracing the model. 
The complexities of changing to practice based on evidence make it a daunting task 
467
 with 
barriers such as: attitudes toward EBP and research,  unmet consumer demand for evidence-
based care, logistical and organizational considerations, requirements of institutional and 
leadership support,  current policies and procedures, access to appropriate evidence 
468
, and 
technologies needed to support EBP. There are also challenges with implementation of EBP 
including dissemination of EBP, audit of EBP approaches, and evaluation of associated 
outcomes.  The framework developed and implemented in this study was designed to address the 
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challenges involved in the integration of evidence into daily medical practice through a 
performance management system.  
3.2. Study Basis and Focus  
The model presented here was developed based on the review of academic peer reviewed 
research literature, industry research reports and white papers on a use of performance 
management in healthcare and other industries. Additionally, the model was founded on the 
review of case studies based on the experience of professionals in healthcare and other industries 
who have successfully developed and implemented performance management systems. Several 
international governmental reports on good practices and resources dealing with the development 
of key performance measures to monitor healthcare quality were consulted. Furthermore, the 
method was designed based on the practical knowledge gained through professional experience 
related to this study. The model contained the critical elements that had been identified as 
necessary for the successful construction of an evidence-based performance management system. 
The factors and processes identified in this method tied strategic objectives of a healthcare 
institution to the latest finding in a field of interest. The method provided a mechanism for 
healthcare organizations to convert their data into meaningful information and knowledge that 
could be applied in practice.  
 
For this study, the discipline of transfusion medicine was chosen with a specific focus on the 
patient blood management (PBM) approach.  This study aimed to integrate evidence-based 
practice (EBP) approaches and relevant data-driven information into the daily practice of 
physicians.   The paradigm of blood utilization has been shifting toward evidence-based practice 
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with a focus on optimal transfusion strategies and utilization of blood products. However, 
healthcare institutions struggle to implement a robust and scalable evidence-based PBM program 
to promote optimal utilization of blood products and to encourage adherence to latest evidence-
based best practice. Optimization of blood product use is complex and challenging but it is an 
important task that has direct implications on patient safety, cost containment, and conservation 
of a valuable and scarce resource. The Figure 1 below highlights the key objectives, strategies, 
and tactics relevant to achieving the goals of a hospital wide evidence-based PBM program. 
 
Figure 1 - Key Objective, Strategies, and Tactics for Implementation of Evidence-Based Patient 
Blood Management Program 
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3.3. Implementation Model for Hospital-wide Evidence-based Program   
3.3.1. Organizational Engagement 
The implementation model which is the focus of this study was put into practice through 
collaboration between BloodCenter of Wisconsin and a large local hospital as a pilot project. The 
pilot hospital was a not-for-profit, full service, short-term, acute-care facility with 396 total 
staffed beds.   Under the pilot agreement, BloodCenter of Wisconsin agreed to create a roadmap 
for identification, prioritization, implementation, and assessment of patient blood management 
initiatives.  
 
Establishment of an evidence-based patient blood management program required close 
collaboration between BloodCenter of Wisconsin and the pilot hospital. The first step was the 
formation of a cross-organizational management team. Figure 2 below presents a graphical 
diagram of the executive sponsors, operation owners, and subject matter expert team leads from 
different departments both at the hospital and the BloodCenter of Wisconsin; and the 
communication flow between the two organizations.  
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Figure 2- Conceptual diagram of communication flow between two organizations. 
In order to develop a broad organizational support a Blood Utilization Governance Committee 
was established. The committee consisted of hospitals executives, administrative, and clinical 
champions including Vice President of Medical Affairs, Vice President of Laboratory, 
Laboratory Medical Director, Laboratory Director, Blood Bank Supervisor, physician champion, 
and Transfusion Safety Nurse champion. The cross-functional team consisted of a broad range of 
proficiencies. A clinical team including physicians and a nurse who specialized in transfusion 
medicine, specifically PBM were part of this core group.  The overarching goal of the Blood 
Utilization Governance Committee was to create a culture of accountability among physicians 
who practiced transfusion therapies. It was very important to involve stakeholders at all levels in 
the process of devising the performance management system to ensure that the individuals 
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impacted understood the measures and metrics and the results in order for the measures to be 
effectively used to track and evaluate performance at multiple levels within the hospital. The 
chart above indicates the broad range of involvement among the two organizations Table 4. 
Table 4 - Roles and responsibilities across organizations. 
Hospital Roles and Responsibilities 
Roles Responsibilities  
Executive Sponsor 
 Has a vested interest in the outcome of the 
project and is its champion.   
 Legitimizes the project‘s goals and 
objectives, is kept apprised of major 
activities, and is the ultimate decision 
maker for the project.   
 Promotes the project within the 
organization, making sure that everyone 
understands the benefits the project will 
provide. 
 Provides support to the Operations 
Manager and Operations Team Lead 
Operations Manager  
 Advocates for the business value of the 
project and identifies the proper resources 
(funding/people) and ensures they are 
available throughout the project 
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Physician Champion(s) 
 Serves as a leader in promoting and 
implementing Patient Blood Management 
and acts as an evangelist for the program 
within the organization 
 Encourages colleagues to see the benefits 
associated with change and to monitor the 
progress of the program 
 Leverages data-driven information in the 
performance management system 
Operations Team Lead (Owner) 
 Responsible for work outside of the IT 
deliverables that is needed to support the 
implementation of performance 
management system (i.e., identifies Subject 
Matter Experts and processes that impact 
metrics, collaborates with the Transfusion 
Safety Officer on User Acceptance Testing, 
etc.) 
 Takes the role hospital‘s Subject Matter 
Expert on the metrics and leads the efforts 
to make the information available 
throughout the organization. 
 The Operations Team Lead is enabled to 
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act across facilities.   
 The Operations Team Lead and the 
Hospital IT Project Manager are peers who 
work together with the Transfusion Safety 
Officer and IS Project Manager to build 
and implement the complete solution.   
Information System Project Manager  
 Has the authority to manage the IS project 
across facilities.  The IT Project Manager 
partners with the BloodCenter of 
Wisconsin IT Project Manager to lead the 
planning and development of all project 
deliverables. 
 Responsible for managing the schedule and 
all project management procedures (scope 
management, issues management, risk 
management, etc.) related to hospital 
resources 
 IT Project Manager and the Operations 
Team Lead are peers who work together 
with the Transfusion Safety Officer and IS 
Project Manager to build and implement 
the complete solution.   
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Analysts/Developer  
 Responsible for creating an initial and 
ongoing data feed that meets the agreed 
upon specification including, but not 
limited to, any transformations from the 
native format and providing evidence of the 
validation of source data. 
 Responsible for engaging the appropriate 
hospital technical resources as needed 
Subject Matter Experts 
 Has superior (expert) knowledge of a 
discipline, technology, product, business 
process or entire business area. 
 Collaborates with the Analyst/Developer to 
ensure that the information contained in the 
data feed accurately captures its intended 
content. 
Integration Analyst 
 Responsible for working with the Hospital 
Analyst/Developer and BloodCenter of 
Wisconsin Analyst/Developer to deliver 
data to BloodCenter of Wisconsin.   
 Responsible for engaging any additional 
hospital technical resources as needed 
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BloodCenter of Wisconsin Roles and Responsibilities 
Program Director  
 Responsible for all the components 
included in the implementation of the 
Program at the hospital 
Transfusion Safety Nurse 
 Responsible expert for the patient blood 
management metrics and partners with the 
Operations Team Lead to advocate for 
successful implementation of the software 
system. 
 Advises the Operations Team Lead on 
process identification for accurate metric 
development, creating user acceptance tests 
with the Operations Team Lead‘s 
assistance, leads user acceptance testing, 
and conducts user training. 
Physician Champion 
 Partners with the hospital‘s Physician 
Champion to promote and implement 
Patient Blood Management within the 
organization.   
 Leverages data-driven information in the 
performance management system to 
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monitor utilization data and assess the 
impact on patient blood management 
strategies 
Information Services Project Manager  Authorize and manage the IT project at 
BloodCenter of Wisconsin. 
 Partners with the hospital‘s IT Project 
Manager to lead the planning and 
development of all project deliverables. 
 Responsible for management of the 
schedule and all project management 
procedures (scope management, issues 
management, risk management, etc.) 
related to BloodCenter of Wisconsin 
resources. 
Analysts/Developer 
 Responsible for ensuring that the 
requirements are captured and documented 
correctly and for understanding the 
business requirements and designing a 
solution that will meet the business needs. 
 Responsible for the actual building of the 
solution and system testing. If a need arises 
for additional internal technical resources, 
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the Analyst/Developer will engage them. 
 
 
Combined Roles and Responsibilities 
Governance Team 
 Responsible for the entire Program and 
includes members of the hospital and 
BloodCenter of Wisconsin organizations, 
including executive and managers, whose 
purpose is to provide guidance to the 
implementation, ensure that functional 
resources are available throughout the 
program, remove obstacles impeding 
progress, and validate that the program 
realizes its intended benefits.    
 The Governance Team includes, but is not 
limited to, the Executive Sponsor, 
Operations Manager, and Program 
Director. 
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3.3.2. Physician Engagement 
The Blood Utilization Governance Committee then established sub-committees for assigning 
specific responsibilities to various working groups with subject matter expertise including 
physician group, laboratory operations, information technology, nursing quality teams.  
Blood Utilization Governance Committee formed a sub-committee that included transfusion 
medicine expertise from BloodCenter of Wisconsin in the hospitals transfusion committee 
known as Transfusion Medicine Steering Committee. The role of the Transfusion Steering 
Committee required medical staff to take leadership role in measurement, assessment, and 
improvement of clinical processes related to use of blood and blood components, and to analyze 
all confirmed transfusion reactions. The committee included: the Laboratory Medical director, 
physician champions, the Transfusion Service Supervisor, a quality improvement nurse, in 
addition to Transfusion Safety Nurse and a physician champion from BloodCenter of Wisconsin. 
In addition, multiple workgroups were formed to serve a variety of purposes. The workgroups 
were made up of individuals with the expertise that was recognized as essential for individual 
project deliverables. Subject experts from multiple hospital departments (e.g. information 
technology, finance, lab, transfusion service, etc.) worked with well-respected physician 
champions who were aware of transfusion medicine initiatives and the rationale behind them. 
The physician champions were coupled with transfusion medicine experts (physicians and 
nurses) from the BloodCenter of Wisconsin to promote various initiatives among the physicians 
and nurses within the hospital. The workgroup  members were responsible for understanding the 
works, planning the activities, completing the assigned work, developing timelines, setting 
quality expectations, informing the project management team of any issues, scope changes, risks, 
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or quality concerns, and proactively communicating status. Detailed definitions of the roles and 
responsibilities of team members were outlined in Table 2. 
 
The BloodCenter of Wisconsin subject matter experts including a transfusion medicine physician 
and a nurse, quality improvement laboratory technologists, information systems analysts met 
with the hospital expert members from the Blood Utilization Governance Committee and the 
Transfusion Medicine Steering Committee in a series of joint strategic meetings to determine the 
strategic goals and objectives for the implementation of evidence-based transfusion medicine 
program.  The team reviewed the hospital‘s goals and objectives, and identified strategies and 
tactics to be considered for the implementation of a hospital-wide evidence-based transfusion 
medicine program. The overarching goal, the objectives, and the strategies helped determine the 
list of tactics needed to achieve particular outcomes.  Current state analysis was conducted and 
hospitalists were determined to be the first group of physicians to incorporate evidence-based 
transfusion medicine program in their daily practice.  
 
The hospital agreed to outsource the implementation of a transfusion medicine PBM program to 
BloodCenter of Wisconsin. The high-level tasks involved included:  
 Development of transfusion medicine best practice guidelines; 
 Education of physicians and other healthcare providers on latest approaches in 
transfusion medicine and particularly PBM; 
 Identification of data elements to track transfusion practices of physicians;  
 Construction of a performance management system to track compliance with evidence 
and appropriateness of transfusion orders; 
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 Distribution of reports to physicians, other healthcare providers, and administrative staff;  
 Construction of an analytics layer to evaluate changes in practice.  
The hospital provided BloodCenter of Wisconsin with the resources required to aggregate, report 
and analyze the identified relevant data. The hospital reviewed the reports in monthly 
Transfusion Medicine Steering Committee meetings and took the necessary actions to help 
encourage adherence to best practice evidence. Quarterly meeting was held with the Blood 
Utilization Governance Committee to provide updates with regard to the advancement of the 
program and to inform of changes in practice since the implementation of the program. 
3.3.3. Promotion of Evidence-Based Medical Practice 
One aspect of the strategic vision was the promotion of evidence-based practice in the area of 
transfusion medicine at all levels of the healthcare system, particularly at the physician level. 
Literature has reported that substantial, unexplained variations in practice at the physician level 
have led to poor quality patient outcomes, inefficient care delivery, and unnecessary or wasteful 
expenditures
126,140,152,155,158,183,193,209,237,433
. The area of focus of this study was the reduction in 
transfusion of blood products, as blood transfusion was one of the most common, resource- 
intensive clinical interventions in the hospital
1,21,133-135
. The strategic objective was to implement 
a model that fostered a shift from authority-based medicine to evidence-based conservative 
transfusion strategies in order to reduce the unexplained differences in practice.  
 
The process began with a series of continuing medical education sessions in which the 
hospitalists were exposed to increasingly refined information on blood transfusion practice. The 
presentations began with general evidence-based transfusion medicine practice, got more 
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specific with patient blood management strategies, and concluded with very specific training in 
the transfusion of individual blood components. 
 
3.3.4. Transforming Data into Meaningful Information 
Performance management is the strategic use of performance standards, measures, progress 
reports, and ongoing quality improvement efforts to ensure an achievement of desired results 
469
. 
It requires the active use of data to measure and improve performance across all areas of activity. 
In the case of transfusion medicine, the ultimate purpose of these efforts is to enhance physician 
knowledge on the latest evidence, improve transfusion practices, improve patient outcomes and 
reduce costs. While the concepts of quality improvement, accountability, and performance are 
not new, they are increasingly embraced by healthcare organizations to evaluate decisions, 
measure activities and processes, in order improve quality of care, patient outcomes, and reduce 
cost. 
 
Critical elements were identified for the successful construction of an evidence-based 
performance management system. The framework provided a means for construction of a 
performance management system that tied evidence-based recommendations to metrics and 
indicators that informed physicians, departments, and healthcare institutions on the level of 
adherence to the recommendations and guidelines and provided the necessary information to 
evaluate outcomes of compliance both from patient care and cost containment measures. It 
included the following performance management components:  
127 
 
 Performance Standards that focused on establishment of organizational standards, goals, 
and targets;  
 Performance Measures that focused on development, application, and use of performance 
measures to assess achievement of standards;  
 Progress Reporting that focused on documentation and reporting of progress in meeting 
the standards;  
 Quality Improvement that focused on establishment of program or processes to achieve 
quality improvement based on performance standards, measurements, and reports
342
. 
 The conceptual framework below Figure 3 represented the overarching model for development, 
implementation, and evaluation of a performance management system as a cornerstone for 
implementation of an evidence-based PBM program within a healthcare institution.  The 
activities were identified through an extensive review and analysis of literature and applied 
knowledge 
341,347,439,470-474
. The conceptual framework highlighted a series of activities which 
must be undertaken throughout the development process of performance measures to ensure 
successful deployment of an evidence-based transfusion medicine program. The activities follow 
a logical order; the order of the activities ensured the comprehensiveness of the approach. Figure 
3 has been periodically referenced throughout the study as a roadmap that highlighted the 
intricacy involved in the development and progression of the steps that were involved in the 
process. Figure 3 represents a conceptual model for development, documentation, 
implementation, and evaluation of a Performance Management System. The modified figure was 
partially adapted from Health Information and Quality Authority 
472
.   
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Figure 3 - Represents a conceptual model for development, documentation, implementation, and 
evaluation of a Performance Management System.  
Evidence-based Performance Standards 
Evidence-based performance standards play a foundational role in efforts to improve the quality 
of patient care in the United States 
475
. Evidence-based performance standards were deployed in 
public and private reporting and payment systems purportedly to shape provider behavior toward 
doing what works and away from rendering inappropriate, even dangerous, care. They were 
based on scientific findings and therefore, represented an objective standard for provider 
behavior. Evidence-based performance standards follow the logic of evidence-based medicine as 
a whole. Clinical science can determine ―what works,‖ and providers can and should replicate 
these findings in the care of individual patients‖ 475. 
 
The first component of a performance management system was the development of evidence-
based standards. The evidence-based performance standards used for this study were based on 
the blood utilization guidelines entitled BloodCenter of Wisconsin 2011 Adult Blood Utilization 
Review Guidelines published by the BloodCenter of Wisconsin (Appendix A). The guidelines 
were developed by the physicians and staff of BloodCenter of Wisconsin Medical Science 
Institute. The evidence-based guidelines were compiled after review of the cited references and 
best available evidence. The review and the final approval were completed by the Medical 
Advisory Committee at the BloodCenter of Wisconsin. The evidence-based guidelines were used 
as a reference for best practices and minimum performance levels in order to encourage 
consistency and uniformity across various service lines. To provide easy access to references and 
the literature used in the blood transfusion guidelines, a commercial reference management 
software package, EndNote by Thompson Reuters (Philadelphia, PA), was used. An EndNote 
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web-based shared reference library was created to provide quick and easy access to detailed 
reference components used in creation of BloodCenter of Wisconsin 2011 Adult Blood 
Utilization Review Guidelines. The web-based shared reference library enabled healthcare 
providers to appraise and assess the validity of the guidelines or find further information on a 
specific topic if needed.  
 
The use of the adult blood utilization review guidelines developed by BloodCenter of Wisconsin 
transfusion medicine experts as the performance standard served to address multiple barriers to 
the creation and use of evidence-based guidelines in clinical practice by the hospital. The use of 
these guidelines minimized barriers such as adequate time and ability of clinicians to review, 
interpret, and synthesize the available evidence, to translate knowledge into clinical practice, and 
to perform deductive reasoning to determine if study findings could be uniformly applied to the 
majority of patients in routine practice. 
 
This study focuses on optimization of red blood cell transfusion according to the latest available 
evidence. Adult blood utilization review guidelines (Appendix B) stated that red cell transfusion 
may be appropriate for improving oxygen carrying capacity. Documentation of the indication(s) 
for transfusion and special circumstances for transfusion that take place outside these guidelines 
is recommended. Indications for transfusion of Red Blood Cell were as follows:  
 Red Blood Cell Indications: 
I. Acute Blood Loss: maintain circulating blood volume and hemoglobin 
concentration ≥7 g/dL in otherwise healthy patients; >8g/dL in elderly patients 
and those with known cardiac or respiratory disease. 
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 15-30% loss of blood volume: RBC transfusion likely not required; 
 30-40% loss of blood volume: RBC transfusion probably required; 
 >40% loss of blood volume: RBC transfusion almost certainly required. 
II. Stable hospitalized patients including those in the critical care unit: hemoglobin 
≤7g/dL. Patients with co-morbid conditions such as coronary artery disease, 
pulmonary disease, or evidence of acute MI have less tolerance for anemia. 
III. Peri-operative transfusions: 
 Hemoglobin concentration <7 g/dL: RBC transfusion usually required; 
 Hemoglobin concentration 7-10 g/dL: RBC transfusion may be 
appropriate if any of the following are present: organ ischemia, increased 
potential for or ongoing blood loss, volume status and risk factors for 
complications of inadequate oxygenation; 
 Hemoglobin concentration >10g/dL: RBC transfusion usually 
unnecessary. 
IV. Symptomatic anemia in a normovolemic patient (generally symptoms from 
anemia donot occur when Hgb ≥10g/dL). 
V. Outpatients with bone marrow failure may be prophylactically transfused to 
maintain Hgb >7g/dl. 
 Outcome Indicators: 
I. Improvement in clinical status of patient (relief of symptoms of decreased oxygen 
carrying capacity); 
II. Improvement in Hgb/Hct (one unit of red cells should raise the Hgb on average 
1g/dL or Hct 3% in an adult). One hour post-transfusion Hgb is equivalent to one 
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drawn within 24 hours of transfusion if there is no ongoing blood loss in a 
normovolemic patient. 
 Comments: 
o Transfusion of a single unit may be sufficient; transfusion of additional units 
should be based on clinical assessment of patient. Avoid transfusions based solely 
on Hgb or Hct value. 
o Transfusions should be performed only after appropriate alternative therapies 
have been considered (e.g. iron, vitamin B12, folate and erythropoietin). 
o Certain patient populations (e.g. patient with hemoglobinopathies) may tolerate 
lower hemoglobin thresholds and transfusions in such patients should not be 
based solely on hemoglobin values. 
Initial Baseline Analysis 
A current state analysis was conducted to understand the hospital‘s transfusion practices. High 
level data was collected to evaluate the total number of units of blood product the hospital 
purchased and the cost per unit, and high level analysis was conducted of the number of 
transfusions. Lean methods
476
 were used to evaluate the work processes, including value stream 
maps, product and operator process flow analyses, and error potential analysis. Orders for testing 
or for blood products were analyzed and timed from the point of entry into the transfusion 
services department until the test results were released or the product was issued. Processes were 
evaluated for the percentage of value-added and non-value added time. Non-value added 
activities were eliminated. Processes were assessed using lean concepts to optimize inputs such 
as labor components, to reallocate intellectual capital in order to enhance service levels and to 
support more effective blood management and utilization. 
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Measures to Track Performance  
An integrated health care system or a hospital may have several distinct levels of organization, 
and therefore, several distinct levels of performance measurement. The same levels will not be 
present in all systems, but there are some that will be common across organizations. For this 
study, the performance management system was designed at the system level (i.e. macro level to 
incorporate the healthcare organization and the hospitals) to be meaningful to the healthcare 
providers whose behavior was reflected in the measures. It was also designed to integrate 
performance measures at the operational level (i.e. micro level to incorporate individual 
physicians, other healthcare providers, clinical specialties, inpatient or outpatient units) with 
measures that could be rolled up to hospital or healthcare organization level, in order to 
incorporate  a consistent set of messages about priorities, goals,  and level of performance. 
Although this study focused on implementation of evidence-based transfusion practice for one 
hospital within a larger healthcare system, the performance management system was designed to 
scale up if the healthcare system decided to implement the program system-wide.  
 
Design of Performance Measure Levels  
The most macro level is the healthcare system itself which is composed of a number of different 
distinct operating units. Macro-level measures reflected performance across all hospitals and 
facilities or performance for major operating units. The macro level measures provided a whole 
system view allowing for assessment of transfusion of blood products across multiple hospitals 
using nationally accepted benchmark metrics, or for evaluation of strategic objectives and the 
effectiveness of individual hospitals on the strategic initiatives, etc.  The next macro unit of 
measurement was the hospital. Measures designed for this level included quality and efficiency 
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measures such as rates of readmission, transfusion of blood products to inpatients and outpatients 
depending on their condition. The performance management system was designed so Dthat if a 
hospital had a specific role within a healthcare system (e.g. mental health vs. acute medical or 
surgical vs. long-term rehabilitation facility), the performance measures could be identified and 
parameters could be changed with a focus on the unique strategic goals and mission for the 
specific hospital.  
 
Although the performance management system was designed with flexibility to allow building of 
unique measures to address specific goals of each hospitals, the same groups of performance 
measures (i.e. utilization, quality, inventory management, appropriateness) allowed comparison 
across an integrated healthcare system. The macro-level performance measures were the stable 
measures used to report to management and executive levels. Some concepts and measures must 
be kept constant over time, so that trends can be analyzed and results of various performance 
enhancement initiatives assessed
477
. Reporting frequency was set at a quarterly basis with the 
capability to compare the current quarter with the prior quarter and with same quarter in the 
previous year.  
 
More granular level measures were built at the micro level, consisting of the measures used by 
departments, clinical service lines, physician groups, and individual clinicians. The micro level 
measures allowed analysis of groupings of physicians based on their primary role within the 
hospital (i.e. hospitalists, internists, cardiologists, intensivists). At this level, measures were 
designed to include analysis based on clinical quality of care and utilization (i.e. rate of 
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transfusion of different blood products, comparison of number of units issued per transfusion 
order, etc.).  
 
Below the micro, clinical service line level, were measures for the analysis of individual 
physicians. The level above the physician level, i.e. department or clinical service line measures, 
allowed for rate analysis. This type of analysis was too small at the physician level to allow for 
calculation of meaningful rates.  Physician profiling was at a low level in the organization 
because of sample size issues and questions related to adjustments of clinical measures for case 
mix differences among physicians. Therefore, to assess physician practice at this level, 
utilization measures, clinical lab values, and outlier measures were used to assess the 
appropriateness of the practice. If a physician was flagged as an outlier in the outlier measures, 
then a process for individual chart review was put into place for further analysis of the patient 
condition and evaluation of the appropriateness of physician‘s practice.     
 
The micro-level measures were more dynamic. The performance management system was 
designed to allow setting of targets and thresholds to track performance and to facilitate retiring 
of measures that were no longer useful or adding measures that reflected new priorities. These 
measures tended to be more specific and smaller for targeted work units and specific groups of 
stakeholders. The micro measures tended to answer questions such as ―How well is my group 
doing? Where do we need to focus our efforts in order to do better?‖ The frequency of reporting 
at micro-level depended on the availability of data and the information needed for stakeholders 
to take action. The goals of the micro-level measures were to create awareness and 
accountability and to encourage change at the smallest levels.  
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Figure 4 depicts the association between organization‘s strategic goals and development of a 
performance management system. It highlights the need for a robust and clear strategic goals and 
objectives to be formulated prior to development of a performance management system. A well 
designed performance management system can directly connect to specific components of 
strategic objectives and measure progress towards the overarching goal. Thus, the metrics were 
designed to tightly relate to the strategic goals and objectives, link with activities to outcomes, in 
order to influence decision making, be consistent with national benchmark metrics, and be 
meaningful to macro and micro level stakeholders. In addition the performance management 
system was designed with an emphasis on a closed feedback loop as a valuable mechanism for 
quantification of change and a means to inform on target areas for improvement, refinement, and 
to avoid unintended consequences by responding to change and outcomes rather than reacting to 
them. 
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Figure 4 - Illustrates association between an organization‘s strategic plan and the performance 
management system. It highlights the continuous feedback loop as a mechanism to respond 
outcomes rather than react. 
 
Data Elements and Appropriate Source Systems to Build Various Indicators 
The performance management system was constructed to provide information that was 
significant in attaining organizational goals and priorities by representing the activities 
associated with each priority and measuring and reporting the outcome of those activities. Four 
major categories were defined for development of measures, metrics and indicators including: 
inventory management metrics, utilization measures, quality metrics, transfusion appropriateness 
indicators and key performance indicators, and benchmark metrics.  Key performance indicators 
were the most specific of performance measures and were an important component of a 
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measuring performance at the micro-level (i.e. clinical specialty and individual physician). 
Meaningful key performance indicators had the potential to influence decision-making at the 
time of care by allowing physicians to consider factors deemed to be important when making 
decisions and by explicitly identifying  desired outcomes. Development of the key performance 
indicators used in this study involved five key steps including; review of the strategic goals and 
objectives; alignment of evidence with activities and linking activities to outcomes; close 
involvement of key stakeholders; development of clear definition around each key performance 
indicators; and evaluation. 
 
Key performance indicators were designed to tie to the hospital and clinical service line strategic 
objectives and required involvement of key stakeholders both on the business administrative and 
the clinical side of a hospital. Key stakeholders reviewed strategic goals and objectives and 
identified strategies and tactics for the implementation of a hospital wide evidence-based 
transfusion medicine program. Goals and objectives helped determine the list of strategies and 
tactics needed to achieve particular outcomes. Tactics and desired outcomes were considered for 
different levels within the organization (i.e. physicians‘ level, departmental level, and facility 
level), with key performance indicators used to measure and track individual performance.  Key 
performance indicators were designed around the results of these identified activities to ensure 
that the hospital could track its success in reaching established goals and objectives. A target was 
determined for each key performance indicators; each target could neither be too easy nor too 
difficult to achieve. Where possible, key performance indicator targets were aligned with 
available benchmarks. Results from the key performance indicators were required to be 
measurable, attainable, accurate, and timely. Each key performance indicator was worded 
139 
 
carefully to ensure that the results being monitored were sufficiently quantifiable and specific 
enough to allow meaningful discussion of performance and evaluation of achievement.  
 
The methodological framework described in this section ensured construction of an effective 
performance management system. The focus had been to design a series of logical steps that took 
into account the interconnectedness of the sequence of events involved in a set of processes 
necessary to achieve an objective. This was in contrast to employment of a variety of measures 
for separate entities to evaluate discreet and fragmented events. This section describes the 
fundamental building blocks in the construction of performance indicators that are repeatable 
measures designed to produce particular outcomes. The use of key performance indicators 
provided a mechanism to quantify progress towards key organizational objectives. This approach 
enabled corrective action to be taken if a particular process or decision failed to meet its 
designated outcome.  
 
Performance Measure Documentation 
Reporting outcomes with a performance management system must go beyond simply reporting 
inputs used during the reporting period e.g., utilization of red blood cells, output of the activity, 
or number of patients transfused. Instead, reporting outcomes must provide information on how 
these inputs and outputs have helped the hospital fulfill its high-level strategy, i.e. reducing 
patient days. The Performance Measure Documentation Form (Table 5) was constructed to 
highlight key elements for documentation of each performance measure. In all tables, including 
Table 5, each element has been accompanied by a definition and examples to clearly identify the 
type of information that must be understood, recorded, and communicated across teams and 
140 
 
functional areas.  Performance measure specification ensures that the results reach the intended 
audience in the most coherent manner and format for interpretation and utilization.  
 
Table 5 - Performance Measure Documentation Form. 
Performance Measure Documentation Form 
Performance 
Measure Type 
 Check one:   ⧠ Metric   ⧠ Indicator   ⧠ Key Performance 
Indicator  
Title  Indicate the exact title  
Unique ID 
 Indicate a unique identification for every performance measure  
 Use alphanumeric format:  
1. Choose a prefix depending on the type of the measure  
APR for Appropriateness of transfusion   
UTZ for Utilization  
INV for Inventory 
2. Flow by using a three digit number starting at 001 
 Example: APP001, UTZ001 etc.  
Version  Indicate version (e.g. 1.0) 
Date  Indicate today‘s date 
Author(s) 
 Indicate the individual(s) responsible for formulating the 
measure 
Name: 
________________________________________________ 
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Department: 
______________Position:_______________________ 
Email: 
__________________________Phone:_________________   
Definition 
 Describe performance measure including targeted population, 
and the audience whom the measure is intended to inform.   
Rational 
 Give rational for measurement (include references).  
 Include reference in a sharable reference library (i.e. End-Note 
Web). 
Objective  
 Indicate the objective behind development of the performance 
measure (i.e. reduction in utilization of a certain test or product 
by 10%). 
Measure Category   Indicate category to which the measure belongs. 
Level of Health 
Information 
 Indicate the level of health information (e.g. Facility, Service 
Line, Physicians, Encounter, and etc.).  
Calculation 
 Indicate how the performance measure is being calculated. 
Include information on numerator and denominators, and 
provide information on inclusion and exclusion criteria.  
 Indicate if there a standardized method of calculation available 
for this performance measure: ⧠ Yes  ⧠ No 
If Yes, indicate if this performance measure is in compliance?  
⧠ Yes  ⧠ No – Provide explanation 
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__________________________ 
Target 
 Establish a target for acceptable level of performance; include 
primary, secondary, tertiary, etc. if necessary.  More 
specifically, the target can be initially establish based on the 
result of the current state (as a baseline), and improve 
incrementally.  
Threshold 
 Establish threshold to indicate minimum level of performance. 
Threshold can be established according to best-practice 
guidelines.     
Graphical 
Presentation 
 Indicate best type of visual presentation for the information.   
Intended Audience  
 Indicate target audience whom this measure is intending to 
inform. 
Approved by 
Name:     Date:     Department:     Position:     Email:     Phone: 
_________________   
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Development of Minimum Data Set 
Identification of a minimum data set was required for 
construction of performance measures. Data set was defined as ―a 
set of data that was collected for a specific purpose‖ and a 
minimum data set was defined as core data elements that were 
essential in construction and operationalization of the 
performance measures, 
471,472,478
.  
Once performance measures were defined based on the 
performance standard, the next step was to identify what data 
elements were required to calculate the performance measure. 
This task was achieved by reviewing the documentation for every 
performance measure in Table 3. The Performance Measure 
Documentation Form identified the category of an indicator (e.g. 
utilization measures) and the types of calculation required to 
build the indicator. This information enabled the identification of 
the data elements that were required to build the performance 
measure and the source systems for extracting the required data. 
Once the data elements were defined, the data elements were 
incorporated into a data dictionary (Figure 5). The data dictionary 
was created as a repository of information which included data 
elements with their definitions and various attributes to support 
consistent identification and aggregation of each data elements. Figure 5 indicates the attributes 
that were captured as part of the data dictionary to ensure each data element and its associated 
Figure 5 - Data 
Dictionary. Contains a 
list of data elements, 
definitions, and 
attributes which supports 
the consistent collection 
of data and information 
about the data. 
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values were clearly defined. Based on the information in the data dictionary, data feeds which 
contained the series of data elements to be extracted from a specific source system (e.g. 
laboratory information system, finance system, etc.) were defined. (This approach varies from 
one hospital to another depending on how the back end infrastructure is set up.)  Once detailed 
information was captured, a Data Specification Documentation form was developed and used 
(Table 6) to document detailed information about the specific set of data elements associated 
with a particular performance measure. The Data Specification Documentation contained 
additional file format information including: the format in which data had to be collected, the 
frequency of collection for a particular performance measure and the contact information for the 
subject matter expert for the specific system.  
 
Table 6 - Data element and data feed specifications documentation form 
Data Element and Data Feed Specification Documentation 
Unique ID  Use the UID from the Performance Measure Documentation Form 
Data Set(s) 
 Indicate core data elements with reference to specific sections of 
the Data Dictionary for complete descriptions 
Data Source(s) 
 Indicate the source system(s), where a data element and/or data set  
is located and extracted from  
Data File Name 
 Indicate the exact name of the file for individual data sets to be 
transfer 
Description  
 Include a brief explanation of file content 
 Indicate whether manual or IT supported feed 
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File Format 
 Indicate the format of the file(s) e.g. .dat, .txt, .csv, .xls, .xml. and 
etc.  
Data Collection 
Frequency 
 Indicate the required frequency of data collection 
⧠ One-Time ⧠ Daily  ⧠ Weekly  ⧠ Biweekly  ⧠ Monthly  ⧠ 
Quarterly  ⧠Annually  ⧠ Other – Provide 
details:____________________       
Contact Information  
 Include the individual(s) responsible for collection and extraction    
Name: ________________________________________________ 
Department: 
______________Position:_______________________ 
Email: __________________________Phone:_________________   
  
Reporting on Performance Measures to Stakeholders   
The next step was to define reporting specifications and the level of health information needed 
for reporting purposes. Once performance measures were defined as part of the process, a plan 
was outlined on how and when to disseminate the results of measurements to the intended 
audience. Table 7 specifies details and definitions on reporting criteria for each performance 
measure. Reports were designed to provide information to multiple audiences rather to an 
individual.  The reporting period and the frequency of publication of the results ensured 
information was made available to the audience in a timely manner. 
 
146 
 
A listing of all reports on which a specific performance measure was used to report ensured 
relevancy of information and provided certainty that the information needs of all stakeholders 
were being met without any duplications or replication. Literature 
479
 suggests that when 
reporting off the same data to various audiences, relevant information should be provided that 
speaks to each of the various audiences (e.g. physicians versus quality improvement personnel). 
In this instance, physicians better understood information with more clinical detail as compared 
to quality improvement personnel who needed the same information at a more summarized level. 
The purpose of each report was to inform each of the audiences from diverse backgrounds on the 
available and relevant information so improvement can be made. Reporting dashboards were an 
example of a method that can be effective in presenting information in a way that facilitates 
informed decision making to various audiences. With dashboards, the outcome of performance 
measures could be presented graphically through a series of charts, gauges or tables. The 
graphical presentation of information facilitated comparison of actual performance against 
desired results. 
 
Table 7 - Reporting specification documentation form. 
Reporting Specification Form 
Unique ID  Use the UID from the Performance Measure Documentation Form. 
Fiscal Year  Indicate organization‘s fiscal year. 
Reporting Period 
 Indicate the period in which data applies 
⧠ Real-time  (Information reported as data generated) 
⧠ Daily  ⧠ Weekly ⧠ Biweekly  ⧠ Monthly ⧠ Quarterly  
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⧠Annually 
(Information is reported within the indicated time period) 
⧠ Monthly in arrears  ⧠ Quarterly  in arrears 
(Information is reported in the following time period) 
⧠ Other – Provide details:________________________________       
Reporting Frequency 
 Indicate the required frequency for reporting. 
⧠ Daily  ⧠ Weekly  ⧠ Biweekly  ⧠ Monthly  ⧠ Quarterly  ⧠ 
Annually 
⧠ Other – Provide details:________________________________       
Frequency of data 
processing & analysis  
 Indicate the frequency of data processing based on the reporting 
frequency chosen above.  
⧠ Daily  ⧠ Weekly  ⧠ Biweekly  ⧠ Monthly  ⧠ Quarterly  ⧠ 
Annually 
⧠ Other – Provide details:________________________________       
 
 If applicable, indicate the frequency of analysis based on the 
reporting frequency chosen above.  
For instance it may be practical to aggregate data on daily basis, but 
for comparison purposes it may be appropriate for the data to be 
analyzed on weekly, monthly, annually, bi-annually.    
⧠ Daily  ⧠ Weekly  ⧠ Biweekly  ⧠ Monthly  ⧠ Quarterly  ⧠ 
Annually 
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⧠ Other – Provide details:________________________________       
Method of Analysis  
 Indicate in detail the method, in which performance measure is 
computed.  
Type of measure   
 Indicate the type of measure (i.e. rate-based, count based, and 
etc.).
472,479
 
⧠ Proportion Measures 
This type of measure allows comparison among organizations or 
trends over period of time. This measure requires both a numerator 
and denominator. The measure identifies target population, the time 
period, which the event may take place (e.g. proportion of 
cardiovascular surgery patients who were transfused). This type of 
measure often is expressed as a percentage and the numerator is 
contained in the denominator.   
⧠ Ratio Measures 
This type of measure the numerator is not contain in denominator 
(i.e. ratio of cardiovascular patients transfused and not transfused) 
⧠ Count Measures 
This type of measure includes number of events without 
denominators (i.e. Number of single RBC units transfused in the 
past month) 
⧠Outlier Measure 
This type of measure highlights events that are inherently 
149 
 
undesirable and usually warrant detailed analysis to determine why 
the event occurred. It indicates poor performance (i.e. Patient 
transfused with Hgb level above 10 g/dL) 
Aggregation Level  
 Indicate the level within the system to which information must be 
reported (i.e. physician level, service line level, department level, 
organizational level, etc.). 
Risk-Adjusted  
 Indicate whether risk adjustment strategy is required. 472,480  
⧠ Required  – Provide details:___________________________ 
⧠ Not Applicable      ⧠ Other – Provide 
details:__________________    
A risk adjustment strategy reduces the possibility of external factors 
influencing the measure and ensures that the measure is a true 
reflection of the process being measured. Certain characteristics 
may influence outcome (i.e. age, disease condition, etc. ) 
List of reports 
performance measure 
is included in 
 List the various reports, where this measure will be used to report 
on performance.  
Comparative 
Analysis 
 Indicate whether the measure is being measured in other healthcare 
institution or nationally for benchmarking purposes. 
Monitoring 
 Indicate how often measure  will be monitored and by whom. 
⧠ Daily  ⧠ Weekly  ⧠ Biweekly  ⧠ Monthly  ⧠ Quarterly  ⧠ 
Annually 
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⧠ Other – Provide details: 
______________________________________ 
 Include the individual(s) responsible for collection and extraction    
Name: ___Department: ____Position:______ Email: ______ 
Phone:______________ 
 
 
Evaluation Criteria 
Once specifications were completed and the indicators were comprehensively defined, the next 
step was to evaluate the attributes of performance management system components (metrics and 
indicators). Table 6 outlines a list of characteristics and related questions for assessment of the 
different components. The criteria were partially adapted from Health Information authority, 
472,479
 World Health Organization 
481
, and the Joint Commission
480
.   Each component of PMS 
had to be approved based on the judgment and consensus of subject matter experts, and, if 
possible, potential users
481,482
.  Measures that had been selected using scientific evidence 
possessed high content validity relating to important aspects of the quality of care provided. 
Measures selected through consensus and guidelines had to have high face validity to ensure that 
performance measurements made logical and clinical sense based on extensive past observations. 
Reliability could be influenced by training, the measure‘s definition and the precision of the data 
collection methods 
483
. Based on the theory of reliability, reliability could not be exact, thus had 
to be  estimated 
484
.  Inter-rater reliability testing compared variations among different evaluators 
performing the same measurement, in order to identify inconsistencies among the evaluators 
472
. 
Internal consistency was used to assess the consistency across results within a test. It examined 
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the relationship between sub-indicators of the same overall measurement, and if reliable, there 
were correlation of the results. Test retest reliability compared the difference in results when the 
same evaluator performed the measurement at different times. The preferred method for 
choosing measures was through the systematic evaluation of the scientific evidence in support of 
a specific measure. This was achieved through rating the strength of the scientific evidence itself. 
For instance, an alphabetical grading scale was used to evaluate the strength of the evidence. The 
rating scale was determined as A through C. Measures supported by meta-analysis of 
randomized controlled trials, controlled studies without randomization, epidemiological studies 
received scores of A, B, and C respectively
485
. In healthcare, there may be limited scientific 
evidence in support of a certain measures, therefore it became necessary to benefit from expert 
opinions
486
.  
 
Data collection feasibility was one of the critical elements of evaluation criteria. The burden of 
collecting the types of data elements required to construct the measure was an important 
consideration. However, it did not outweigh the value of information that could potentially be 
obtained. The driving force behind data collection programs has to be focused on continuous 
improvement of processes and domain knowledge, with the goal of applying that knowledge to 
devising improved performance management strategies. Data collection and analysis were 
considered as the foundation on which sound performance management system strategies could 
be devised and implemented. Data collection must take on a culture that begins at the onset of a 
key improvement initiative and is maintained throughout its life as long as it is economical. In 
other words, the value of information gained from the data must outweigh the cost of collection 
and analysis of the data.
487
.  Cost benefit analyses was done to determine the cost effectiveness 
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of data collection. This included the type of approaches that were used to collect data and the 
limitations of the systems used for collection.  Reporting arrangements was outlined, including 
reporting arrangements for existing data collection and frequency of data collection and analyses. 
 
Table 8 - Performance measure evaluation criteria. 
Performance Measure Evaluation Criteria 
Title  . 
Unique ID  Use the UID from the Performance Measure Documentation Form 
Version  Indicate version (e.g. 1.0). 
Date  Indicate today‘s date. 
Validity  
 Does the measure what it is supposed to measure? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
 
A valid (metric, indicator, or key performance indicator) measures 
what it is supposed to measure and captures an important aspect of 
quality that can be influenced by the healthcare facility or system. 
Ideally performance measures selected should have links to 
processes and outcomes through scientific evidence. 
Reliability  
 Does the measure provide a consistent output? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
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The metric, indicator, or key performance indicator should provide 
a consistent measure in the same population and settings 
irrespective of who performs the measurement. Reliability is 
similar to reproducibility to the extent that if the measure is 
repeated the same result should be obtained. Any variations in the 
result of the metric, indicator, or key performance indicator should 
reflect actual changes in the process or outcome.  
Evidence-Based 
Explicitness  
 Is the measure supported by scientific evidence or the consensus of 
experts? 
Score:________   ⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
 
Metric, indicator, or key performance indicator should be based on 
scientific evidence, the consensus of expert opinions among health 
professionals or on clinical guidelines. 
Acceptability 
 Is the metric, indicator, or key performance indicator acceptable? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
 
The data collected should be acceptable to key stake holders (i.e. 
Physicians, Transfusion Service, etc.) those being assessed and to 
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those carrying out the assessment. 
Data Collection 
Effort and Feasibility  
 Is it possible to collect the required data? Is it worth the resources? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
 
Required data elements must be available and accessible 
The feasibility analysis should determine what data sources are 
currently available, resources required to collect required data, and 
if they are relevant to the needs of the current project. This will 
include determining if there are existing metric, indicators, key 
performance indicator, or benchmarking processes based on these 
data sources.  
 
There should be a feasibility analysis carried out to determine what 
types of data are currently being collected in what format, and 
whether those can be leveraged, also the resources required to 
collect any additional required data. 
Sensitivity  
 Are small changes reflected in the results? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
Changes in the component of care being measured should be 
captured by the measurement process and reflected in the results.  
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Specificity 
 Does the measure actually capture changes that occur in the service 
for which the measure is intended? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
Changes in the component of care being measured should be 
captured by the measurement process and reflected in the results. 
The measure should be capable of detecting changes in the quality 
of care and these changes must be reflected in the resulting values. 
Results 
Interpretability  
 Can the rational and the result of the measure be easily understood 
by the intended audience?   
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
Presentation of the results and information must be demonstrated in 
a meaningful manner to ensure intended audience can understand 
and interpret the results and information in a same manner and with 
no variation for decision making purposes. 
Relevance  
 Does a decision(s) can be made from the measure? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
The results of the measurement should be of use in planning and the 
subsequent delivery of healthcare and contribute to performance 
improvement 
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Balance 
 Is there a set of measures that calculate different aspects of the 
service? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
The final suite of indicators should measure different aspects of the 
service in order to provide a comprehensive picture of performance, 
including user perspective
488
.  
Tested 
 Have national and international measures been considered? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
Consideration must be given to measures that have been tried and 
tested in the national and international arena rather than developing 
new indicators for the same purpose. 
Safe 
 Will an unwarranted focus on the measure lead to potential adverse 
effects on other aspects of quality and safety? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
The indicator should not lead to an undue focus on the aspect of 
care being measured that may in turn lead to a compromise in the 
quality and safety of other aspects of the service. 
Duplicated  
 Has other previously developed measures been reviewed to ensure 
measure is not duplicated or overlapped?   
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⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
Prior to developing the measure, considerations must be made to 
ensure none of the measures are duplicated or the results overlap 
with one another. Individual measure should be distinct in the 
measure itself and the result of the measure to prevent any 
confusion or misinterpretation of results.    
 
Has consideration been given to other projects or initiatives? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
Prior to developing the indicator consideration should be given to 
other projects or initiatives to ensure that there will not be a 
duplication of data collection. 
Timeliness 
 Will the information be available within an acceptable time period 
to inform decision-makers? 
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
The data should be available within a time period to empower 
decision-makers to utilize the result to inform their decision-making 
process.  (i.e. If the data is required for operational purposes, then it 
will be required within a shorter timeframe than data used for long 
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term strategic purposes). 
Accreditation 
Usefulness  
 Does the measure provide capability to supplement or enhance the 
current accreditation process and support healthcare organization 
quality improvement efforts?  
⧠ Yes     ⧠ No     ⧠ Not Applicable  
⧠ Other – Provide details:_________________________________ 
 
Consensus, evidence, or guideline must provide information on the 
usefulness of the measure for the purpose of benchmarking or 
identification of best-practice. 
Final Consensus  
 The measure: 
⧠ Pass     ⧠ Fail- See notes below   ⧠ Re-evaluation Required: 
⧠ Other – Provide details:_______________________ Notes: 
3.3.5. Identification of Information Silos 
Using the method described system feasibility, analysis, and design for the transfusion medicine 
PBM data systems were conducted by reviewing the reporting requirements of the PBM program 
in relation to the available data sources. After deciphering the content of the hospital‘s current 
information systems, five major source systems were identified as holding the required data 
elements. The sources systems are listed in Table 9; the source systems identified and cross-
examined for development of transfusion medicine performance management system. 
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Table 9 - List of required source systems for generation of data feeds. 
Source Systems Content 
Finance Information System Patient days and patient admission information 
Health Information System Patient encounter, discharge information 
Transfusion Service Information 
System 
Patient Transfusion and crossmatch information.  
Blood products inventory and wastage 
information 
Lab Information System Patient lab results information 
Medical Credentialing System 
Information on all current and historical 
healthcare providers  
 
Minimum datasets were identified from each of the above systems. The datasets were 
sufficiently refined to enable cross-examination at levels required to ensure a contextual view of 
information. A single database was created at the BloodCenter of Wisconsin to collect and link 
the hospital‘s diverse source systems from existing databases in order to provide reports and 
perform analytics related to transfusion medicine practices. 
 
Extract Contextual Dataset 
An analytic and reporting solution was needed in order to code and construct performance 
measures for the study. It was necessary to aggregate relevant data and information from the 
hospital‘s diverse source systems in order to build reports and perform the analytical (e.g. 
statistical and quantitative) manipulations required to support informed decision making.  
InSight™ is a reporting and analytics solution from Mediware based in Lenexa, KS which had 
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been licensed by BloodCenter of Wisconsin.  InSight™ is a performance management solution 
designed to optimize operational performance through presentation of trends. InSight™ 
performance management solution encompasses a back-end called DataLoader, which provides 
limited, non-enterprise-level Extract – Transform –Load or ―ETL‖ capabilities. This function 
most readily integrates with Microsoft and SQL databases. The front end is called InSight, which 
provides a web interface to the end users as a portal to view pre-defined reports and dashboards. 
In addition, the solution offers array of capabilities, few include: 
 Customization and dynamic viewing of reports,  
 Sequential drill down capabilities on performance measures to view the information from 
top-level to the most granular detail levels,  
 Graphical display of information, 
 Interactive reporting capabilities,  
 Customizable graphs and changeable time periods,  
 Integrated email and export functionality to Excel.  
A license agreement was drafted with Mediware (Lenexa, KS) to allow both internal (i.e. 
BloodCenter of Wisconsin Transfusion Medicine team) and external users (i.e. hospital‘s end 
users) to access the portal for reporting and viewing purposes. The data sets were transferred 
from the hospital to BloodCenter of Wisconsin using a secure file transfer protocol (sFTP) and 
were stored in a central repository (Figure 6 and 7).       
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Figure 6 - Conceptual representation of data acquisition, aggregation, processing, and reporting. 
 
Data Sources  
There was an abundance of data surrounding transfusion medicine. These data often resided in 
several different ‗transactional‘ systems. In general, transactional systems are designed for the 
various aspects of running day to day operations. These systems are considered the originators of 
data for analytics purposes. Although, it may be possible to run reports directly out of the 
transactional systems, there are cautionary reasons to avoid direct manipulation of data in a 
transactional system including the possibility of slowing down or compromising the source 
system. In addition, in the case of transfusion medicine which spans across multiple departments, 
the majority of reports required data from more than one transactional system. Therefore, for this 
162 
 
study data had to be moved into a different data repository, a SQL database that was located at 
BloodCenter of Wisconsin, for data processing, analysis, and reporting. The hospital was 
responsible for providing the required data on a routine basis to BloodCenter of Wisconsin for 
processing using a secure file transfer mechanism. In order to comprehensively complete this 
phase, a high-level questionnaire was drafted that was used as a discussion guide to learn about 
the various health information systems and other transactional systems within the hospitals. The 
questionnaire was aimed at identifying various source systems for aggregation of relevant data, 
confirming the availability of certain data elements in specific source systems and accessing 
support from the hospital Information Technology Department when necessary for aggregation 
and transfer of data. Ultimately, to successfully implement the analytics program, a cross-
organizational project team was engaged.  The key milestones of an implementation and the 
roles of individuals required for the success of an implementation were outlined and reviewed 
(Appendix B). 
 
Data Transport 
In order to transfer the data from the hospital to BloodCenter of Wisconsin, a Secure File 
Transfer Protocol (sFTP) was established for accessing and managing the data file transfers. A 
lightweight enterprise service bus, MuleSoft (San Francisco, CA) was employed as integration 
software to pick up the data files from the sFTP server and deliver them to an internal repository 
at BloodCenter of Wisconsin (Figure 7). 
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Figure 7 - Overview of connection architecture. 
 
Data Intake 
 Once data was securely received from the hospital‘s diverse and disparate source systems, data 
was loaded and transferred into a data repository. This process is typically referred to as ―ETL‖ 
and is the process of taking selected transactional data (both structured and unstructured) into a 
type of a data store (i.e. data warehouse, data mart, operational data store, analytic databases, 
etc.) in an organized form. More specifically, extract was the process of reading data from a 
database. Transform was the process of converting the extracted data from its previous form into 
the form it needs to be in so that it could be placed into another database. Transformation 
occurred by using rules or lookup tables or by combining the data with other data. Load was the 
process of writing the data into the target database. Data Loader offered basic ETL capabilities to 
perform this step.  
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Data Linkage 
There were no direct links between patients‘ administrative and clinical system records. Even 
among clinical records there was no links among datasets from the lab information system and 
the transfusion service information system dataset. There was the same lack of a linkage of 
various events and procedures for healthcare provider among the various health information 
systems. Only actual blood transfusion sessions (excluding wastage) and laboratory results were 
linked with the administrative records which indicated blood information and laboratory results 
with the dates and times that fell between admission and discharge data and time. To protect 
patient privacy of information across the diverse source systems, a single unique identifier was 
created. The identifier employed a combination of patient encounter identification and facility 
designation. The patient medical record number, a single unique patient identifier, was only used 
for validation of the linkage on the back end system and was not reported. 
 
Database Design 
 Once data was successfully loaded into Data Loader, they were stored in a relational SQL server 
database, which was considered the operational data store. A unified metadata layer was defined; 
and data from the various source systems were mapped to enable contextual information. 
Various views (virtual tables) were created to join subset of data from different tables (populated 
from disparate information systems) with coded logics built-in for contextual view of data, and 
to limit exposure to the underlying source data. The logics were coded in the views to link data 
on patient, provider, blood products and clinical details that were required to for individual 
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measures in the performance management system. Finally, the data was configured through the 
design of various data models to match the constructed measures. 
Security Measures  
Health information is very sensitive and has formal definitions around the security of patient 
data. Data feeds were partially de-identified to reduce the risk of exposure of patient health 
information. Patient identifier data elements that were used to validate patient records across 
different source systems were minimized. In addition, access to the data repository, Data Loader, 
and InSight™ web application were restricted through authorization and authentication.  Audit 
services were put in place to track access to different the types of data and measures. Session 
timeout was placed for InSight web application to prevent users to remain logged in for a long 
period of time.  
 
End-User Analytical Capabilities 
The Insight application provided the end users with a portal to view pre-defined reports and a 
dash board. It enabled more advanced users to export data into Microsoft Excel for further 
analysis. Most of the capabilities have been mentioned above.    
 
Develop a Performance Management System 
Once the identified data feeds were received through the mechanism described above, the next 
step was to construct the performance measures (Figure 8). Figure 8 represents a simplified 
overview of the performance measures build process from raw data to the metrics and indicators. 
The construction of the performance measures followed the instruction provided by Mediware 
(Lenexa, KS). Briefly, Data Loader allowed administrators to setup data flows that import legacy 
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data into the database and perform calculations on it so that its data can be utilized by InSight 
web application.  InSight web application allowed users to view the information using the 
performance measures and 
perform further analysis if 
needed for reporting and 
management purposes. 
―Measures‖ were used to answer 
questions as to the performance 
of monitored services. 
―Indicators‖ were used to give 
the users the information so that 
they could manage performance proactively. ―Data flows‖ indicated all the steps required to 
transform raw data from a text file, Excel file, or a database table, or a view into one or more 
measure(s). A data flow consisted of three components of ―job‖, ―template‖, and ―table‖. The 
table stored the data. The template helped transform the data in the text file, Excel file or 
database table/view into a table. One or more job(s) were required to perform operations on the 
data, including the file processing step to transform the data into the table.   
 
To design data flows, raw data was received from the hospital. The acceptable data sources were 
delimited text files, fixed width text files, Microsoft Excel files, Microsoft SQL server database 
or Microsoft Access both using a Microsoft Data Link (UDL) file. The table consisted of three 
different table structures: time series, reference tables, and hierarchies tables. Time series table 
held a set of information over time that measured a process. This information was typically 
Figure 8 - Represents the conceptual view of the processes 
involved in building of a performance measure. 
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intended to be displayed in the InSight web application for the end users. Reference tables 
contained data whose purpose was to be mapped into time series tables. They could contain any 
combination of text and numerical data. Reference tables allowed the combination of data from 
different systems for use in a single table. The tables received and held the data. Hierarchies 
tables enabled drill down capabilities to provide granularity in viewing the information. It 
enabled the user to progressively delve into increasing level of detail.  
 
Once the tables were set up, the next step was to develop the jobs for the import processes into 
the time series tables for display of the information on the InSight web application. Prior to 
publishing the information on the web application, it was important to note that both Data Loader 
and the InSight web application used tables to store table structures and their corresponding data. 
In this context, a table encompassed both a Data Loader table and a data table. A Data Loader 
table was a collection of data that represents the structure of a data table in the database. It 
specified the format of the table, table fields and field types contained, etc. The Data Loader 
table contained the meta-data for a data table.  Data table was a SQL table that contained the data 
itself for a table. Data tables used jobs for the import of data. The template related the data fields 
in the source repository to data fields in a target database table. It allowed the user to link 
between fields, add expressions to set the value of database fields and add variables that could be 
used in other expressions.  
 
All database tables were initially populated with data as specified in a template. Templates were 
used by the process file job step which took the data from the source system and used it to add 
data into a target database table. The template was the second of three arguments used by the 
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process file job step. A job was a set of steps that processed the data and loaded it into a table for 
delivery and viewing in the InSight web application. The job(s) were first run to populate the 
reference tables and then run the second time to import data into the time series table. As 
indicated, jobs could have one or more steps. A job always contained the ‗get parameters‘ job 
step as the first step. The ‗get parameter‘ step was not editable in the Data Loader user interface. 
In addition, the jobs had parameters; supplying parameter values to the job gave Data Loader the 
information to supply parameter values to all the steps defined for the job.  
 
Every different step required different parameters, which had to be set individually.  Common 
job parameters included input files, input template, and production table. The input file 
parameters were typically used when the job contained a process file job step to import data from 
a source system into a database table. The process file step defined which type of file would be 
obtained from the source data (i.e. file that contained a flat data file or a file that told that step 
where to get the data from was referred to as data link file or UDL).The input file parameter was 
typically used when the job contained the process file step to import source data into a database 
table. This parameter referred the process file step to which template should be used to map the 
source data to the database target table. The production table parameter told the job from which 
database table the data should be used. Once data flow was processed and deployed successfully, 
the performance measure would be ready for viewing by the end user on the InSight web 
application. 
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3.3.6. Awareness and Education 
Healthcare Performance Management Dashboard  
Performance dashboards were a component of the performance management system that enabled 
communication of strategic goals and empowered the stakeholders to measure, monitor, and 
manage key initiatives and processes required to meet objectives and accomplish tasks. 
Dashboards provided tailored reports that informed specific individuals or groups of 
administrators and healthcare professionals.  For example, a clinical dashboard had to provide 
the capability to:  
i. Monitor defined processes and activities using measures and to show trends that identify 
potential problems;  
ii. Facilitate analysis of the root cause of problems by exploring relevant and timely 
information from multiple perspectives and at various levels of granularity;  
iii. Inform management of individuals‘ performance and processes to improve decisions, 
optimize performance, and guide the program towards the intended objective. 
The next step was the integration and display of the information in a timely and meaningful 
manner to the intended audiences (physicians, administrators, managers, department heads, etc). 
InSight web application provided physicians, other healthcare providers, and administrators with 
access to the aggregated information in a form of a report which promoted informed decision 
making and allowed tracking trends of individual healthcare provider or service line groups. User 
access to the dashboards was defined for the end users using a uniform resource locator (URL). 
 
For this study, the dashboard was utilized to monitor blood product utilization, transfusion 
appropriateness based on pre-transfusion lab values, quality of blood products transfused, and to 
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inform hospital management and administrator of the transfusion medicine practice. The 
dashboard was customized to take into account specific department‘s information needs.  It was 
designed to provide custom reports to individual groups of stakeholders such as physicians, 
nurses, transfusion service lab technicians, departments, executives and the medical director of 
transfusion safety committee. The customization enabled a specific set of information to be 
presented to the intended audience. This ensured security of information and provided a means to 
avoid information overload which remains a barrier to healthcare providers using specialized 
resources. Therefore, designing the level of granularity, type of information, and method of 
presentation were key factors in designing dashboards that presented measures in a meaningful 
way while avoiding fatigue and desensitization. The dashboard followed a build instruction 
provided by the software vendor.   
     
Effective Interventions to Encourage Best Practices 
A multi-pronged intervention strategy was adopted to encourage continuous adherence to 
transfusion medicine best-practice guidelines. The strategy was based in part on an extensive 
review of literature on the most effective education strategies that affect physician behavior, 
performance, and healthcare outcomes.  The search included a bibliographic search of published 
research and a citation review of relevant articles. In addition, past approaches of the transfusion 
safety nurse were evaluated to determine any correlation between educational and reporting 
interventions (i.e. dissemination and review of reports with department heads, individual 
physicians, educational newsletters, formal presentations, posters, blogs, etc.), and change in the 
associated transfusion practice trend. Periodic conversations with the medical director of the 
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transfusion committee also were used to determine best approaches and incentives to help 
change inappropriate transfusion practices. The intervention strategy included: 
i. Distribution of evidence-based practice guidelines as a performance standards;  
ii. Use of newsletters and posters on transfusion best practices;  
iii. Creation of continuing medical education courses on evidence-based transfusion 
practices;  
iv. Distribution of paper transfusion summary reports to individual physicians and 
department heads; 
v. Review of outlier (i.e. physicians not practicing in accordance with evidence-based 
guidelines) reports by the Transfusion Committee Medical Director followed, when 
necessary, with a formal letter citing cases and recommendations.   
vi. Creation of an environment focused on information, not punishment. (Reports would 
eventually be tied to Physician Performance Evaluation reviews.) 
vii. Evaluation of the effect of blinded and un-blinded reports for comparing individual 
physicians with their peers.  
 
3.3.7. Develop Feedback Mechanism 
In order to assess the changes in physician practice an analytics framework was developed and 
used to address the following fundamental questions:  
 What types of improvements (quality, performance, safety) were desired?  
 What processes had to change or be created to result in improvement?  
 What change (if any) had occurred? 
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Figure 9 represents the position of the analytics framework in the context of information value 
chain. The goal of the analytics is to continuously improve efficiency and effectiveness of every 
decision and action. Figure 10 details the steps involved in the analytics framework used for this 
study. It begins with the emphasis on data quality, addresses cross functional inefficiencies due 
to heterogeneity of various information systems and data silos, emphasizes contextual 
development of data models, and enables use of different applications of analytics from 
diagnostics and, to predictive and perspective, it incorporates statistical framework to understand 
sources of uncertainty between observation and what actually occurred. The analytics model 
below took into account system of tools, technologies, techniques, and people to consistently and 
reliably generate data-driven information with the focus to drive clinical insight needed to take 
appropriate actions and achieve measurable and desired outcomes.  
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Figure 9 - Details the steps involved in building and using the analytics framework. 
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Figure 10 - Details the steps involved in building and using the analytics framework. 
 
Moreover, the information value chain served as continuous feedback mechanism loop to 
evaluate changes directly impacted by the promotion of restrictive transfusion approach, to 
identify new areas for improvement, and avoid unintended consequences and outcomes. 
 
3.3.8. Evaluation of Change in Physicians Practice  
Evaluation of physician performance and feedback across multiple organizational levels were 
key components in the success of the project. Evaluation was based on the performance of 
hospitalists relative to the consensus RBC utilization recommendations which included:  
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 A restrictive transfusion strategy with a transfusion threshold of hemoglobin level of 7 
g/dL, or 8 g/dL for patients with cardiac conditions.   
 Order of single-unit RBC transfusions with a restrictive pre-transfusion Hgb trigger. 
 Post-transfusion reassessment for determination of patients need for subsequent 
transfusion. 
Pursuant to transfusion medicine best practices education programs, the transfusion medicine 
PBM performance management system tracked various aspects of healthcare providers‘ 
transfusion practices. Hospital data was actively used to develop reports and an analytical 
framework was used to retrospectively evaluate changes in the transfusion practices of the 
hospitalists. The hospitalists and department heads were provided with reports on individual 
physicians‘ which included transfusion metrics on RBC ordering on a quarterly basis. For the 
purpose of the global review, the report to the department chair was unblinded with identified 
physicians and their transfusion information; the report to individual hospitalists was blinded to 
allow comparison of each. Corrective feedback on the reports was provided as needed through 
multiple avenues including: further education, peer to peer education, formal letters from the 
Transfusion Steering Committee Chair, and reflection on performance evaluations.  
 
Data analysis was conducted over a 24 month period in order to evaluate pre and post 
intervention periods. The time period for data collection and analysis was from October 1, 2012 
to September 30, 2014. The 24 month period was chosen to take into account 12 months of pre-
intervention and 12 months of post-intervention and to allow for the seasonality that was 
observed in the number of patient admissions to the hospital in different months. The patient type 
included in this study was hospitalized individuals with an inpatient designation. 
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Cost Analysis of Red Blood Cell Utilization 
A value stream map based on lean management methods for analysis of current and future state 
was employed.  Diagnostics, therapeutic, technical, laboratory, logistics, administrative, 
education, and quality activities associated with RBC transfusion ordered for patients were 
observed and documented by the transfusion safety officer prior to implementation of the 
framework. To determine activity-based cost of RBC transfusion, processes and activities 
associated with RBC transfusion were divided into six major categories including:  
 Maintenance of blood products by blood bank including activities such as: inventory 
monitoring, blood components ordering, unit checking, blood grouping, returns 
processing, antigen screening, etc. 
 Pre-transfusion activities including: physician evaluation of patient, obtaining pre-
transfusion samples, sample processing, Hgb and CBC testing, and etc.  
 RBC unit preparation by transfusion service including: receiving and processing 
transfusion order, label creation, delivery to patient, patient type and screen, 
reconfirmation of patient blood type, unit selection, unit labeling, etc. 
 Transfusion nursing staff including: ordering transfusion, verification of entered order, 
consent form preparation and completion, assembly of supply, receipt and verification of 
blood unit, verification of match, re-identification of patient, monitoring patient vitals 
every 15 minutes, monitoring patient for duration of transfusion, documentation, post-
transfusion assessment, transfusion reaction support, etc.  
 Post transfusion activities including: Hgb and CBC testing, transport of samples to the 
lab, receipt and log of samples, post transfusion testing and assessment, etc. 
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 Other activities include: rework factor, overhead, product and supply wastage, inventory 
carry cost, and etc.   
 
A cost model adapted from a landmark  study that focused on an in-depth examination of the 
complex array of activities surrounding the decision to transfuse on transfusion activity-based 
cost 
21
 was used to determine the cost of RBC transfusion. 
3.4. Statistical Analysis 
After receiving approval from the hospital under Business Associate Agreement, 24 months of 
data from October 2012 to September 2014 was collected for inpatient encounters (32, 870) at 
the institution. Neonate patients less than 1 year of age (3,652) were eliminated due to higher 
Oxygen binding affinity of fetal hgb. There were 11,553 inpatients whose attending physicians 
were hospitalists (35 physicians with hospitalist designation as primary specialty). ETL 
processes, mapping and linkage of data were performed prior to storage of data in a central SQL 
server repository using a performance management analytics portal (InSight, Mediware Inc., 
Lenexa, KS). The central repository contained data from the hospital‘s diverse and disparate 
information source systems (including: finance, transfusion service, laboratory, medical staff 
services, and EHR systems).  Data was extracted from the central repository using SQL queries, 
and was processed and analyzed using software programs including Excel statistical package 
(Microsoft Inc., Richmond VA), and MATLAB (MathWorks Inc., Natick, MA). Categorical 
variables were reported as frequencies and percentages; continuous variables were reported as 
means with standard deviations. Comparisons of categorical and continuous variables were done 
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using Pearson Chi-Square test and two sample t-test, respectively. All significance tests were 
two-tailed, with α level of 0.05 to denote statistical significance. 
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Chapter 4: Results 
The study results are based on 32,870 patient encounters with inpatient status from October 1, 
2012, to September 30, 2104. During this time period, 9.12% of discharged inpatients received 
RBC transfusions using a total of 8,905 RBC units (not including wasted units). Patient 
information was linked across disparate source systems using a composite unique key which 
consisted of the hospital facility code and an encounter identification number. Approximately 
99.15% of discharged inpatients were linked to their transfusion events and clinical details.  
 
October 1, 2012 to September 30, 2013 represents pre-implementation of an evidence-based 
restrictive transfusion medicine framework. October 1, 2013 to September 30, 2014 represents 
post-implementation of the evidence-based restrictive transfusion medicine framework period. 
The post-implementation period included the following hospital-wide interventions: 
 Recommended a restrictive transfusion strategy with a transfusion threshold of 
hemoglobin level of 7 g/dL, or 8 g/dL for patients with cardiac conditions.   
 Recommended orders of single-unit RBC transfusions for non-bleeding stable medical 
patients with a restrictive pre-transfusion Hgb trigger. 
 Recommended post-transfusion reassessment for determination of patients need for 
subsequent transfusion.  
 Offered continuing medical education courses on the latest evidence-based approaches to 
transfusion medicine. 
 Distributed educational and materials in the form of newsletters, posters, and flyers.   
 Constructed and implemented performance management system to track and measure the 
evidence-based recommendations. 
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 Implemented transfusion medicine reporting and utilized data analytics software to 
analyze the trend and report on transfusion practices. 
 Distributed transfusion reports targeted to individual hospitalists and department heads 
for all relevant service lines. 
 Implemented an analytics framework to evaluate changes directly impacted by the 
promotion of restrictive transfusion strategies, to identify new areas for improvement, 
and to avoid unintended consequences and outcomes. 
4.1. Performance Management System  
A performance management system (PMS) was constructed to achieve the following objectives 
in transfusion medicine including: identification of areas for best practices, facilitation of actions 
to improve health services, improvement of patient care and outcomes, and assurance that 
operational activities are linked to the overall organizational strategies.    
 
Specifications documents were used (Tables 3-7) to construct the different metrics and indicators 
as part of PMS which: helped define targets and thresholds across key aspects of service delivery 
including management of resources (e.g. blood products); enabled a comprehensive picture of 
the service lines (e.g. hospitalists) progress towards achieving goals recommended by the 
evidence-based best practice guidelines; provided a mechanism for early indication of emerging 
issues that may require corrective actions; and indicated where there was a potential to improve 
the cost effeteness of services.  
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4.1.1. Performance Monitoring       
The hospital, as part of a larger healthcare system, was composed of a number of separate and 
distinct levels of operating units. To accommodate the different levels of operating units, the 
performance measures were designed and constructed to accomplish a granular level of reporting 
(e.g. system, hospital, clinical service line, and individual physician) pertaining to these different 
units. There were dimensions that were different across service lines, but there were also 
dimensions that were common. The PMS system was designed and constructed to scale as 
additional hospitals were added in the future (Figure 11).  Figure 11 represents a conceptual 
representation of the PMS for the hospital. It represents a combination of performance measure 
including: measures (e.g. Hgb, INR, Fibrinogen lab values), metrics (i.e. blood products 
utilization metrics), scorecards (i.e. tracking physicians‘ ordering of blood product transfusions), 
and key performance indicators (i.e. measure progress towards achieving objectives). Scorecards 
play a key role within a PMS. They enable translation of strategic goals into tangible objectives 
and measures. It allows measuring, monitoring, and assigning key performance indicators to 
track and optimize performance towards organizational goals.   
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Figure 11 - Conceptual representation of the performance management system for the hospital. 
The construct PMS was used to implement evidence-based transfusion medicine strategies in the 
hospital.  
4.2. Hospital Activity Profile 
4.2.1. All Inpatient Demographics and Hospital Activity Profile  
The hospital‘s activity profile and patient demographic during the study time period are 
represented in Table 10 using descriptive statistics. 
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Table 10 - Hospital activity profile and patient demographic. 
 
4.2.2. Transfused Inpatient Demographic and Hospital Activity Profile  
Table 11 represents the demographic of inpatients who received at least one unit of RBC 
transfusion using descriptive statistics. The rate of inpatients that were transfused with RBC unit 
was significantly decreased during post intervention period X
2 
(1, N = 32870) = 18.66, p < 0.01. 
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Table 11 - Hospital wide transfused patient demographic. 
 
4.3. Current State Assessment of RBC Usage  
The percentage of RBC units in individual clinical service lines compared to total hospital wide 
RBC units was calculated as a baseline analysis for the pre-intervention period (Oct. 2012 to 
Sep. 2013) 2013 (Figure 12).  During the pre-intervention period 4910 RBC unit were 
transfused. Hospital Medicine represented 34.09 % (1,674 Units) of RBC usage, followed by 
Cardiothoracic Surgery 12.53 % (615 Units), General Surgery 9.84% (483 Units), Hematology 
and Oncology 9.41 (462 Units), and Pulmonary Medicine 8.76% (430 Units). The five clinical 
specialties accounted for 74.62 % of the hospitals total RBC use. In this study the specialty is 
defined as the physician in charge of ordering the RBC transfusion.  
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Figure 12 - Hospital wide usage of RBC units by clinical specialties. 
 
Following AABB guidelines for PBM 
489
 as a starting point, annual, and later quarterly, data on 
the overall RBC usage adjusted per 1000 patients  was collated. The collated data provided a 
mechanism for benchmarking the hospital against itself and in the future against similar hospitals 
with a similar patient mix. Blood component usage data was collated by clinical service line (e.g. 
internal medicine, hospitalists, hematology/oncology, cardiothoracic surgery, orthopedic 
surgery) and even more specifically by physician group and individual healthcare provider which 
allowed focusing the efforts on identifying clinical service lines that utilized the most blood 
products and thus targeting the areas where education and change would have the greatest 
impact.   (Figure 13) shows RBC transfusion per 1000 patient days by clinical service line. 
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Clinical specialties with the highest yield of RBC transfusion per 1000 patient days included: 
Hospital Medicine with 21.73, followed by Cardiothoracic Surgery with 7.98, General Surgery 
with 6.27, Hematology and Oncology 6.00, and Pulmonary Medicine with 5.58 RBC units 
transfused per 1000 patient days.   
 
Figure 13 – Hospital-wide inpatient RBC transfusions per 1000 patient days. 
4.4. The Impact of the Model on Hospitalists Transfusion Practice   
Figure 14 is adapted from Dzik, W. Transfusion 2003; 43 (9):1190-1199. The figure represents 
the spectrum of activities and processes involved in transfusion of blood component(s). The 
overarching aim of this study was to implement restrictive transfusion strategies among 
hospitalists, using evidence-based guidelines, data analytics, reporting, meaningful presentation 
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of information, and focused education to drive appropriate decision making and interventions 
prior to formulating the decision to transfuse and prior to issuing of blood component(s). The 
arrow on Figure 14 represents the point on the transfusion spectrum where this study aims to 
influence the hospitalist‘s decision of whether to transfuse or not and how much.   
 
Figure 14. Represents the spectrum of activities and processes involved in transfusion of blood 
or blood components (adapted from Dzik, W. Transfusion 2003;43 (9):1190-1199). The arrow 
shows the stage in the process at which the framework was employed to influence physicians‘ 
transfusion decisions. 
 
Figure 14 - Represents the spectrum of activities and processes involved in transfusion of blood 
or blood components. 
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4.4.1. Changes in RBC Transfusions 1000 Patient Days  
Figure 15 and 16 represents changes in inpatient RBC transfusions per 1000 patient days by 
hospitalists, comparing pre and post intervention periods. The dotted line identifies the 
separation between the Pre-Intervention and Post-Intervention time periods. Comparison of 
quarterly percent difference of Hospitalists‘ RBC transfusion activity per 1000 patient days 
showed a significant decline of 26.23% (p < 0.01), when comparing the Post-Intervention with 
that of Pre-Intervention periods. The average inpatient RBC transfusion per 1000 patient day 
during pre-intervention (Oct. 2012 to Sep. 2013) was 21.67±2.29 compared to 15.69±1.91 during 
post-intervention time period (Oct. 2013 – Sep. 2014).   
 
 
Figure 15 - Trend in Inpatient RBC transfusions per 1000 patient days among hospitalists. 
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Figure 16 represents quarterly changes in inpatient RBC transfusions per 1000 patient days by 
hospitalists and interventions that took place during pre and post intervention periods.   The 
diamond end dotted line indicates circulation of newsletters (Appendix C) on the latest evidence 
on restrictive RBC transfusion approaches and a newsletter on one vs. two unit RBC ordering 
practice highlighting the following factors:  
 Recommended a restrictive transfusion strategy with a transfusion threshold of 
hemoglobin level of 7 g/dL, or 8 g/dL for patients with cardiac conditions.   
 Recommended orders of single-unit RBC transfusions for non-bleeding stable medical 
patients with a restrictive pre-transfusion Hgb trigger. 
 Recommended post-transfusion reassessment for determination of patients need for 
subsequent transfusion  
The solid line indicates continuing medical education on pillars of PBM (Appendix C). The 
green and blue arrows represent distribution of physician performance measure unblinded reports 
(created using InSight data analytics and reporting software) to the department heads for 
different clinical service lines and reports to individual hospitalists using a blinded comparison 
approach to their peers. The (Figure 16) represents quarterly changes in inpatient RBC 
transfusions per 1000 patient days by hospitalists and interventions that took place during pre 
and post intervention periods and timing of continuing medical education and reporting.    
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Figure 16 - Trend in Inpatient RBC transfusions per 1000 patient days among hospitalists and 
representation of the interventions. 
4.4.2. Change in Transfusion Medicine Practice  
Performance of individual physicians and the capability to assess that performance are 
increasingly the key drivers for improving the quality and efficiency with which health care is 
delivered. Expanding the capabilities to measure, report, and improve physician performance is 
among key initiatives that could be employed by wide variety of stakeholders (physician group, 
quality improvement team, etc.) in the hospital. This study reported performance information to 
individual physicians that followed objectives outlined in evidence-based transfusion guidelines 
(performance standard) and PBM newsletters highlighting three key areas including: 
 Transfusion threshold of hemoglobin level of 7 g/dL, or 8 g/dL for patients with cardiac 
conditions;  
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 Orders of single-unit RBC transfusions for non-bleeding stable medical patients with a 
restrictive pre-transfusion Hgb trigger; 
 Post-transfusion reassessment for determination of patients need for subsequent 
transfusion.  
The underlying goal was to make physicians aware of their performance based on the evidence-
based guidelines and to encourage improvement in specific aspects indicated above. Since the 
implementation of the evidence-based transfusion medicine framework, change was observed 
among hospitalists‘ transfusion practices. 
 
4.4.3. Change in RBC Unit Orders   
Figure 17 Comparison of pre – intervention (Oct 2012 – Sep 2013) orders (n = 1093) and post – 
intervention (Oct 2013 – Sep2014) orders (n = 800) showed a significant change in overall RBC 
ordering practice X
2 
(2, N = 1893) = 49.07, p < 0.01; analysis of one vs. two unit RBC orders 
also showed a significant change in X
2 
(1, N = 1847) = 43.90, p < 0.01. The percent of one-unit 
orders to total orders increased by 31.7%, and the percent of two-unit orders to total orders 
decreased by 30.9%. The green and blue arrows represent distribution of physician performance 
measure unblinded reports (created using InSight data analytics and reporting software) to the 
hospitalists‘ department head and reports to individual hospitalists using a blinded comparison 
approach to their peers. 
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Figure 17 - Trend in hospitalists RBC unit ordering practice. 
 
4.4.4. Change in Pre-Transfusion Hemoglobin Threshold  
Figure 18, 19 represents analysis performed on one-unit and two-unit orders to determine 
whether there was a change in the transfusion threshold of hemoglobin level based on the 
performance standard. One-unit orders with pre-order Hgb values  7 and > 7 g/dL showed a 
significant shift towards a lower pre-transfusion Hgb trigger when the pre- and post-intervention 
periods were compared using a Chi-Square test X
2 
(1, N = 849) = 4.60, p = 0.032. Analysis of the 
mean pre-transfusion Hgb for one-unit orders during the pre-intervention period was 8.0 g/dL 
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(SD =0.71); the pre-transfusion Hgb trigger lowered to 7.7 g/dL (SD = 0.69) during the post-
intervention period. Two-unit orders with pre-order Hgb values  7 and > 7 g/dL showed no 
significant change towards a lower pre-transfusion Hgb trigger when the pre and post periods 
were compared using a Chi-Square analysis X
2 
(1, N = 701) = 3.52, p = 0.06. Analysis of the 
mean pre-transfusion Hgb for two-unit orders during the pre-intervention period was 7.5 g/dL 
(SD =0.80); the pre-transfusion Hgb trigger lowered to 7.4 g/dL (SD = 0.90) during the post-
intervention period with no statistical significance. Although results are statistically not 
significant the trend is moving towards lower pre order Hgb trigger (Hgb values  7 g/dL 
(21.38% to 27.73%) and > 7 g/dL (78.62% to 72.27%) when compared pre to post intervention 
periods.  Figure 18 and 19 represent the observed changes in pre-transfusion Hgb (g/dL) 
threshold.  
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Figure 18 - Comparison of pre-order Hgb (g/dL) trigger for one-unit RBC transfusion orders 
among hospitalists. 
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Figure 19 - Comparison of pre-order Hgb (g/dL) trigger for two-unit RBC transfusion orders 
among hospitalists. 
 
4.4.5. Change in Post-Transfusion Assessment  
Post-transfusion assessment of the effect of the RBC transfusion, specifically the increment in 
hemoglobin and hematocrit, is important. Blood specimen were collected as ordered by the 
hospitalists, however, timing of the phlebotomy may vary depending on the clinical condition of 
patient.  Post-transfusion reassessment was quantified by examining the post-transfusion Hgb 
testing. Figure 20 for one-unit orders with pre-order Hgb value =< 7; Chi- Square analysis of the 
post-transfusion reassessment rate showed a significant change during post-intervention period 
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(X
2 
(1, N = 90) = 12.52, p < 0.01). The odds ratio analysis showed the odds of post-transfusion 
Hgb reassessment were 5.41 times greater during post-intervention period. The same analysis 
was conducted for one-unit orders with pre-order Hgb value > 7. The post-transfusion 
reassessment rate showed no change X
2 
(1, N = 759) = 0.04, p = 0.831, however the 
reassessment rate after transfusion of one unit with pre-transfusion Hgb >7 g/dL remained steady 
during pre and post intervention periods with 84.91 and 85.52 percent respectively. The same 
analysis was performed for two-unit orders. For two-unit orders with pre-order Hgb value =< 7; 
Chi- Square analysis of the post-transfusion reassessment rate showed no significant statistical 
change X
2 
(1, N = 165) = 0.17, p = 0.674. The rate of post transfusion reassessment after 
transfusion of two unit RBC orders remained steady during pre and post intervention periods 
with 93.94 and 94.45 percent respectively. The same analysis was conducted for two-unit orders 
with pre-order Hgb value > 7; the post-transfusion reassessment rate did not show a change X
2 
(1, N = 530) = 2.49, p = 0.11. The rate of post-transfusion reassessment after transfusion of one 
unit RBC order with pre-transfusion Hgb >7 g/dL also remained steady during pre and post 
intervention periods with 98.90 and 96.99 percent respectively. The analysis showed no 
significant difference for post-transfusion reassessment Hgb testing because the rate of testing 
was already close to the maximum.   
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Figure 20 - Post-transfusion Hgb (g/dL) reassessment of one-unit and two-unit orders. 
 
4.5. Economic Impact of the Change in Practice  
4.5.1. RBC Transfusion Cost Breakdown  
The cost model included product acquisition cost, and direct and indirect overhead costs. Direct 
overhead costs included elements such as blood bank staff (manager, laboratory, technician, 
etc.), related overhead costs for the blood bank, laboratory, nursing staff, and pathologist. 
Indirect overhead costs included three major process steps such as patient testing, pre-transfusion 
processes, and administering and monitoring transfusions.  The national average blood product 
acquisition cost of $210.74 ± 37.9 was used based on  the latest hospital-based blood banks and 
transfusion services 2011 survey 
133
. This cost did not include wasted RBC units and additional 
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services such as irradiating, washing, or warming of RBC units. Product acquisition cost 
contributed 33.19 % of the total cost of transfusion. The evaluation of direct overhead cost 
contributed a small percentage (8.91 %) of the overall blood-related costs; the indirect cost 
contributed the highest proportion of total transfusion cost of 57.90 %.  Using the cost model, the 
total cost per RBC unit transfusion was determined to be $ 634.97 ± 36.76 (Mean, SD). Using 
the cost model, an estimated 33.19 % (210.74 ± 37.9) of the total cost of transfusion was 
associated with the product acquisition cost and the remaining 66.81 % (424.23) was attributed 
to direct and indirect overhead cost (Figure 21.). 
 
Figure 21 - Total cost breakdown per RBC unit transfusion. 
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4.5.2. Cost Analysis RBC Orders among Hospitalist and Non-Hospitalists  
Based on the above cost estimates, the total cost of inpatient RBC transfusions among 
hospitalists and non-hospitalists during pre and post intervention periods was compared using the 
RBC unit acquisition cost and RBC transfusion activity-based cost An independent sample t-test 
was conducted to compare unit cost of RBC transfusions among hospitalists (1675 to 1085 
issued units) and non-hospitalists (3184 to 3005 issued units) during pre and post intervention 
periods. The cost analysis of RBC orders by hospitalists during the post-intervention time period 
showed a significant 27.49 percent decrease in cost per unit of RBC transfusion per 1000 Patient 
Days when compared the post-intervention period (M = $3,296.95, SD = 397.39), with the pre-
intervention period (M = $4,547.08, SD = 485.46), p < 0.01. The same analysis was performed 
for non-hospitalists. The comparison of the post intervention period (M = $9,151.80, SD = 
1,542.01) with the pre-intervention period (M = $8,673.77, SD = 1,211.53), p = 0.42 showed no 
statistical change in cost of RBC utilization among non-hospitalists.  
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Figure 22 - Comparison of total cost per 1000 patient days of RBC transfusion (cost per unit and 
activity-based cost) during pre- and post-intervention periods among hospitalist. 
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Figure 23 - Comparison of total cost per 1000 patient days of RBC transfusion (cost per unit and 
activity-based cost) during pre- and post-intervention periods among non-hospitalist. 
 
4.5.3. Trend Cost Analysis of Hospitalists Practice 
The cost analysis breakdown of inpatient RBC orders among hospitalists showed a significant 
overall decrease of 27 percent (p < 0.01) in cost of RBC transfusion per 1000 patient days as a 
result of the decline in the number of orders.  Figure 24 represents the trend in quarter-year 
decline in the cost of RBC orders per 1000 patient days including one, two, and three or more 
unit RBC orders.   
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Figure 24 - Quarterly trend in hospitalist utilization and total cost of RBC transfusion per 1000 
patient days. 
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Chapter 5: Discussion 
 
Rising healthcare costs and declining quality of care have heightened the need to identify and 
implement new strategies to address shortcomings in the United States healthcare system. This 
study focuses on promoting evidence-based medical practice and leveraging healthcare data to 
improve quality of care, outcomes, and control costs. The study demonstrates the effectiveness of 
a framework that bridges the gaps that exist between data, knowledge, and practice in a 
healthcare setting through the use of evidence-based guidelines, enhanced contextualized data-
driven reports, analytics and education focused on current evidence.  
 
This study focuses on transfusion medicine. Transfusion is one of the top ten coded hospital 
procedures in the United States. Unfortunately, the costs of transfusion are underestimated and 
the benefits overestimated. The particular aim of the study was to reduce practice inconsistencies 
in red blood cell transfusion among hospitalists in a large urban hospital using focused 
education, evidence-based guidelines, and reporting based on physician-specific data to drive 
appropriate decision-making prior to the decision to transfuse or prior to issuing the blood 
component, and data analytics to serve as a feedback mechanism to evaluate changes in behavior 
and practice. The study‘s integrated framework proved to be effective in encouraging evidence-
based best practices and lowering costs.  
 
This study sought to achieve an institutional shift to evidence-based transfusion medicine 
practice using a framework that took into account the administrative, cultural, clinical, and 
technical issues that make the implementation of an evidence-based program and utilization of 
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healthcare data so challenging. What follows is a discussion of the components of the framework 
that proved to be effective in addressing the issues associated with the study‘s deployment of 
healthcare data in the shift to evidence-based medicine. 
5.1.  Administrative Issues 
5.1.1. Strategic Focus 
There were challenges related to the introduction of the strategic and organizational changes that 
were needed to promote new programs and that would encourage the uptake and use of new 
knowledge. This required clear top down direction, administrative support and action, 
collaboration, re-working of resources and priorities, resource dedication to goals that were 
specific to evidence-based practice, and commitment to dedicating the skills and technologies 
needed to measure changes, track and evaluate programs
77,279,282,490-494
.  High level support and 
involvement were needed to meet the ambitious goal of encouraging hospitalists to move from a 
culture of delivering care based on tradition, intuition, and authority, to a system in which 
decisions were guided and justified through education, awareness of the best available evidence, 
and measure of performance based on physicians‘ specific practice data.  
5.1.2. Resource Commitment 
Administrative buy-in and support at the highest levels of the organization was essential for the 
successful implementation of this hospital-wide, cross-departmental, evidence-based patient 
blood management program with its heavy reliance on a performance management system, data 
analytics, and reporting. While the healthcare organization may have already recognized the 
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importance of  the use of data, it was critical that they make the resource commitment to address 
issues related to the development of the components of the performance management system  
including: data location (diverse and disparate information ecosystem); data definitions ( 
inconsistencies in data definitions subjected based on the source system); data structure 
(inconsistency in data capture structured vs non-structured); data complexity (presence of 
numerous identical parts in amalgam of individual systems) , and staff allocation (with 
appropriate skills and time) .  
 
5.1.3. Coordination 
It was important that structures be put into place that insured ongoing communication and 
coordination between the hospital and BloodCenter of Wisconsin and as well as among all the 
involved individuals and departments within the hospital. The Blood Utilization Governance 
Committee was established as a way to develop and sustain broad organizational support. The 
overarching goal of this committee was to create a culture of accountability among physicians 
who practiced transfusion therapy. The committee consisted of hospital executives, 
administrative, and clinical champions including the Vice President of Medical Affairs, the Vice 
President of Laboratory, the Laboratory Medical Director, the Blood Bank Supervisor, a 
hospitalist physician champion, and transfusion safety nurse champion.  The Blood Utilization 
Governance Committee established sub-committees that assigned specific responsibilities to 
various working groups.  
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5.1.4. Ongoing Feedback 
Developing an analytics framework to provide a continuous feedback mechanism contributed to 
the overall success of the program and provided the tools to inform the executives and 
administration on progress. The framework served to provide a feedback mechanism relative to 
the strategic objectives, aggregate data obtained from the performance management system, and 
the effectiveness of the education that healthcare providers received.  The analytics framework, 
through quantification and long-term reassessment of trends, facilitated a deeper understanding 
of the clinical changes that the hospitalists made in their transfusion practice as a result of 
informed decision-making. In addition, it enabled evaluation of changes directly impacted by the 
program, identified new areas for improvement, and helped avoid unintended consequences and 
outcomes. A set of high-level indicators were used to provide feedback to the Blood Utilization 
Governance Committee for determination and any needed adjustment to goals, objectives, 
priorities and strategies. The operational indicators included: hospital-wide trends of blood 
product inventory and rate of wastage; total number of blood products transfused by product 
type, patient type, and by nursing unit; and measures of blood product ordered by various clinical 
specialties. In addition to reporting the operational indicators, a set of nationally accepted 
benchmark indicators were constructed and used to inform the Blood Utilization Governance 
Committee with regard to the hospital‘s current trends on patient transfusions and blood product 
utilization. These benchmark indicators included: measure of inpatient and outpatient 
transfusions per 1000 patient days based on patient census, and measures of admitted patients 
who received transfusions by a specific blood product.  
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5.2. Cultural Issues 
5.2.1. Behavioral Change 
An informative rather than punitive approach was employed with regard to implementation of 
the evidence-based PBM program in order for the message to be well-received among physicians 
and other healthcare providers. Strategies included physician education promoting conservative 
RBC transfusion strategies through continuing medical education courses, newsletters, and 
posters and quarterly reports to department chairs and to individual hospitalists highlighting RBC 
ordering practices of the physicians and other healthcare providers. The department reports on 
physicians‘ transfusion practice was unblinded for the review of the department chair. The 
individual physician report was blinded using a system-generated identifier for each physician to 
allow comparison of individual physicians to their peers. Individual physicians responded 
differently making varying levels of intervention (e.g. education, peer-to-peer discussions, 
performance reports, letters from the department head and performance review consequences) a 
valuable framework component. 
 
5.2.2. Tradition, Intuition and Authority 
Studies have shown each unit of allogeneic RBC increases the rate of nosocomial infection by 
fifty percent; transfusion of patients with two units of RBC can highly increase the rate of 
hospital acquired infections 
409,495-498
 .  Thus  the common practice to ―automatically place  two-
unit RBC orders makes no sense from a resource consumption or patient safety standpoint
498‖.  It 
has been more than a decade since the publication of the landmark study ―Transfusion 
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Requirements in Critical Care (TRICC) trial‖ 148 and many others studies 140,142,149,155,182-184 
supporting the restriction of RBC transfusions for patients 
185
. Since then, there have been some 
reports indicating improvements in transfusion practices, mostly with regard to reduced 
hemoglobin thresholds at which patients are transfused 
186-188
. Nonetheless, the overall use of 
allogeneic RBC transfusions in clinical practice remains relatively high and still varies widely 
among many centers and practitioners 
185,189-191
. One underlying issue is that many physicians 
were trained before transfusion research and evidence were available regarding transfusions. 
Historically, some physicians have been taught liberal transfusion practice and to follow the 
maxim ―if you are going to transfuse, why not give two‖ 15,194,195. Now, however, numerous 
research studies have examined RBC 
148,149,155,162,182,183,196,197
 and platelet use 
27,198-202
. 
Nonetheless, many clinicians are slow to change 
15
, and some are even skeptical without seeing 
hard evidence, such as individualized data-driven reports, information on latest research 
evidence in practice, reports on their individual practice and the practice of their peers. The 
framework developed for this study was designed to promote a move beyond tradition, intuition 
and authority-based practice to practice informed by education focused on current evidence, 
evidence-based guidelines, and enhanced contextualized data-driven reports. 
 
5.2.3. Transfusion Medicine Expertise 
The practice of transfusion medicine extends across multiple specialties and covers diverse 
clinical and laboratory services. It requires specialized subject matter expertise and an 
understanding of the intricacies, underlying complexities and latest transfusion medicine best-
practice evidence.  In transfusion medicine, as in other areas of medical practice, there is a gap 
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between the latest knowledge and current physician practice. As commonly as transfusions occur 
in the United States, one may assume that physicians practice transfusion medicine based on 
strict standard guidelines. However, the efficacy of blood transfusion is poorly understood 
among practicing physicians 
139-143
. Partnering with BloodCenter of Wisconsin  to provide access 
to best-practice expertise and the latest research findings was essential in off-setting any lack of 
transfusion medicine expertise among the hospitalists. The committee used the performance 
standard, BloodCenter of Wisconsin 2011 Adult Blood Utilization Review Guidelines, to establish 
key objectives and relied on BCW expertise throughout the process.  
 
5.4. Clinical Issues 
5.4.1. Relevant Clinical Information and Evidence 
Challenges in a shift from authority-based medicine to evidence-based medicine include the lack 
of relevant clinical information, inadequate time and the inability of physicians to review and 
interpret available evidence and translate new knowledge into clinical practice 
4
.  Offering 
continuing medical education courses, training, and distributing educational materials on 
conservative transfusion therapy strategies (including lower pre-transfusion Hgb trigger and 
transfusion of a single RBC unit followed by patient reassessment for determination of additional 
interventions) and appropriate and inappropriate use of blood products (including adverse effects 
of blood products, misuse and overuse of blood components that increases the risk of morbidity 
in patients, cost and financial resources associated with unwarranted blood transfusions) were 
important parts of the strategy to change or enhance clinical practice. In addition to the courses, 
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training sessions and educational materials, physicians were provided access to EndNote to allow 
them to delve further into relevant information. 
 
5.4.2. Performance Management System 
Use of a performance management system improved transfusion medicine practice through the 
synthesis and utilization of scientific evidence and the more rigorous use of data analytics to 
provide meaningful information and to guide daily activities of physicians by creating a culture 
of accountability.  In addition it provided a feedback mechanism for assessment and 
reassessment of change and the evaluation of the impact of strategic decisions. Developing and 
using a performance management system served to identify, select objectives and set goals, 
increase awareness on the latest evidence to promote conservative strategies on transfusion 
therapies and to create a culture of accountability by tracking physicians‘ transfusion criteria in 
accordance with the latest evidence. The performance management system aimed to optimize 
transfusion decision-making, reduce inappropriate transfusions, improve patient outcomes, 
reduce cost, and preserve a scarce resource through consolidation of measures to monitor  and 
manage physicians‘ performance according to set of indicators and key performance indicators.  
 
5.4.3. Dynamism in Medicine 
Another aspect that adds to the complexity of evidence-based practice is its dynamic nature.  As 
research advances, medical knowledge is enriched; thus clinical practice and healthcare 
technology evolve and new best-practices arise with new definitions of terms, new criteria, and 
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different approaches. As a result, evidence-based best-practices continue to be redefined in an 
unpredictable manner and with it clinical approaches, regulatory, and reporting requirements 
change. It was for this reason that highly specialized subject matter expertise, flexible and 
scalable performance management systems, and a feedback mechanisms were built into the 
framework. 
 
5.5. Technical Issues 
5.5.1. Data Silos 
A central database and the performance management system architecture were fundamental to 
the patient blood management program. The linkage of transfusion-related data across the 
hospital‘s disparate source systems was an essential first step to monitor compliance with 
transfusion best-practice guidelines across various clinical service lines. A patient blood 
management database was established at BloodCenter of Wisconsin to centralize data from the 
disparate source systems from within the hospital and as a means to evaluate the hospital‘s 
transfusion practices both as a baseline before intervention (the implementation of transfusion 
medicine best practice program) and as an ongoing monitoring system. There were three critical 
components to the success of this implementation model including: 1) the ability to collect and 
use recent and precise data that could be processed into meaningful information to show where, 
how, by whom, and how much blood product was used within the hospital wards; 2) the ability 
to use the information gained from data in a continuous feedback mechanism to inform the 
strategic decision makers as a means to assist in the strategic level decision making process; and 
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3) the ability to use the clinical practice data to benchmark clinical performance and blood 
product utilization. 
5.5.2. Data Determination 
The method used to identify relevant and contextual data elements across the source systems 
included the involvement  of the of Blood Utilization Governance Committee in reviewing the 
organizational and departmental (i.e. clinical service lines) strategic goals and priorities; 
determining of target audiences aligning of patient blood management evidence-based guidelines 
to the strategic goals; identifying activities to track progress toward the established goals; linking  
the activities to a specific measure or group of measures; setting target and threshold for 
expected outcomes; and developing meaningful reports from the measures to inform on the 
outcome and progress. The approach facilitated construction of the performance management 
system through identification of relevant datasets and the correct source system for extraction of 
the data.  For each department and the source system, characteristics of data and the quality of 
source system was determined. Based on the frequency of data capture, automated or semi-
automated data feeds were scheduled to actively (depending on the specific processes and 
timeliness of data capture on a daily, weekly, or monthly intervals) transfer the data into the 
central repository for processing. 
5.5.3. Data Linkage 
The linkage of transfusion-related data across the hospital‘s disparate source systems was a 
fundamental first step in monitoring compliance with transfusion best-practice guidelines across 
clinical service lines. Using the study method, 99.15 percent of discharged inpatients were linked 
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to their transfusion events and clinical detail; 97.77 percent of physicians and other healthcare 
providers (including physician‘s assistants and nurse practitioners) were linked to their primary 
clinical specialty within the hospital. Thus 99.98 percent of inpatients who received at least one 
unit of blood products were linked to their transfusion event and clinical details, in addition to 
the issuing physician information. Once the linkage of patients to their clinical detail and 
providers was completed, the performance measures were used to track and trend healthcare 
providers‘ practice and blood product utilization across the hospital. 
5.5.4. Data Transfer 
The data feeds were transferred to the central repository via a secure file transfer (e.g. sFTP) 
connection. A unified metadata layer was defined; and data from the various source systems 
were mapped to enable contextual information. Data was stored in SQL database, where 
numerous views (virtual tables) were created to join the subset of data from various tables 
(populated from disparate information systems) with coded logics built-in for contextual view of 
data, and to limit exposure to the underlying data. The logics were coded in the views to link data 
on patient, provider, blood products and clinical details that were required to for individual 
measures in the performance management system. InSight (Lenexa, KS), an analytics and 
reporting software, was used for construction of the measure as part of the performance 
management system with dashboard and reporting capabilities for dynamic views of information. 
The reports from the performance measures were presented back to the hospital via a secure 
web-based portal which depicted blood product use, and physician ordering practice at multiple 
levels including by system, facility, cost center, clinical service line, and healthcare provider.   
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5.5.5. Information Reporting 
Data analysis was regularly communicated throughout multiple levels of the healthcare 
organization including at healthcare system level, hospital level, clinical service line level, and 
physician level based on guidelines established by the Blood Utilization Governance Committee. 
Dashboards were tailored to meet the information requirements of administrative and clinical 
personnel. 
 
5.6 Study Outcome 
The Blood Utilization Governance Committee made the determination to target RBC utilization 
as the most frequently issued blood component (69.75% RBC, 22.73% FFP, 6.81% PL, and 
0.72% CRYO), and hospitalists as the highest users of RBC units. The indicator measuring the 
percentage of RBC units in individual clinical service lines compared to total hospital wide RBC 
units was calculated as a baseline analysis for the pre-intervention period (Oct. 2012 to Sep. 
2013). It showed hospitalists (34.09%) were the highest users of RBC units, followed by 
cardiothoracic surgery (12.563%), and general surgery (9.84%). The first five clinical specialties 
(e.g. Hospital Medicine, Cardiothoracic Surgery, General Surgery, Hematology/ Oncology and 
Pulmonary Medicine), accounted for 74.62 % of the hospitals total RBC use. Benchmark 
indicators showed an annual rate of RBC transfusions per 1000 patient days to be 62.95 and 
21.67 across all clinical service lines and hospitalists respectively during pre-intervention period.  
The study focused on reducing the inconsistencies in practice of transfusion medicine, 
particularly in the transfusion of allogeneic RBC among Hospitalists in the hospital.  
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Retrospective analysis of hospitalists practice during pre (Oct. 2012 – Sep. 2013) and post (Oct. 
2013 – Sep. 2014) intervention periods showed a 27.62 percent decline in inpatient RBC 
transfusion per 1000 patient days.  Analysis of hospitalists ordering practice showed a significant 
change in number of one and two unit RBC orders. The rate of two-unit RBC orders significantly 
decreased by 30.88 percent (p < 0.01), while the rate of one-unit RBC orders significantly 
increased by 31.67 percent (p < 0.01).  
 
More in-depth analysis was performed on one-unit and two-unit orders to determine whether 
there was a change in transfusion threshold of Hgb level based on the performance standard. 
Comparison of the mean Hgb threshold for one-unit orders during pre and post intervention 
periods (8.0 ± 0.71 to 7.7 ± 0.69, p < 0.01 ) showed a significant shift towards lower pre-
transfusion Hgb threshold. Although, the trend showed a positive shift toward lower Hgb 
threshold, hospitalists‘ decisions on transfusion triggers  will require more interventions to 
further lower transfusion triggers (Hgb concentration of 7 g/dL or less for non-bleeding stable 
patients or 8 g/dL for patients with cardiac conditions). The same analysis was performed for 
two-unit orders and no statistically significant change was observed. Post-transfusion assessment 
of the effect of the RBC transfusion for assessment of incremental change in hemoglobin and 
hematocrit level was quantified by the rate of post-transfusion Hgb testing. For one-unit orders in 
patients with pre-order Hgb value =< 7, the post transfusion assessment rate showed a significant 
increase of 35.06 percent (p < 0.001). The same analysis was performed for two-unit orders and 
no statistical significant change was observed. However, during the pre and post-intervention 
period the rate of post transfusion assessment after transfusion of two unit RBC order had 
remained steady with the average of 94.19 % ± 0.36 in across the two time periods. 
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The post-intervention period showed a 35.24 percent (p < 0.001) reduction in the total number of 
RBC units issued by hospitalists. The reduction in the number of RBC unit transfusions had a 
significant financial impact, which had led to an annual saving of $124,337 based on the price-
per-unit (national average) of RBC acquisition alone during post intervention period. However, 
estimating cost of transfusion based on the price-per-unit acquisition cost has been criticized by 
the Cost of Blood Consensus Conference. Traditional cost models lack the complex pre-
transfusion preparation and post transfusion steps, thus attributable cost per unit has been greatly 
underestimated
135
. A recently developed cost model by the Cost of Blood Consensus Conference 
included activity-based costing, which comprehensively accounted for the cost of transfusion 
through analysis of technical, administrative, and clinical processes. Using the activity based cost 
model, the technical, administrative, and clinical processes that occurred sequentially and in 
parallel were mapped.   Each process step that involved diverse personnel, capital, and 
consumable resources was multiplied by the usage frequencies. National average price per unit 
acquisition cost of RBC unit and the activity based cost analysis of a single unit RBC transfusion 
at the hospital were estimated to be $ 210.74 ± 37.9 and $424.23 respectively. Total cost of a 
single unit RBC transfusion per patient was determined to be around $634.97. Analysis of the 
reduction in hospitalist RBC transfusions using total cost RBC transfusion (price per unit 
acquisition cost and activity based cost) showed and annual saving of $374,632 during post 
intervention period.  
 
The effectiveness of the various educational and reporting interventions used during the study 
time period to influence prescribing behavior were evaluated. Although the report to the 
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department chair provided visibility to hospitalists‘ practices and allowed for an avenue of 
conversation, individual peer-comparison-blinded reports had the greatest impact in changing the 
practice of the hospitalists. Trends began to significantly shift when the individual hospitalists 
were able to view their practice information and compare themselves to their peers.     
 
The study model empowered the hospital, through the Blood Utilization Governance Committee 
and the Transfusion Medicine Steering Committee to encourage hospitalists to move from a 
culture of delivering care based on tradition, intuition, and authority, to a system in which 
decisions were guided and justified by education, awareness of the best available evidence and 
specific data relative to performance-based measures. The model provided an effective way for 
hospitalists to avoid over-transfusion of their patients through the order of one RBC unit at a 
time in stable non-bleeding patients, and re-assessment of the patient prior to ordering additional 
RBC units. If a single unit increased the patients Hgb into 7 to 8 g/dL range, the needed 
symptomatic patient relief was achieved.  Thus, the hospitalists were able to avoid over-
transfusion, which would only increase the future risk of adverse outcomes to their patients. This 
approach facilitated a sense of accountability among hospitalists by holding them accountable for 
their decisions on a daily basis. The totality of all hospitalists being accountable for their 
decisions served to create accountability at individual, department, and organization level. . The 
success of the pilot program that was executed for this study has led to the expansion of the 
program to all of the healthcare system‘s other hospitals. . 
 
 
218 
 
A way to address unexplained differences in clinical practice requires evidence-based guidelines, 
identification and collection of contextual data from diverse and disparate source systems, 
development and use of a performance management system, analysis of healthcare providers‘ 
transfusion practice data, and meaningful presentation of information firmly coupled with topic-
focused education to drive appropriate decision-making and interventions. In addition, the model 
requires a closed feedback mechanism to quantify and evaluate the changes in practice. 
Reporting on compliance to evidence-based guidelines and performance measures are 
foundational; the addition of an analytics framework as a feedback mechanism is essential to 
further evaluate changes related to implementation and adherence to an evidence-based program.  
The study demonstrated that focus on tight integration of the above elements can bridge the gap 
that exists between knowledge and practice, and thereby can alter behavior. 
5.7. Study Limitations 
5.7.1. Organizational Agreements  
Legal agreement between the two organizations imposes a rigid boundary around the scope of 
the project, and resources. Additionally, limited opportunities for interactions with key 
stakeholders and practitioners confines opportunities and makes it difficult to test new ideas or 
hypotheses.  
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5.7.2. Software System 
Historically, business intelligence and reporting consisted of pre-defined reports and data 
visualizations that centered on classic tables, pie charts, and bar charts.  BI tools have evolved to 
contain advanced analytics and visualizations, which encourage business users to have a more 
active role in data analysis.  InSight™ is a metrics-based dashboarding software system that 
adheres to the out-dated business intelligence model.  InSight™ has limitations that preclude it 
from fulfilling the evolving needs of end-users.  
 ETL / Data Warehouse Capabilities  
InSight™ provides limited, non enterprise-level ETL capabilities and no true data 
warehouse functions.  It most readily integrates with Microsoft databases and flat files, 
but does not easily integrate with other types of databases (i.e. Oracle) or any other data 
sources.  The ETL processes are fragile and prone to failure which requires manual 
intervention on a regular basis. 
 
 Scalability & Multi-Tenancy 
InSight™ is not a scalable solution and does not support multi-tenancy. The study needs 
a single view of the data that spans multiple healthcare systems in order to inform 
performance within each hospital, create benchmarks for partner organizations, and to 
provide an internal view of program success.  Due to its architecture, requires its own 
development and production databases, and application environment for every healthcare 
system.  
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 Rigid Metric Hierarchy 
The metric implementation is rigid; the drill down paths are confining and do not allow 
users to apply multiple filters to the data set (i.e., select a service line AND a type of 
blood product.)  The lack of flexibility requires multiple measures to be created for each 
hierarchy drill path.   
 
 Visual Analysis 
InSight™ contains very limited visual analysis capabilities. Users are unable to create the 
simplest visual representations such as clustered or stacked bar charts; this requires 
transfer of data to Excel for further graphical capabilits.   
 
 Report Creation 
The lack of presentation capabilities necessitates users to export most data into Excel to 
prepare the information for analysis or for presentation back to the healthcare systems. 
The Insight™ does not create pixel perfect reports for electronic distribution or print. 
 
 Dashboard 
Dashboards are inflexible, and the configuration required to create and maintain them 
does not provide a sustainable model. The Flash player tool becomes overwhelmed with a 
large data set and it can take several minutes (3-4) to add a single row to a view.  
 
 Ease of Use 
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The product is not positioned as a business user solution because complex SQL is needed 
to create views for reporting purposes. 
 
 Data Discovery & Ad hoc Analytics 
The product does not support data discovery capability or ad hoc analytics to enable 
system users to slice and dice data. 
 
 Collaboration 
InSight™ only supports file export, print, and email capabilities.  There is no ability to 
notate or collaborate within the tool. 
 
 System Integration 
InSight™ does not provide the ability to embed its metrics into other websites.  
222 
 
References 
1. Hofmann A, Ozawa S, Farrugia A, Farmer SL, Shander A. Economic considerations on 
transfusion medicine and patient blood management. Best Pract Res Clin Anaesthesiol 
2013;27:59-68. 
 
2. Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the 
Austrian benchmark study. Transfusion 2007;47:1468-80. 
 
3. Gerris J. The legacy of Archibald Cochrane: from authority based -towards evidence 
based medicine. Facts Views Vis Obgyn 2011;3:233-7. 
 
4. Mamdani M, Ching A, Golden B, Melo M, Menzefricke U. Challenges to evidence-based 
prescribing in clinical practice. Ann Pharmacother 2008;42:704-7. 
 
5. Groves P, Kayyali B, Knott D, Van Kuiken S. The Big Data Revolution in Healthcare. 
McKinsey & Company Center for U.S. Health System Reform Business Technology 
Office; 2013. 
 
6. Heddle NM. Evidence-based decision making in transfusion medicine. Vox Sang 
2006;91:214-20. 
 
7. Grol R. Successes and Failures in the Implementation of Evidence-Based Guidelines for 
Clinical Practice.  Medical Care2001:46-54. 
 
8. Bodenheimer T. The American health care system--the movement for improved quality 
in health care. N Engl J Med 1999;340:488-92. 
 
9. Schuster MA, McGlynn EA, Brook RH. How good is the quality of health care in the 
United States? Milbank Q 1998;76:517-63, 09. 
 
10. Mowatt G, Grimshaw JM, Davis DA, Mazmanian PE. Getting evidence into practice: the 
work of the Cochrane Effective Practice and Organization of care Group (EPOC). J 
Contin Educ Health Prof 2001;21:55-60. 
 
11. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of 
change in patients' care. Lancet 2003;362:1225-30. 
 
12. Pfuntner AW, Lauren M., Stocks C. Most Frequent Procedures Performed in U.S. 
Hospitals, 2010: H.CUP Healthcare Cost and Utilization Project; 2013. 
 
13. Pfuntner A, Wier LM, Stocks C. Most Frequent Procedures Performed in U.S. Hospitals, 
2011: H.CUP Healthcare Cost and Utilization Project; 2013. 
 
 
223 
 
14. AABB. Patient Blood Management. Advancing Transfusion and Cellular Therapies 
Worldwide; 2015. 
 
15. Cohn CS, Welbig J, Bowman R, Kammann S, Frey K, Zantek N. A data-driven approach 
to patient blood management. Transfusion 2014;54:316-22. 
 
16. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg 
2009;108:759-69. 
 
17. Gilliss BM, Looney MR, Gropper MA. Reducing noninfectious risks of blood 
transfusion. Anesthesiology 2011;115:635-49. 
 
18. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of 
allogeneic blood transfusion and the available strategies for their prevention. Blood 
2009;113:3406-17. 
 
19. Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce 
allogeneic blood transfusion-related mortality. Transfus Med Rev 2010;24:77-124. 
 
20. Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood 
transfusion with increased mortality in myocardial infarction: a meta-analysis and 
diversity-adjusted study sequential analysis. JAMA Intern Med 2013;173:132-9. 
 
21. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-
based costs of blood transfusions in surgical patients at four hospitals. Transfusion 
2010;50:753-65. 
 
22. Grazzini G. Clinical appropriateness of blood component transfusion: regulatory 
requirements and standards set by the Scientific Society in Italy. Blood Transfus 
2008;6:186-90. 
 
23. World Health Organization. Total expenditure on health as a percentage of gross 
domestic product (US$): World Health Organization; 2012. 
 
24. Min H. Healthcare Supply Chain Management: Basic Concepts and Principles. Business 
Expert Press; 2014. 
 
25. de Rugy V. US Health Care Spending More Than Twice the Average for Developed 
Countries. Mercatus Center at George Mason University2013. 
 
26. Advisers TCoE. The Economic Case for Health Care Reform. The White House2009. 
 
27. Davis K, Schoen C, Stremikis K. Mirror, Mirror on the Wall: How the Performance of 
the U.S. Health Care System Compares Internationally, 2010 Update. The 
Commonwealth Fund2010. 
224 
 
 
28. Moses H, Matheson DH, Dorsey ER, George BP, Sadoff D, Yoshimura S. The anatomy 
of health care in the United States. JAMA 2013;310:1947-63. 
 
29. Porter ME, Lee TH. The Strategy That Will Fix Health Care. Harvard Business 
Review2013. 
 
30. Grossmann C, Goolsby WA, Olsen L, McGinnis JM. Engineering a Learning Healthcare 
System: A Look at the Future: Workshop Summary. Washington D.C.: The National 
Academies Press; 2011. 
 
31. Vicini J, Stempel J. WRAPUP 4-US top court upholds healthcare law in Obama triumph. 
Reuters2012. 
 
32. Foundation TKF. Summary of the Affordable Care Act. Focus on Health Reform: The 
Henry J. Kaiser Family Foundation; 2013. 
 
33. Harrison S, Kennedy S, Pollard L. How Hospitals Are Shifting Resources Post-Reform. 
Becker's Hospital CFO: Becker's Hospital Review; 2014. 
 
34. Rosenbaum S. The Patient Protection and Affordable Care Act: implications for public 
health policy and practice. Public Health Rep 2011;126:130-5. 
 
35. ACHE. Top Issues Confronting Hospitals: 2013. Research & Resource: American 
College of Health Executives; 2013. 
 
36. Davis SB, Robinson, Phillip J. Healthcare Providers under Pressure:Make the Most of 
Challenging Times Accounting Matters. Association of Healthcare Internal 
Auditors2010. 
 
37. Meyer H, Evans M. Outlook 2014: The year ahead in healthcare business. Modern 
Healthcare2014. 
 
38. Mertz G. What Healthcare Reform Means for Physicians Physician's PracticeYour 
Practice Your way2013. 
 
39. Clough J, Adams M, Afable R, et al. Hospitals and Care Systems of Future. American 
Hospital Association2011. 
 
40. Grol R. Personal paper. Beliefs and evidence in changing clinical practice. BMJ 
1997;315:418-21. 
 
41. Institute of Medicine (US) Roundtable on Value & Science-Driven Health Care. U.S. 
Healthcare Data Today: Current State of Play. Washington, DC: Institute of 
Medicine 2010. 
225 
 
 
42. Kalakota R. Informatics or Analytics? Understanding Digital Health Use Cases.  
Business Analytics 302013. 
 
43. Committee on Quality of Health Care in America - Institute of Medicine. Crossing the 
Quality Chasm: A New Health System for the 21st Century. Journal of the American 
Medical Association: National Academies Press; 2001. 
 
44. Institute of Medicine (IOM). Beyond the HIPAA Privacy Rule: Enhancing Privacy, 
Improving Health Through Research. Washington, DC: Institute of Medicine 
(IOM),Committee on Health Research and the Privacy of Health Information:The 
HIPAA Privacy Rule; 2009. 
 
45. Safran C, Bloomrosen M, Hammond WE, et al. Toward a national framework for the 
secondary use of health data: an American Medical Informatics Association White Paper. 
J Am Med Inform Assoc 2007;14:1-9. 
 
46. Wickramasinghe N, Schaffer JL. Creating knowledge-driven healthcare processes with 
the Intelligence Continuum. Int J Electron Healthc 2006;2:164-74. 
 
47. Smith SE, Drake LE, Harris JG, Watson K, Pohlner PG. Clinical informatics: a 
workforce priority for 21st century healthcare. Aust Health Rev 2011;35:130-5. 
 
48. French CS. Data Processing and Information Technology. 10 ed: Cengage Learning 
Business Press; 1996. 
 
49. Shah ND, Pathak J. Why Health Care May Finally Be Ready for Big Data. Harvard 
Business Review2014. 
 
50. Quality Profiles: Focus on Supporting Quality Improvement Through the Use of Health 
Information Technology: Pfizer and NCQA; 2009. 
 
51. Goodwin S. Data rich, information poor (DRIP) syndrome: is there a treatment? Radiol 
Manage 1996;18:45-9. 
 
52. Blumenthal D. Launching HITECH. N Engl J Med 2010;362:382-5. 
 
53. Blumenthal D, Tavenner M. The "meaningful use" regulation for electronic health 
records. N Engl J Med 2010;363:501-4. 
 
54. Health Information Technology in the United States: Progress and Challenges Ahead, 
2014. Robert Wood Johnson Foundation; 2014. 
 
55. Jaén CR. Successful health information technology implementation requires practice and 
health care system transformation. Ann Fam Med 2011;9:388-9. 
226 
 
 
56. AHRQ. Health Information Technology: Best Practices Transforming Quality and 
Efficiency Barriers to HIT Implementation: Agency for Healthcare Research and Quality; 
2012. 
 
57. Cresswell K, Sheikh A. Organizational issues in the implementation and adoption of 
health information technology innovations: an interpretative review. Int J Med Inform 
2013;82:e73-86. 
 
58. Friedman J, Metzler I, Detmer D, Selzer D, Meara JG. Health information technology, 
meaningful use criteria, and their effects on surgeons. Bull Am Coll Surg 2012;97:12-9. 
 
59. Sanders D, Burton DA, Protti D. The Healthcare Analytics Adoption Model: A 
Framework and Roadmap. Health Catalyst; 2013. 
 
60. Biesdorf S, Niedermann F. Healthcare's Digital Future.  Insights from our international 
survey can help healthcare organizations plan their next moves in the journey toward full 
digitization: McKinsey & Company; 2014. 
 
61. Garrett P, Seidman J. EMR vs EHR - What is the Difference?  Electronic Health and 
Medical Record: Health IT Buzz; 2011. 
 
62. Clayton PD. Obstacles to the Implementation and Acceptance of Electronic Medical 
Record Systems. Washington, DC: The National Academies Press; 2005. 
 
63. O'Malley AS, Grossman JM, Cohen GR, Kemper NM, Pham HH. Are electronic medical 
records helpful for care coordination? Experiences of physician practices. J Gen Intern 
Med 2010;25:177-85. 
 
64. Health Information and Management System Society (HIMSS). Electronic Health 
Record  
 
65. Menachemi N, Collum TH. Benefits and drawbacks of electronic health record systems. 
Risk Manag Healthc Policy 2011;4:47-55. 
 
66. Burton D. How to Unlock the Analytic Value of Your EHR.  Health Catalyst 
Insights2014. 
 
67. Cortada JW, Gordon D, Lenihan B. The value of analytics in healthcare: From insights to 
outcomes IBM Institute for Business Value; 2012. 
 
68. Philips. Making Sense of The Chaos: From Data Mining to Data Meaning. Koninklijke 
Philips Electronics N.V.: Philips Design; 2012. 
 
69. Moore-Colyer R. Big data success needs analytics and programming skills. V3; 2014. 
227 
 
 
70. SAS. Big Data: What it is and why it matters. 
 
71. Grossmann C, Goodby AW, Olsen LA, McGinnis JM. Clinical Data as the Basic Staple 
of Health Learning: Creating and Protecting a Public Good: Workshop Summary 
 Washington, DC: The National Academies Press; 2010. 
 
72. Strome T. Root Causes: Mitigating the Gap and in Healthcare Analytics. TechTarget; 
2014. 
 
73. Ferguson D. Healthcare Analytics-Where to Begin. National Research Corporation; 2013. 
 
74. Sackett DL. Evidence-based medicine. Semin Perinatol 1997;21:3-5. 
 
75. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based 
medicine: what it is and what it isn't. BMJ 1996;312:71-2. 
 
76. Bennett S, Tooth L, McKenna K, et al. Perceptions of Evidence-Based Practice: A 
Survey Of Australian Occupational Therapists.  Australian Occupational Therapy 
Journal2003:13-22. 
 
77. Majid S, Foo S, Luyt B, et al. Adopting evidence-based practice in clinical decision 
making: nurses' perceptions, knowledge, and barriers. J Med Libr Assoc 2011;99:229-36. 
 
78. Youngblut JM, Brooten D. Evidence-based nursing practice: why is it important? AACN 
Clin Issues 2001;12:468-76. 
 
79. Alper BS, Hand JA, Elliott SG, et al. How much effort is needed to keep up with the 
literature relevant for primary care? J Med Libr Assoc 2004;92:429-37. 
 
80. van Dijk N, Hooft L, Wieringa-de Waard M. What are the barriers to residents' practicing 
evidence-based medicine? A systematic review. Acad Med 2010;85:1163-70. 
 
81. Swennen MH, van der Heijden GJ, Boeije HR, et al. Doctors' perceptions and use of 
evidence-based medicine: a systematic review and thematic synthesis of qualitative 
studies. Acad Med 2013;88:1384-96. 
 
82. Sadeghi-Bazargani H, Sadegh Tabrizi J, Azami-Aghdash S. Barriers to evidence-based 
medicine: a systematic review.  Journal of Evaluation in Clinical Practice: John Wiley & 
Sons, Ltd.; 2014:793-802. 
 
83. McQueen MJ. Overview of evidence-based medicine: challenges for evidence-based 
laboratory medicine. Clin Chem 2001;47:1536-46. 
 
228 
 
84. Sackett DL, Richardson WS, W. R, R.B. H. Evidence-based medicine: how to practice 
and teach EBM. Edinburgh, Scotland. . Churchill Livingstone 2000. 
 
85. IOM. Evidence-Based Medicine and the Changing Nature of Healthcare: 2007 IOM 
Annual Meeting Summary. In: Medicine Io, ed. Washington, DC: National Academies 
Press; 2008. 
 
86. IOM. Evidence-Based Medicine and the Changing Nature of Healthcare: 2007 IOM 
Annual Meeting Summary. In: Cortese DA, ed. The Need for Better Evidence. 
Washington, DC: National Academies Press; 2008. 
 
87. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the 
Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51. 
 
88. Croft P, Malmivaara A, van Tulder M. The pros and cons of evidence-based medicine. 
Spine (Phila Pa 1976) 2011;36:E1121-5. 
 
89. Bouffard M, Reid G. The good, the bad, and the ugly of evidence-based practice. Adapt 
Phys Activ Q 2012;29:1-24. 
 
90. Del Mar C, Glasziou P, Mayer D. Teaching evidence based medicine. BMJ 
2004;329:989-90. 
 
91. Haynes RB. Where‘s the meat in clinical journals? : ACP Journal Club; 
1993:993;119:A22. 
 
92. Druss BG, Marcus SC. Growth and decentralization of the medical literature: 
implications for evidence-based medicine. J Med Libr Assoc 2005;93:499-501. 
 
93. Rezazadeh E, Hachesu PR, Rezapoor A, Alireza K. Evidence-based medicine: going 
beyond improving care provider viewpoints, using and challenges upcoming. J Evid 
Based Med 2014;7:26-31. 
 
94. Sadeghi M, Khanjani N, Motamedi F, Saber M, Rad GS. Familiarity of medical residents 
at Kerman Medical University with evidence based medicine databases. J Res Med Sci 
2011;16:1372-7. 
 
95. Park M. Development of Evidence based Nursing Practice Guideline Document Model 
for Electronic Distribution. J Korean Soc Med Inform. ; 2004. 
 
96. Young JM, Solomon MJ. How to critically appraise an article. Nat Clin Pract 
Gastroenterol Hepatol 2009;6:82-91. 
 
229 
 
97. Nicholson LJ, Warde CM, Boker JR. Faculty training in evidence-based medicine: 
improving evidence acquisition and critical appraisal. J Contin Educ Health Prof 
2007;27:28-33. 
 
98. Green ML. Evidence-based medicine training in internal medicine residency programs a 
national survey. J Gen Intern Med 2000;15:129-33. 
 
99. Grimshaw JM, Eccles MP, Walker AE, Thomas RE. Changing physicians' behavior: 
what works and thoughts on getting more things to work. J Contin Educ Health Prof 
2002;22:237-43. 
 
100. Hammer GP, du Prel JB, Blettner M. Avoiding bias in observational studies: part 8 in a 
series of articles on evaluation of scientific publications. Dtsch Arztebl Int 2009;106:664-
8. 
 
101. Jepsen P, Johnsen SP, Gillman MW, Sørensen HT. Interpretation of observational 
studies. Heart 2004;90:956-60. 
 
102. Solomons NM, Spross JA. Evidence-based practice barriers and facilitators from a 
continuous quality improvement perspective: an integrative review. J Nurs Manag 
2011;19:109-20. 
 
103. Shortell SM, Bennett CL, Byck GR. Assessing the impact of continuous quality 
improvement on clinical practice: what it will take to accelerate progress. Milbank Q 
1998;76:593-624, 510. 
 
104. Hall D, Zezza M. Developing an Incentives Playbook: Aligning Influences in the Era of 
Reform. American Journal of Managed Care 201. 
 
105. Evans M. Consolidation Creating Giant Hospital Systems.  Modern Healthcare2014. 
 
106. Kocher R, Sahnil NR. Hospitals' Race to Employ Physicians — The Logic behind a 
Money-Losing Proposition. The New England Journal of Medicine 2011:1790-3. 
 
107. Miltenberger RG. Behavior Modification: Principles and Procedures. 5 ed: Wadsworth 
Publishing; 2011. 
 
108. Torchiana DF, Colton DG, Rao SK, Lenz SK, Meyer GS, Ferris TG. Massachusetts 
General Physicians Organization's quality incentive program produces encouraging 
results. Health Aff (Millwood) 2013;32:1748-56. 
 
109. Mehrotra A, Sorbero ME, Damberg CL. Using the lessons of behavioral economics to 
design more effective pay-for-performance programs. Am J Manag Care 2010;16:497-
503. 
 
230 
 
110. Gneezy U, Rustichini A. Pay Enough or Don't Pay at All. The Quarterly Journal of 
Economics 2000;115:791-810. 
 
111. McDonald R, Harrison S, Checkland K, Campbell SM, Roland M. Impact of financial 
incentives on clinical autonomy and internal motivation in primary care: ethnographic 
study. British Medical Journal 2007;334. 
 
112. Cunningham AT, Lynch TJ, Cassel CK. Catalyzing Physician Engagement: The Roles of 
Intrinsic and Extrinsic Motivation.  ABIM Foundation Forum2013. 
 
113. Kolstad J. Information and quality when motivation is intrinsic: Evidence from surgeon 
report cards. . American Economic Review;103:2875-910. 
 
114. Meeker D, Knight TK, Friedberg MW, et al. Nudging guideline-concordant antibiotic 
prescribing: a randomized clinical trial. JAMA Intern Med 2014;174:425-31. 
 
115. Curry LA, Spatz E, Cherlin E, et al. What distinguishes top-performing hospitals in acute 
myocardial infarction mortality rates? A qualitative study. Ann Intern Med 
2011;154:384-90. 
 
116. Flodgren G, Eccles MP, Shepperd S, Scott A, Parmelli E, Beyer FR. An overview of 
reviews evaluating the effectiveness of financial incentives in changing healthcare 
professional behaviours and patient outcomes. Cochrane Database Syst Rev 
2011:CD009255. 
 
117. Grossman C, Powers B, McGinnis JM. Learning What Works. Washington, DC: National 
Academy of Sciences; 2011. Report No.: ISBN-13: 978-0-309-12068-5. 
 
118. Olsen L, Aisner D, McGinnis JM. The Learning Healthcare System. Washington, DC: 
Institute of Medicine; 20007. 
 
119. Corrigan J, McNeill D. Building organizational capacity: a cornerstone of health system 
reform. Health Aff (Millwood) 2009;28:w205-15. 
 
120. Ortiz E, Clancy CM, AHRQ. Use of information technology to improve the quality of 
health care in the United States. Health Serv Res 2003;38:xi-xxii. 
 
121. Snyder CF, Wu AW, Miller RS, Jensen RE, Bantug ET, Wolff AC. The role of 
informatics in promoting patient-centered care. Cancer J 2011;17:211-8. 
 
122. Rohm BWT, Rohm CET. Clinical Informatics: A New Paradigm for Advances in 
BioMedical Informatics. Clinical Informatics 2007;3:100-8. 
 
231 
 
123. Health Informatics Society of Australia. A Review of the Australian Health Informatics 
Workforce: A Report by the Health Informatics Society of Australia.  Health Informatics 
Society of Australia Melbourne 2009. 
 
124. Hersh W. New IOM Report on Implementing the Learning Healthcare System: It's All in 
the Information.  Informatics Professor2012. 
 
125. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. A 
systematic review of the effect of continuing medical education strategies. JAMA 
1995;274:700-5. 
 
126. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased 
mortality, postoperative morbidity, and cost after red blood cell transfusion in patients 
having cardiac surgery. Circulation 2007;116:2544-52. 
 
127. Anonymous. Actionable Patient Safety Solution (APSS) #3:SUB-OPTIMAL RED Blood 
Cell Transfusion Patient Safety.Org; 2014. 
 
128. Agency for Healthcare Research and Quality. Inpatient Sample. Agency for Healthcare 
Research and Quality; 1997-2007. 
 
129. Patient Safety Movement. Actionable Patient Safety Solution (APSS) #3:SUB-Optimal 
Red Blood Cell Transfusion Patient Safety.Org; 2014. 
 
130. AHRQ. Inpatient Sample. Agency for Healthcare Research and Quality; 1997-2007. 
 
131. Puca KE, Fredrick N, Slapak C. Beyond the Lab into Patient Blood 
Management American Society for Clinical Pathology; 2014. 
 
132. Analysis PHA. Standardization of blood utilization practices could provide opportunity 
for improved outcomes, reduced costs Premier; 2012. 
 
133. Toner RW, Pizzi L, Leas B, Ballas SK, Quigley A, Goldfarb NI. Costs to hospitals of 
acquiring and processing blood in the US: a survey of hospital-based blood banks and 
transfusion services. Appl Health Econ Health Policy 2011;9:29-37. 
 
134. The cost of blood: multidisciplinary consensus conference for a standard methodology. 
Transfus Med Rev 2005;19:66-78. 
 
135. Shander A, Hofmann A, Gombotz H, Theusinger OM, Spahn DR. Estimating the cost of 
blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007;21:271-
89. 
 
136. Corporation M. New Published Study Finds the Cost of Blood Transfusions is 
Significantly Underestimated, Establishes True Cost at $522 to $1,183 Per Unit. 2014. 
232 
 
 
137. Crémieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in 
cancer patients. J Clin Oncol 2000;18:2755-61. 
 
138. Patterson JA, Roberts CL, Isbister JP, et al. What factors contribute to hospital variation 
in obstetric transfusion rates? Vox Sang 2015;108:37-45. 
 
139. Carson JL, Hill S, Carless P, Hébert P, Henry D. Transfusion triggers: a systematic 
review of the literature. Transfus Med Rev 2002;16:187-99. 
 
140. Carson JL, Armas-Loughran B. Blood transfusion: less is more? Crit Care Med 
2003;31:2409-10. 
 
141. Corwin HL, Shorr AF. Red blood cell transfusion in the critically ill: when is it time to 
say enough? Crit Care Med 2009;37:2114-6. 
 
142. Shander A, Fink A, Javidroozi M, et al. Appropriateness of allogeneic red blood cell 
transfusion: the international consensus conference on transfusion outcomes. Transfus 
Med Rev 2011;25:232-46.e53. 
 
143. TxMD. Success in Cardiac Surgery Blood Management: 45% Reduction in Coronary 
Artery Bypass Graft (CABG) Intraoperative Transfusion BloodCenter of Wisconsin. 
 
144. McQuilten ZK, Andrianopoulos N, Wood EM, et al. Transfusion practice varies widely 
in cardiac surgery: Results from a national registry. J Thorac Cardiovasc Surg 
2014;147:1684-90. 
 
145. Hébert PC, Wells G, Martin C, et al. Variation in red cell transfusion practice in the 
intensive care unit: a multicentre cohort study. Crit Care 1999;3:57-63. 
 
146. Bennett-Guerrero E, Zhao Y, O'Brien SM, et al. Variation in use of blood transfusion in 
coronary artery bypass graft surgery. JAMA 2010;304:1568-75. 
 
147. Lozano M, Cid J. Transfusion medicine as of 2014. F1000Prime Rep 2014;6:105. 
 
148. Hébert PC. Transfusion requirements in critical care (TRICC): a multicentre, 
randomized, controlled clinical study. Transfusion Requirements in Critical Care 
Investigators and the Canadian Critical care Trials Group. Br J Anaesth 1998;81 Suppl 
1:25-33. 
 
149. Carless PA, Henry DA, Carson JL, Hebert PP, McClelland B, Ker K. Transfusion 
thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane 
Database Syst Rev 2010:CD002042. 
 
233 
 
150. Blumberg N, Hicks GL, Heal JM, Rogers M. Study Links Blood Transfusions to Surgery 
Complications in Women. University of Rochester Medical Center2007. 
 
151. Rohde JM, Dimcheff DE, Blumberg N, et al. Health care-associated infection after red 
blood cell transfusion: a systematic review and meta-analysis. JAMA 2014;311:1317-26. 
 
152. Isbister JP, Shander A, Spahn DR, Erhard J, Farmer SL, Hofmann A. Adverse blood 
transfusion outcomes: establishing causation. Transfus Med Rev 2011;25:89-101. 
 
153. Weisel RD, Dennis RC, Manny J, Mannick JA, Valeri CR, Hechtman HB. Adverse 
effects of transfusion therapy during abdominal aortic aneurysectomy. Surgery 
1978;83:682-90. 
 
154. Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic 
review of the literature. Anesthesiology 2010;113:482-95. 
 
155. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk 
patients after hip surgery. N Engl J Med 2011;365:2453-62. 
 
156. Society for The Advancement of Blood Management. Transfusion Overuse – Exposing 
and International Problem and Patient Safety Issue. . 
 
157. Petrides M, Aubuchon JP. To transfuse or not to transfuse: An assessment of risks and 
benefits. In: Mintz PD, ed. Transfusion therapy:Clinical principles and practice. 3rd ed. 
Bethesda, MD: AABB Press, 2011.  AABB Press. Bethesda, MD: Transfusion 
therapy:Clinical principles and practice; 2011. 
 
158. Goodnough LT, Shander A. Risk and complications of blood transfusions: optimizing 
outcomes for patientswith chemotherapy induced anemia.  Advanced Studies in 
Medicine2008:357–62. 
 
159. Whitaker BI, Hinkins S. The 2011 National Blood Collection and Utilization Survey 
Report. he U.S. Department of Health and Human Services2011. 
 
160. Whitaker BI, Green J, King MR, et al. The 2007 National Blood Collection and 
Utilization Survey Report: The United States Department of Health and Human Services; 
2007. 
 
161. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of 
transfusion-transmitted viral infections based on rates of detection of recently infected 
donors. Transfusion 2005;45:254-64. 
 
162. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice 
guideline from the AABB. Ann Intern Med 2012;157:49-58. 
 
234 
 
163. Cullen KA, Arguin PM, Division of Parasitic Diseases and Malaria CfGH, C.nters for 
Disease Control and Prevention (CDC). Malaria surveillance--United States, 2011. 
MMWR Surveill Summ 2013;62:1-17. 
 
164. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. 
Lancet 2003;361:161-9. 
 
165. Kevin L. Risky Business? The Relative Infectious Risks of Blood Transfusion.  The 
Bloody Truth Medical Blog; The Truth About Blood Transfusions Patient Safety2012. 
 
166. Li G, Rachmale S, Kojicic M, et al. Incidence and transfusion risk factors for transfusion-
associated circulatory overload among medical intensive care unit patients. Transfusion 
2011;51:338-43. 
 
167. ABC. Infectious Risks of Blood Transfusion. . Washington, DC. : Blood 
Bulletin. America‘s Blood Centers. ; 2001. 
 
168. ABC. Non-infectious Serious Hazards of Transfusion.  Blood Bulletin  Washington, DC:: 
America‘s Blood Centers.; 2002. 
 
169. CDC. Fatal West Nile virus infection after probable transfusion-associated transmission--
Colorado, 2012. MMWR Morb Mortal Wkly Rep 2013;62:622-4. 
 
170. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 
1997;72:1-10. 
 
171. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted 
viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 
1996;334:1685-90. 
 
172. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections 
among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J 
Med 2004;351:760-8. 
 
173. Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab 
Med 2007;131:702-7. 
 
174. AABB. Technical Manual, 17th edition. Bethesda, MD: AABB Press; 2011. 
 
175. AABB. Update to Transfusion. AABB Resources. 2009:107-9S. 
 
176. Crosse MG. Blood Supply: Transfusion-associated risks: Diane Pub Co; 1997. 
 
235 
 
177. Young C, Chawla A, Berardi V, et al. Preventing transfusion-transmitted babesiosis: 
preliminary experience of the first laboratory-based blood donor screening program. 
Transfusion 2012;52:1523-9. 
 
178. Services UB. Risks Associated with Transfusion. United Blood Services for Hospitals 
and Physicians. 
 
179. AABB. Non-Infectious Hazards of Transfusion. Bethesda, MD2008. 
 
180. Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: 
an analysis of 10 years' experience. Transfusion 2000;40:1207-13. 
 
181. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a 
systematic review of the literature. Crit Care Med 2008;36:2667-74. 
 
182. Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: 
the TRACS randomized controlled trial. JAMA 2010;304:1559-67. 
 
183. Hill SR, Carless PA, Henry DA, et al. Transfusion thresholds and other strategies for 
guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 
2002:CD002042. 
 
184. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet 
2007;370:415-26. 
 
185. Shander A, Gross I, Hill S, et al. A new perspective on best transfusion practices. Blood 
Transfus 2013;11:193-202. 
 
186. Long TR, Curry TB, Stemmann JL, et al. Changes in red blood cell transfusion practice 
during the turn of the millennium: a retrospective analysis of adult patients undergoing 
elective open abdominal aortic aneurysm repair using the Mayo database. Ann Vasc Surg 
2010;24:447-54. 
 
187. Vuille-Lessard E, Boudreault D, Girard F, Ruel M, Chagnon M, Hardy JF. Red blood cell 
transfusion practice in elective orthopedic surgery: a multicenter cohort study. 
Transfusion 2010;50:2117-24. 
 
188. Wass CT, Long TR, Faust RJ, Yaszemski MJ, Joyner MJ. Changes in red blood cell 
transfusion practice during the past two decades: a retrospective analysis, with the Mayo 
database, of adult patients undergoing major spine surgery. Transfusion 2007;47:1022-7. 
 
189. Ferraris VA, Brown JR, Despotis GJ, et al. 2011 Update to The Society of Thoracic 
Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation 
Clinical Practice Guidelines. Ann Thorac Surg 2011. 
 
236 
 
190. Maddux FW, Dickinson TA, Rilla D, et al. Institutional variability of intraoperative red 
blood cell utilization in coronary artery bypass graft surgery. Am J Med Qual 
2009;24:403-11. 
 
191. Turgeon AF, Fergusson DA, Doucette S, et al. Red blood cell transfusion practices 
amongst Canadian anesthesiologists: a survey. Can J Anaesth 2006;53:344-52. 
 
192. Spahn DR, Theusinger OM, Hofmann A. Patient blood management is a win-win: a 
wake-up call. Br J Anaesth 2012;108:889-92. 
 
193. Goodnough LT, Shander A, Spivak JL, et al. Detection, evaluation, and management of 
anemia in the elective surgical patient. Anesth Analg 2005;101:1858-61. 
 
194. Graham-Stewart CW. A clinical survey of blood-transfusion. Lancet 1960;2:421-4. 
 
195. Reece RL, Beckett RS. Epidemiology of single-unit transfusion. A one-year experience 
in a community hospital. JAMA 1966;195:801-16. 
 
196. Murphy MF, Wallington TB, Kelsey P, et al. Guidelines for the clinical use of red cell 
transfusions. Br J Haematol 2001;113:24-31. 
 
197. Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: red blood cell 
transfusion in adult trauma and critical care. Crit Care Med 2009;37:3124-57. 
 
198. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and 
hemorrhage in patients with acute leukemia. N Engl J Med 1962;266:905-9. 
 
199. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic 
patients. Transfus Med Rev 2004;18:153-67. 
 
200. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with 
cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin 
Oncol 2001;19:1519-38. 
 
201. Heddle NM, Cook RJ, Sigouin C, et al. A descriptive analysis of international transfusion 
practice and bleeding outcomes in patients with acute leukemia. Transfusion 
2006;46:903-11. 
 
202. Wall MH, Prielipp RC. Transfusion in the operating room and the intensive care unit: 
current practice and future directions. Int Anesthesiol Clin 2000;38:149-69. 
 
203. Roback JD, Caldwell S, Carson J, et al. Evidence-based practice guidelines for plasma 
transfusion. Transfusion 2010;50:1227-39. 
 
237 
 
204. SABM. Patient Blood Management.  SABM's Annual Meeting. sabm.org: Society for 
The Advancement of Blood Management. 
 
205. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical 
trial of transfusion requirements in critical care. Transfusion Requirements in Critical 
Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-17. 
 
206. Carson JL, Duff A, Berlin JA, et al. Perioperative blood transfusion and postoperative 
mortality. JAMA 1998;279:199-205. 
 
207. Krausz MM, Dennis RC, Utsunomiya T, et al. Cardiopulmonary function following 
transfusion of three red blood cell products in elective abdominal aortic aneurysmectomy. 
Ann Surg 1981;194:616-24. 
 
208. Johnson RG, Thurer RL, Kruskall MS, et al. Comparison of two transfusion strategies 
after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg 
1992;104:307-14. 
 
209. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for 
guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 
2012;4:CD002042. 
 
210. JC. Joint Commission Perspectives. The Joint Commission Continues to Study Overuse 
Issues.: The Joint Commission; 2012:4-8. 
 
211. McCarthy LJ, Emmett D, Smith S, Holland V. Evidence-based medicine in transfusion 
medicine: an update. ISBT Science Series; 2007:36-40. 
 
212. Blajchman MA. Landmark studies that have changed the practice of transfusion 
medicine. Transfusion 2005;45:1523-30. 
 
213. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly 
patients with acute myocardial infarction. N Engl J Med 2001;345:1230-6. 
 
214. Wu WC, Trivedi A, Friedmann PD, et al. Association between hospital intraoperative 
blood transfusion practices for surgical blood loss and hospital surgical mortality rates. 
Ann Surg 2012;255:708-14. 
 
215. Llewelyn CA, Taylor RS, Todd AA, et al. The effect of universal leukoreduction on 
postoperative infections and length of hospital stay in elective orthopedic and cardiac 
surgery. Transfusion 2004;44:489-500. 
 
216. Go JT, Vaughan-Sarrazin M, Auerbach A, et al. Do hospitalists affect clinical outcomes 
and efficiency for patients with acute upper gastrointestinal hemorrhage (UGIH)? J Hosp 
Med 2010;5:133-9. 
238 
 
 
217. Friedman MT. Blood transfusion practices: a little consistency please. Blood Transfus 
2011;9:362-5. 
 
218. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: Anemia and Blood 
Transfusion in the Critically Ill - Current Clinical Practice in the United States.  Crit Care 
Med. 32(1); 2004. 
 
219. Rana R, Afessa B, Keegan MT, et al. Evidence-based red cell transfusion in the critically 
ill: quality improvement using computerized physician order entry. Crit Care Med 
2006;34:1892-7. 
 
220. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill 
patients. JAMA 2002;288:1499-507. 
 
221. Roubinian NH, Murphy EL, Swain BE, et al. Predicting red blood cell transfusion in 
hospitalized patients: role of hemoglobin level, comorbidities, and illness severity. BMC 
Health Serv Res 2014;14:213. 
 
222. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper 
gastrointestinal bleeding. N Engl J Med 2013;368:11-21. 
 
223. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal 
hemorrhage: a population-based study. Am J Gastroenterol 1995;90:206-10. 
 
224. So-Osman C, Cicilia J, Brand A, Schipperus M, Berning B, Scherjon S. Triggers and 
appropriateness of red blood cell transfusions in the postpartum patient--a retrospective 
audit. Vox Sang 2010;98:65-9. 
 
225. Silverman JA, Barrett J, Callum JL. The appropriateness of red blood cell transfusions in 
the peripartum patient. Obstet Gynecol 2004;104:1000-4. 
 
226. Qian F, Osler TM, Eaton MP, et al. Variation of blood transfusion in patients undergoing 
major noncardiac surgery. Ann Surg 2013;257:266-78. 
 
227. Welsby I, Crow J, Bandarenko N, Lappas G, Phillips-Bute B, Stafford-Smith M. A 
clinical prediction tool to estimate the number of units of red blood cells needed in 
primary elective coronary artery bypass surgery. Transfusion 2010;50:2337-43. 
 
228. Sherwood MW, Wang Y, Curtis JP, Peterson ED, Rao SV. Patterns and outcomes of red 
blood cell transfusion in patients undergoing percutaneous coronary intervention. JAMA 
2014;311:836-43. 
 
239 
 
229. Carson JL, Terrin ML, Barton FB, et al. A pilot randomized trial comparing symptomatic 
vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. 
Transfusion 1998;38:522-9. 
 
230. Banerjee S, Issa K, Kapadia BH, et al. Intraoperative nonpharmacotherapeutic blood 
management strategies in total knee arthroplasty. J Knee Surg 2013;26:387-93. 
 
231. Newman ET, Watters TS, Lewis JS, et al. Impact of perioperative allogeneic and 
autologous blood transfusion on acute wound infection following total knee and total hip 
arthroplasty. J Bone Joint Surg Am 2014;96:279-84. 
 
232. Friedman R, Homering M, Holberg G, Berkowitz SD. Allogeneic blood transfusions and 
postoperative infections after total hip or knee arthroplasty. J Bone Joint Surg Am 
2014;96:272-8. 
 
233. Schwarzkopf R, Chung C, Park JJ, Walsh M, Spivak JM, Steiger D. Effects of 
perioperative blood product use on surgical site infection following thoracic and lumbar 
spinal surgery. Spine (Phila Pa 1976) 2010;35:340-6. 
 
234. Woods BI, Rosario BL, Chen A, et al. The association between perioperative allogeneic 
transfusion volume and postoperative infection in patients following lumbar spine 
surgery. J Bone Joint Surg Am 2013;95:2105-10. 
 
235. Levi N, Sandberg T. Blood transfusion and postoperative wound infection in 
intracapsular femoral neck fractures. Bull Hosp Jt Dis 1998;57:69-73. 
 
236. Verlicchi F, Desalvo F, Zanotti G, Morotti L, Tomasini I. Red cell transfusion in 
orthopaedic surgery: a benchmark study performed combining data from different data 
sources. Blood Transfus 2011;9:383-7. 
 
237. Shander A, Javidroozi M, Ozawa S, Hare GM. What is really dangerous: anaemia or 
transfusion? Br J Anaesth 2011;107 Suppl 1:i41-59. 
 
238. Haynes SL, Torella F. The role of hospital transfusion committees in blood product 
conservation. Transfus Med Rev 2004;18:93-104. 
 
239. Liumbruno GM, Rafanelli D. Appropriateness of blood transfusion and physicians' 
education: a continuous challenge for Hospital Transfusion Committees? Blood Transfus 
2012;10:1-3. 
 
240. Haspel RL, Lin Y, Mallick R, et al. Internal medicine resident knowledge of transfusion 
medicine: results from the BEST-TEST international education needs assessment. 
Transfusion 2014. 
 
240 
 
241. Clark P, Rennie I, Rawlinson S. Quality improvement report: Effect of a formal 
education programme on safety of transfusions. BMJ 2001;323:1118-20. 
 
242. Louw VJ, Nel MM, Hay JF. Postgraduate education in transfusion medicine in the 
absence of formal residency training: assessment of factors needed to develop and sustain 
a postgraduate diploma program. Transfus Apher Sci 2013;49:681-6. 
 
243. Corwin HL, Theus JW, Cargile CS, Lang NP. Red blood cell transfusion: impact of an 
education program and a clinical guideline on transfusion practice. J Hosp Med 
2014;9:745-9. 
 
244. Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood 
conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of 
Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 
2007;83:S27-86. 
 
245. Goodnough LT, Shander A. Patient blood management. Anesthesiology 2012;116:1367-
76. 
 
246. Shander A, Javidroozi M. Patient Blood Management: Beyond Sensible Use of Blood for 
Better Outcomes Central Jeresy Blood Center2014. 
 
247. Shander A. Committee News: Committee on Blood Management. AMERICAN Society 
of Anesthesiologists 2013. 
 
248. Goodnough LT, Shander A. Blood management. Arch Pathol Lab Med 2007;131:695-
701. 
 
249. Shander A, Moskowitz DM, Javidroozi M. Blood conservation in practice: an overview. 
Br J Hosp Med (Lond) 2009;70:16-21. 
 
250. Shander A, Waters J. Developments in patient blood management. American Society of 
Anesthesiologists Newsletter 75:30 –22011. 
 
251. Shander A. Patient Blood Management: a multidisciplinary strategy to reduce the need 
for allogeneic blood. European Society of Anaesthesiology2011. 
 
252. Advisory Q. Appropriate Use of Medical Resouces: Patient Blood Management.  
American Hospital Association Quality Advisory2014. 
 
253. Dzik WH. The Changing Landscape of Transfusion Medicine: 2004–2015. Transfusion 
Medicine; 2005:69-82. 
 
254. Thomson A, Farmer S, Hofmann A, Isbister J, Shander A. Patient blood management – a 
new paradigm for transfusion medicine? .  ISBT Science Series 2009:423-35. 
241 
 
 
255. Thurer R. GNYHA Symposium Patient Blood Management. HaemoneticsThe Blood 
Management Company 2014. 
 
256. Government WA. Hospital Patient Blood Management Communication Strategies. 
Government of Western Australia2012. 
 
257. Tan JKH. Health Management Information Systems: Methods and Practical Applications: 
Aspen Publishers Inc.; 2001. 
 
258. IMPACT. Actionable Data for Measureable Results. Haemonetics. 
 
259. Jadwin D. Improving Blood Transfusion; Hemoglobin Level an Inadequate Metric. Lab 
Soft News2014. 
 
260. Management SftAoB. Transfusion Overuse Exposing an International Problem and 
Patient Safety Issue - For Nurses2014. 
 
261. Hewitt D, Richards T. Challenges in evidence-based medicine. Can Fam Physician 
2006;52:23-4. 
 
262. Nelson TD, Steele RG, Mize JA. Practitioner Attitudes Toward Evidence-based Practice: 
Themes and Challenges. Adm Policy Ment Health & Ment Health Serv Res 2006;33:398-
409. 
 
263. M.G. T. The Evidence for Evidence-Based Practice Implementation. Rockville, MD: 
Agency for Healthcare Research and Quality (US); 2008. 
 
264. Shander A, Hofmann A, Isbister J, Van Aken H. Patient blood management--the new 
frontier. Best Pract Res Clin Anaesthesiol 2013;27:5-10. 
 
265. Vincent JL, Sakr Y, De Backer D, Van der Linden P. Efficacy of allogeneic red blood 
cell transfusions. Best Pract Res Clin Anaesthesiol 2007;21:209-19. 
 
266. Rosenberg W, Donald A. Evidence based medicine: an approach to clinical problem-
solving. BMJ 1995;310:1122-6. 
 
267. Haines A, Jones R. Implementing findings of research. BMJ 1994;308:1488-92. 
 
268. Chalmers I, Dickersin K, Chalmers TC. Getting to grips with Archie Cochrane's agenda. 
BMJ 1992;305:786-8. 
 
269. Thyer BA. Foundation of Evidence-Based Social Work Practice. New York, New York: 
Oxford University Press Inc.; 2006. 
 
242 
 
270. Sudsawad P. Knowledge Translation: Introduction to Models, Strategies, and Measures. 
The National Center for the Dissemination of Disability Research: Center on Knowledge 
Translation for Disability and Rehabilitation Research; 2007. 
 
271. Canadian Institutes of Health Research. About Knowledge Translation.2005. 
 
272. World Health Organization. Bridging the "Know-Do" gap: Meeting on knowledge 
translation in global health.2005. 
 
273. Lang ES, Wyer PC, Haynes RB. Knowledge translation: closing the evidence-to-practice 
gap. Ann Emerg Med 2007;49:355-63. 
 
274. Canadian Institutes of Health Research. Knowledge translation strategy 2004-2009: 
Innovation in Action.2004. 
 
275. Armstrong K, Kendall E. Translating knowledge into practice and policy: the role of 
knowledge networks in primary health care. HIM J 2010;39:9-17. 
 
276. Graham ID, Logan J, Harrison MB, et al. Lost in knowledge translation: time for a map? 
J Contin Educ Health Prof 2006;26:13-24. 
 
277. Sung NS, Crowley WF, Genel M, et al. Central challenges facing the national clinical 
research enterprise. JAMA 2003;289:1278-87. 
 
278. Wang Y. The ―Valley Of Death‖ In Medicine Is Not Only A Knowledge Translation But 
Also A Socio-Cultural And Institutional Problem. : Case Western Reserve University; 
2012. 
 
279. Browman GP. Challenges in knowledge translation: the early years of Cancer Care 
Ontario's Program in Evidence-Based Care. Curr Oncol 2012;19:27-35. 
 
280. Grimshaw JM, Eccles MP, Lavis JN, Hill SJ, Squires JE. Knowledge translation of 
research findings. Implement Sci 2012;7:50. 
 
281. McKenna HP, Ashton S, Keeney S. Barriers to evidence-based practice in primary care. J 
Adv Nurs 2004;45:178-89. 
 
282. O'Connor S, Pettigrew CM. The barriers perceived to prevent the successful 
implementation of evidence-based practice by speech and language therapists. Int J Lang 
Commun Disord 2009;44:1018-35. 
 
283. Haines A, Kuruvilla S, Borchert M. Bridging the implementation gap between knowledge 
and action for health: World Health Organization; 2004. 
 
243 
 
284. Harington L. Technology Today. American Association of Critical-Care Nurses 
2014;25:15-7. 
 
285. Healthcare Information and Management Systems Society (HIMSS). Dictionary of 
Health Information Technology Terms, Acronyms, and Organizations Chicago2006. 
 
286. Harington L. Technology and the Digitization of Health Care. American Association of 
Critical-Care Nurses 2014;25:15-7. 
 
287. Topol E. The Creative Destruction of Medicine: How the digital Revolution Will Create a 
Better Healthcare. New York, New York: Basic Books; 2012. 
 
288. Longworth DL. Accountable care organizations, the patient-centered medical home, and 
health care reform: what does it all mean? Cleve Clin J Med 2011;78:571-82. 
 
289. Aiga H, Kuroiwa C, Takizawa I, Yamagata R. The reality of health information systems: 
challenges for standardization. Biosci Trends 2008;2:5-9. 
 
290. Iroju O, Soriyan A, Gambo I, Olaleke J. Interoperability in Healthcare: Benefits, 
Challenges and Resolutions International Journal of Innovation and Applied Studies: 
Innovative Space of Scientific Research Journals 2013:pp. 262-70. 
 
291. LeSueur D. 5 Reasons Healthcare Data Is Difficult to Measure. Data Quality and 
Governance: Health catalyst; 2014. 
 
292. Clark J, Demster B, Solberg CJ. Managing a Data Dictionary. Journal of AHIMA; 
2012:48-52. 
 
293. Heubusch K. Interoperability: what it means, why it matters. J AHIMA 2006;77:26-30; 
quiz 3-4. 
 
294. Avanavadi P. A Mediating Schema Approach to the Data Transfer between 
Heterogeneous Health Care Systems. Social Science Research Network2006. 
 
295. Capurro D, PhD MY, van Eaton E, Black R, Tarczy-Hornoch P. Availability of 
structured and unstructured clinical data for comparative effectiveness research and 
quality improvement: a multisite assessment. EGEMS (Wash DC) 2014;2:1079. 
 
296. American Hospital Association. Clinical Integration – The Key to Real Reform. 
AHA.org2010. 
 
297. Suter E, Oelke ND, Adair CE, Armitage GD. Ten key principles for successful health 
systems integration. Healthc Q 2009;13 Spec No:16-23. 
 
244 
 
298. Guyatt G, Rennie D, Meade M, Cook D. Users' Guides to the Medical Literature: A 
Manual for Evidence-Based Clinical Practice2008. 
 
299. Mandl KD, Kohane IS. Escaping the EHR trap--the future of health IT. N Engl J Med 
2012;366:2240-2. 
 
300. Brailer DJ. Interoperability: the key to the future health care system. Health Aff 
(Millwood) 2005;Suppl Web Exclusives:W5-19-W5-21. 
 
301. Interoperability Issues in Healthcare. http://ranger.uta.edu/~zikos/courses/5339-
4392_content_repository/week4/WEEK4-Notes.pdf  
 
302. Bensen T. Principles of Health Interoperability HL7 and SNOMED. Second ed: Springer-
Verlag London; 2012. 
 
303. HIMSS. Dictionary of Health Information Technology Terms, Acronyms, and 
Organizations Chicago2006. 
 
304. Gibbons P, Arzt N, Burke-Beebe S, et al. Coming to Terms: Scoping Interoperability for 
Health Care2007. 
 
305. Swarup D. Managing Complexity In Clinical Quality Measurement.  Health IT 
Outcomes2013. 
 
306. Fritsch J. Three Hidden Obstacles To Healthcare Interoperability.  M*Modal: MModal IP 
LLC; 2014. 
 
307. EN13606 Association Site. Semantic interoperability of health information.  CEN/ISO 
13606 EHR. 
 
308. Rosenbloom ST, Denny JC, Xu H, Lorenzi N, Stead WW, Johnson KB. Data from 
clinical notes: a perspective on the tension between structure and flexible documentation. 
J Am Med Inform Assoc 2011;18:181-6. 
 
309. Ramakrishnan R. Applications of Logic Databases. New York, New York: Springer; 
1995. 
 
310. Kim K. Clinical Data Standards in Healthcare: Five Case Studies. iHealth Report2005. 
 
311. Axway. Interoperability is the Future. HIMSS2013. 
 
312. Healthcare Information and Management System Society. Interoperability is the Future.  
 
313. Manos D. Interoperability Still A Barrier to Meaningful Use, Experts Find.  Healthcare 
IT News2012. 
245 
 
 
314. Berger JE. Breaking Down Another Healthcare Silo. American Journal of Managed 
Car2011. 
 
315. Smith N, O'Connell P. To Build Your Business, Smash Your Silos: Palgrave Macmillan 
Trade; 2012. 
 
316. National Academy of Engineering (US) and Institute of Medicine (US) Committee on 
Engineering and the Health Care System. Building a Better Delivery System: A New 
Engineering/Health Care Partnership. Washington, DC: Institute of Medicine; 2005. 
 
317. Reid PP, Compton WD, Grossman JH, Fanjiang G. Building a Better Delivery System: A 
New Engineering/Health Care Partnership National Academies Press; 2005. 
 
318. Henry D, Buckley P, Gill G, LaPorte S. The Emerging Digital Economy II. U.S. 
Department of Commerce1999. 
 
319. Myers JE. Data Modeling for Healthcare Systems Integration: Use of the MetaModel.  
Metadata. 
 
320. Perficient. Business Intelligence and Analytics for Healthcare. 2014. 
 
321. Analytics H. Clinical Analytics: Can Organizations Maximize Clinical Data? 2010. 
 
322. Healthcare Information and Management Systems Society (HIMSS). Clinical Analytics: 
Can Organizations Maximize Clinical Data? 2010. 
 
323. LaValle S, Hopkins M, Lesser E, Shockley R, Kruschwitz N. How the smartest 
organizations are embedding analytics to transform insights into action  Massachusetts 
Institute of TechnologyIBM Institute for Business Value; 2010. 
 
324. Institute of Medicine (IOM). Crossing the Quality Chasm: A New Health System for the 
21st Century. Washington, DC2001. 
 
325. Ritchie A, Marbury D, Verdon DR, Mazzolini C, Bolyes S. Shifting reimbursement 
models: The risks and rewards for primary care Medical Economics2014. 
 
326. Damberg C, Grazier K, Greenfield S, et al. Advancing Physician Performance 
MeasurementUsing Administrative Data to Assess Physician Quality and Efficiency: 
Pacific Business Group on Health; 2005. 
 
327. Scholle SH, Roski J, Dunn DL, et al. Availability of data for measuring physician quality 
performance. Am J Manag Care 2009;15:67-72. 
 
246 
 
328. Galvin R, Milstein A. Large employers' new strategies in health care. N Engl J Med 
2002;347:939-42. 
 
329. Dobbs D, Burkhart T, Halper R, et al. Clinical & Business Intelligence: Data 
Management – A Foundation for Analytics Healthcare Information and Management 
Systems Society (HiMSS)2013. 
 
330. IBM. What is Data Integration?  Data Integration: IBM.com. 
 
331. Kilbridge PM, Classen DC. The informatics opportunities at the intersection of patient 
safety and clinical informatics. J Am Med Inform Assoc 2008;15:397-407. 
 
332. Hoffman G, Molesworth R. Integrated Data Analytics in an Era of Reform: Ten 
Observations From the Trenches: eHealth InitiativeTruven Health; 2012. 
 
333. Lu Z, Su J. Clinical data management: Current status, challenges, and future directions 
from industry perspectives. Dove Press Journal - Open Access Journal of Clinical Trials 
2010. 
 
334. Initiative e. The State of Health Analytics in 2013: Improving Quality and Lowering 
Costs. McKessen2013. 
 
335. Gregg H. Data Analytics: Opportunities and Challenges.  Health Information 
Technology. Becker's Hospital CIO: Asc Communications; 2014. 
 
336. eHealth Initiative. The State of Health Analytics in 2013: Improving Quality and 
Lowering Costs. McKessen2013. 
 
337. Rudman WJ, Eberhardt JS, Pierce W, Hart-Hester S. Healthcare fraud and abuse. 
Perspect Health Inf Manag 2009;6:1g. 
 
338. Transformation IfHT. Population Health Management: A Roadmap for Provider-
Based Automation in a New Era of Healthcare. Institute for Health Technology 
Transformation2012. 
 
339. Crosson K. Improving Health Care Quality: Fact Sheet. Agency for Healthcare Research 
and Quality.2002. 
 
340. Fielding D. Claims Data ACO: ACOs' Best Source of Patient Health Information. 2013. 
 
341. Neely A, Adams C, Kennerley M, Prof Andy Neely (Author) CAA, Dr Mike Kennerley 
(Author). The Performance Prism: The Scorecard for Measuring and Managing Business 
Success: The Scorecard for Measuring and Managing Stakeholder Relationships 
(Financial Times Series): Pearson Education Limited; 2002. 
 
247 
 
342. Administration USDoHaHSHRaS. Performance Management and 
Measurement HRSA2011. 
 
343. IEEE. Standard Glossary of Software Engineering Terminology, IEEE Std 729 1983. 
 
344. IEEE. Standard Glossary of Software Engineering Terminology, IEEE Std 610.12 1990. 
 
345. HIMSS. The Many Types of Clinical Analytics (Module 3). Healthcare Information and 
Management Systems Socienty2014. 
 
346. Dictionary MsM. Patient Day.  The Free Dictionary by Farlex. 8 ed. Elsevier2009. 
 
347. Barbuio F. Performance Measurement: A Practical Guide to KPIs and Benchmarking in 
Public Broadcasters. Commonwealth Broadcasting Association. 
 
348. Williams L. Role of Key Performance Indicators in Successful Business Organizations. 
Active Garage2011. 
 
349. Sauer DA, McDonald CE, Boshkov L. Errors in Transfusion Medicine. Laboratory 
Medicine; 2001. 
 
350. Fastman BR, Kaplan HS. Errors in transfusion medicine: have we learned our lesson? Mt 
Sinai J Med 2011;78:854-64. 
 
351. Kohn LT, Corrigan JM, Donaldson MS. To Err Is Human: Building a Safer Health 
System: The National Academies Press; 2000. 
 
352. Classen DC, Resar R, Griffin F, et al. 'Global trigger tool' shows that adverse events in 
hospitals may be ten times greater than previously measured. Health Aff (Millwood) 
2011;30:581-9. 
 
353. Stainsby D, Russell J, Cohen H, Lilleyman J. Reducing adverse events in blood 
transfusion. Br J Haematol 2005;131:8-12. 
 
354. Carayon P, Wood KE. Patient safety - the role of human factors and systems engineering. 
Stud Health Technol Inform 2010;153:23-46. 
 
355. Adibi H, Khalesi N, Ravaghi H, Jafari M, Jeddian AR. Root-cause analysis of a 
potentially sentinel transfusion event: lessons for improvement of patient safety. Acta 
Med Iran 2012;50:624-31. 
 
356. Murphy MFP, Derwood H., Heddle NM. Practical Transfusion Medicine. 4 ed: Wiley-
Blackwell; 2013. 
 
357. World Health Organization. Blood transfusion safety2015. 
248 
 
 
358. Prevention CfDCa. Blood Safety Basics. 2011. 
 
359. Goodman C, Chan S, Collins P, Haught R, Chen YJ. Ensuring blood safety and 
availability in the US: technological advances, costs, and challenges to payment--final 
report. Transfusion 2003;43:3S-46S. 
 
360. Ness PM. The broken reimbursement system: putting the brakes on the blood safety train. 
Transfusion 2003;43:1S-2S. 
 
361. Liberman A, Rotarius T. A new cost allocation method for hospital-based clinical 
laboratories and transfusion services: implications for transfusion medicine. Transfusion 
2005;45:1684-8. 
 
362. The Lewin Group. Ensuring Blood Safety and Availability in the U.S.: Technological 
Advances, Costs, and Challenges to Payment2002. 
 
363. Szczepiorkowski ZM, Dunbar NM. Transfusion guidelines: when to transfuse. 
Hematology Am Soc Hematol Educ Program 2013;2013:638-44. 
 
364. Shander A, Javidroozi M, Ozawa S, Hare GMT. What is really dangerous: anaemia or 
transfusion? British Journal of Anesthesia 2011;107:41-59. 
 
365. Carson JL. Transfusion triggers: state of the art in 2010. Acta Anaesthesiol Belg 
2010;61:145. 
 
366. Pape A, Stein P, Horn O, Habler O. Clinical evidence of blood transfusion effectiveness. 
Blood Transfus 2009;7:250-8. 
 
367. America's Blood Centers. Infectious Risks of Blood Transfusion. . Washington, DC. : 
Blood Bulletin. America‘s Blood Centers. ; 2001. 
 
368. America's Blood Centers. Non-infectious Serious Hazards of Transfusion.  Blood 
Bulletin  Washington, DC:: America‘s Blood Centers.; 2002. 
 
369. Maxwell MJ, Wilson MJ. Complications of blood transfusion. Contin Educ Anaesth Crit 
Care Pain2006:225-9. 
 
370. Kopko PM, Holland PV. Mechanisms of severe transfusion reactions. Transfusion 
Clinique et Biologique2001:278-81. 
 
371. Prevention CfDCa. Blood Safety. Last Updated 2013. 
 
372. Perrotta PL, Snyder EL. Blood transfusion. Oxford Textbook of Medicine: 
Oxford: Oxford University Press; 2003:791-800. 
249 
 
 
373. Singh G, Sehgal R. Transfusion-transmitted parasitic infections. Asian J Transfus Sci 
2010;4:73-7. 
 
374. Yeh SP, Chang CW, Chen JC, et al. A well-designed online transfusion reaction 
reporting system improves the estimation of transfusion reaction incidence and quality of 
care in transfusion practice. Am J Clin Pathol 2011;136:842-7. 
 
375. AABB, DHHS. Nationwide Blood Collection and Utilization Survey Report. 2007. 
 
376. FDA. Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual 
Summary for Fiscal Year 2012.  Vaccines, Blood & BiologicsUpdated March 2014. 
 
377. Goodnough LT. Risks of blood transfusion. Crit Care Med 2003;31:S678-86. 
 
378. Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. 
Transfusion 1992;32:601-6. 
 
379. Klein H, Spahn D, Carson J. Red blood cell transfusion in clinical practice.  Lancet2007. 
 
380. Anderson K. Broadening the spectrum of patient groups at risk for transfusion-associated 
GVHD: implications for universal irradiation of cellular blood components. Transfusion 
2003;43:1652-4. 
 
381. Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and 
transfusion associated circulatory overload. Curr Opin Hematol 2007;14:682-7. 
 
382. Middelburg RA, van de Watering LM, Briët E, van der Bom JG. Storage time of red 
blood cells and mortality of transfusion recipients. Transfus Med Rev 2013;27:36-43. 
 
383. Triulzi DJ, Yazer MH. Clinical studies of the effect of blood storage on patient outcomes. 
Transfus Apher Sci 2010;43:95-106. 
 
384. van de Watering LM. Effects of red blood cell storage in heavily transfused patients. Curr 
Opin Anaesthesiol 2013;26:204-7. 
 
385. Lelubre C, Vincent JL. Relationship between red cell storage duration and outcomes in 
adults receiving red cell transfusions: a systematic review. Crit Care 2013;17:R66. 
 
386. Fergusson D, Hutton B, Hogan DL, et al. The age of red blood cells in premature infants 
(ARIPI) randomized controlled trial: study design. Transfus Med Rev 2009;23:55-61. 
 
387. Lacroix J, Hébert P, Fergusson D, et al. The Age of Blood Evaluation (ABLE) 
randomized controlled trial: study design. Transfus Med Rev 2011;25:197-205. 
 
250 
 
388. Steiner ME, Assmann SF, Levy JH, et al. Addressing the question of the effect of RBC 
storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 
7). Transfus Apher Sci 2010;43:107-16. 
 
389. AABB Advancing Transfusion and Cellular Therapies Worldwide (AABB). Nationwide 
Blood Collection and Utilization Survey Report2007. 
 
390. U.S. Food and Drug Administration. Fatalities Reported to FDA Following Blood 
Collection and Transfusion: Annual Summary for Fiscal Year 2013: U.S. Food and Drug 
Administration; 2014. 
 
391. Blumberg N. Allogeneic transfusion and infection: economic and clinical implications. 
Semin Hematol 1997;34:34-40. 
 
392. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of 
two parts--blood transfusion. N Engl J Med 1999;340:438-47. 
 
393. Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) 
initiative: analysis of the first two annual reports. BMJ 1999;319:16-9. 
 
394. Sazama K, DeChristopher PJ, Dodd R, et al. Practice parameter for the recognition, 
management, and prevention of adverse consequences of blood transfusion. College of 
American Pathologists. Arch Pathol Lab Med 2000;124:61-70. 
 
395. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev 
2001;15:69-83. 
 
396. Klein HG. Allogeneic transfusion risks in the surgical patient. Am J Surg 1995;170:21S-
6S. 
 
397. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-
related acute lung injury: report of a clinical look-back investigation. JAMA 
2002;287:1968-71. 
 
398. Cote C, MacLeod JB, Yip AM, et al. Variation in transfusion rates within a single 
institution: exploring the effect of differing practice patterns on the likelihood of blood 
product transfusion in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 
2015;149:297-302. 
 
399. Capraro L, Nuutinen L, Myllylä G. Transfusion thresholds in common elective surgical 
procedures in Finland. Vox Sang 2000;78:96-100. 
 
400. Goodnough LT, Soegiarso RW, Birkmeyer JD, Welch HG. Economic impact of 
inappropriate blood transfusions in coronary artery bypass graft surgery. Am J Med 
1993;94:509-14. 
251 
 
 
401. Oddason KE, Guđbjartsson T, Guđmundsson S, Kárason S, Hreinsson K, Sigurđsson GH. 
Inappropriate use of blood components in critical care?. Laeknabladid 2014;100:11-7. 
 
402. Casina T. References for "Transfusion Medicine Reactions". Advanced Healthcare 
Network for Laboratory2014:20. 
 
403. Administration FaD. Fatalities Reported to FDA Following Blood Collection and 
Transfusion. Washington, DC: Government Printing Office; 2011. 
 
404. Hull RJ, Bray RA, Hillyer C, Swerlick RA. Transfusion-associated chronic cutaneous 
graft-versus-host disease. J Am Acad Dermatol 1995;33:327-32. 
 
405. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood 
2005;105:2266-73. 
 
406. Lichtiger B, Perry-Thornton E. Hemolytic transfusion reactions in oncology patients: 
experience in a large cancer center. J Clin Oncol 1984;2:438-42. 
 
407. Narvios AB, Lichtiger B, Neumann JL. Underreporting of minor transfusion reactions in 
cancer patients. MedGenMed 2004;6:17. 
 
408. Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM. Perioperative anemia: an 
independent risk factor for infection, mortality, and resource utilization in surgery. J Surg 
Res 2002;102:237-44. 
 
409. Taylor RW, O'Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial 
infections in critically ill patients. Crit Care Med 2006;34:2302-8. 
 
410. Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk 
factor for postinjury multiple organ failure. Am J Surg 1999;178:570-2. 
 
411. Moore FA, Moore EE, Sauaia A. Blood transfusion. An independent risk factor for 
postinjury multiple organ failure. Arch Surg 1997;132:620-4; discussion 4-5. 
 
412. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: Anemia and blood transfusion 
in the critically ill--current clinical practice in the United States. Crit Care Med 
2004;32:39-52. 
 
413. Vamvakas EC, Carven JH. Allogeneic blood transfusion, hospital charges, and length of 
hospitalization: a study of 487 consecutive patients undergoing colorectal cancer 
resection. Arch Pathol Lab Med 1998;122:145-51. 
 
414. Sharma S, Sharma P, Tyler LN. Transfusion of blood and blood products: indications and 
complications. Am Fam Physician 2011;83:719-24. 
252 
 
 
415. Goodnough LT, Maggio P, Hadhazy E, et al. Restrictive blood transfusion practices are 
associated with improved patient outcomes. Transfusion 2014. 
 
416. RC A, JS L. Anesthesia in cases of poor risk: Some suggestions for decreasing the risk.  
Surg Gynecol Obstet1942. 
 
417. Madjdpour C, Spahn DR, Weiskopf RB. Anemia and perioperative red blood cell 
transfusion: a matter of tolerance. Crit Care Med 2006;34:S102-8. 
 
418. Corwin HL. Critical Care Issues For The Nephrologist: Anemia and Red Blood Cell 
Transfusion in the Critically Ill Seminars in Dialysis 2006;19:513-6. 
 
419. Beattie WS, Karkouti K, Wijeysundera DN, Tait G. Risk associated with preoperative 
anemia in noncardiac surgery: a single-center cohort study. Anesthesiology 
2009;110:574-81. 
 
420. Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically 
ill: prospective nested case-control study. Am J Respir Crit Care Med 2007;176:886-91. 
 
421. Jawa RS, Anillo S, Kulaylat MN. Transfusion-related acute lung injury. J Intensive Care 
Med 2008;23:109-21. 
 
422. Karp JK. Transfusion-Related Acute Lung Injury (TRALI).  CAP Transfusion Medicine 
Resource Committee NewsPath (Pathology News for Medical Community). 
 
423. Karkouti K, Wijeysundera DN, Beattie WS, Investigators RBiCSR. Risk associated with 
preoperative anemia in cardiac surgery: a multicenter cohort study. Circulation 
2008;117:478-84. 
 
424. Pedersen AB, Mehnert F, Overgaard S, Johnsen SP. Allogeneic blood transfusion and 
prognosis following total hip replacement: a population-based follow up study. BMC 
Musculoskelet Disord 2009;10:167. 
 
425. Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwischenberger JB. Intraoperative 
transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day 
mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J Am 
Coll Surg 2009;208:931-7, 7.e1-2; discussion 8-9. 
 
426. Ferraris VA, Davenport DL, Saha SP, Austin PC, Zwischenberger JB. Surgical outcomes 
and transfusion of minimal amounts of blood in the operating room. Arch Surg 
2012;147:49-55. 
 
253 
 
427. Castillo JJ, Dalia S, Pascual SK. Association between red blood cell transfusions and 
development of non-Hodgkin lymphoma: a meta-analysis of observational studies. Blood 
2010;116:2897-907. 
 
428. Vamvakas EC. Establishing causation in transfusion medicine and related tribulations. 
Transfus Med Rev 2011;25:81-8. 
 
429. Salem-Schatz SR, Avorn J, Soumerai SB. Influence of clinical knowledge, organizational 
context, and practice style on transfusion decision making. Implications for practice 
change strategies. JAMA 1990;264:476-83. 
 
430. Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol 
Lab Med 2007;131:708-18. 
 
431. Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless 
challenges and remarkable progress. Transfusion 2010;50:2080-99. 
 
432. Glance LG, Dick AW, Mukamel DB, et al. Association between intraoperative blood 
transfusion and mortality and morbidity in patients undergoing noncardiac surgery. 
Anesthesiology 2011;114:283-92. 
 
433. Shander A, Spence RK, Adams D, Shore-Lesserson L, Walawander CA. Timing and 
incidence of postoperative infections associated with blood transfusion: analysis of 1,489 
orthopedic and cardiac surgery patients. Surg Infect (Larchmt) 2009;10:277-83. 
 
434. McCullough J. Innovation in transfusion medicine and blood banking: documenting the 
record in 50 years of TRANSFUSION. Transfusion 2010;50:2542-6. 
 
435. Boucher BA, Hannon TJ. Blood management: a primer for clinicians. Pharmacotherapy 
2007;27:1394-411. 
 
436. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical 
outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-62. 
 
437. Society for The Advancement of Blood Management. What is blood management? 
 
438. AABB. Patient Blood Management  American Association of Blood Banks. 
 
439. Gammon HM, Waters JH, Watt A, Loeb JM, Donini-Lenhoff A. Developing 
performance measures for patient blood management. Transfusion 2011;51:2500-9. 
 
440. Organization WH. Availability, safety and quality of blood products. Sixty-Third World 
Health Assembly WHA 63.12. 2010. 
 
254 
 
441. Mbanya D. Barriers and enablers to introducing comprehensive patient blood 
management in the hospital. Biologicals 2012;40:205-8. 
 
442. Gombotz H. Patient Blood Management (PBM): A New Perioperative Transfusion 
Concept. 2011. 
 
443. Isbister JP. The three-pillar matrix of patient blood management--an overview. Best Pract 
Res Clin Anaesthesiol 2013;27:69-84. 
 
444. Theusinger OM, Kind SL, Seifert B, Borgeat L, Gerber C, Spahn DR. Patient blood 
management in orthopaedic surgery: a four-year follow-up of transfusion requirements 
and blood loss from 2008 to 2011 at the Balgrist University Hospital in Zurich, 
Switzerland. Blood Transfus 2014;12:195-203. 
 
445. Isbister JP. The three-pillar matrix of patient blood management – An overview. In: 
setting. Sociattpopbmitp-o, ed. Best Practice & Research Clinical Anaesthesiology2013. 
 
446. Shander A, Goodnough L. Blood transfusion as a quality indicator in cardiac surgery.  
Journal of American Medical Association2010:1610-1. 
 
447. The Joint Commission. Inspiring health care excellence. 2014. 
 
448. Lucas MT. Joint Commission Blood Management Performance Measures. 
jointcommission.org2011. 
 
449. Knowles W. The Benefits of Patient Blood Management.  Hospitals and Health 
Networks2014. 
 
450. Commission J. Implementation Guide for The Joint Commission Patient Blood 
Management Performance Measures. 2011. 
 
451. The Joint Commission. Implementation Guide for The Joint Commission Patient Blood 
Management Performance Measures 2011. 
 
452. Haemonetics: The Blood Management Company. Actionable Data for Measureable 
Results. BraintrBraintree, MA: Haemonetics Corporation; 2010. 
 
453. Friedman B. Improving Blood Transfusion Hemoglobin Level an Inadeqate Metric: Lab 
Soft; 2014. 
 
454. Institute of Medicine. The Promise of Health Information Technologies. Washington, 
DC: Institute of Medicine,; 2008. 
 
455. Hayward R. Information Technology Tools to Support Best Practices in Healthcare: 2007 
IOM Annual Meeting Summary. Washington, DC: Institute of Medicine; 2007. 
255 
 
456. Kania-Lachance DM, Best PJ, McDonah MR, Ghosh AK. Evidence-based practice and 
the nurse practitioner. Nurse Pract 2006;31:46-54. 
 
457. Jette DU, Bacon K, Batty C, et al. Evidence-based practice: beliefs, attitudes, knowledge, 
and behaviors of physical therapists. Phys Ther 2003;83:786-805. 
 
458. Paul RW. Critical Thinking: What Every Person Needs to Survive in a Rapidly Changing 
World 2ed: Foundation for Critical Thinki; 1993. 
 
459. Rodrigues RJ. Information systems: the key to evidence-based health practice. Bull 
World Health Organ 2000;78:1344-51. 
 
460. Zvárová J. On the medical informatics structure. International Journal of Medical 
Informatics 1997;4:75-81. 
 
461. Dickinson E. Clinical effectiveness for health care quality improvement. J Qual Clin 
Pract 1998;18:37-46. 
 
462. Michelsen K, Brand H, Achterberg P, Wilkinson J. Promoting better integration of health 
information systems: best practices and challenges: World Health Organization Europe; 
2015. 
 
463. Advancing Transfusion and Cellular Therapies Worldwide (AABB). Patient Blood 
Management  American Association of Blood Banks. 
 
464. Mukhtar SA, Leahy MF, Koay K, et al. Effectiveness of a patient blood management data 
system in monitoring blood use in Western Australia. Anaesth Intensive Care 
2013;41:207-15. 
 
465. Frank SM, Savage WJ, Rothschild JA, et al. Variability in blood and blood component 
utilization as assessed by an anesthesia information management system. Anesthesiology 
2012;117:99-106. 
 
466. Leach MJ. Evidence-based practice: a framework for clinical practice and research 
design. Int J Nurs Pract 2006;12:248-51. 
 
467. Houser J, Oman KS. Evidence-Based Practice: An Implementation Guide for Healthcare 
Organizations. 1st ed. Sudbury, MA: Jones & Bartlett Learning; 2011. 
 
468. Pagoto SL, Spring B, Coups EJ, Mulvaney S, Coutu MF, Ozakinci G. Barriers and 
facilitators of evidence-based practice perceived by behavioral science health 
professionals. J Clin Psychol 2007;63:695-705. 
 
469. Public Health Foundation. From Silos to Systems: Using Performance 
256 
 
Management to Improve the Public's Health.  Performance Management National 
Excellence Collaborative. Seattle, Washington: TurningPoint. 
 
470. Doyle J, Gaston M, Nyquist P, Seredynski G, Skulmoski J, Carson J. Guide For 
Developing Relevant Key Performance Indicators For Public Sector Reporting 2010. 
 
471. Welfare AIOHA. A guide to data development. Australian Institute of Health and 
Welfare (AIHW)2007. Report No.: AIHW Cat. no. HWI 94. 
 
472. Authority HIaQ. Guidance on Developing Key Performance Indicators and Minimum 
Data Sets to Monitor Healthcare Quality Health Information and Quality Authority2013. 
 
473. McLoughlin V, Leatherman S, Fletcher M, Owen J. Improving performances using 
indicators. Recent experiences in the United States, United Kingdom and 
Australia.:International Journal for Quality in Health Care; 2009:455-62. 
 
474. Commission H. The Better Metrics project. Healthcare Commission2008. 
 
475. Tanenbaum SJ. Improving the quality of medical care: the normativity of evidence-based 
performance standards. Theor Med Bioeth 2012;33:263-77. 
 
476. South SF, Hegarty JAS. Using Lean to Identify Process Improvement Opportunities and 
Improve Effectiveness of Transfusion Professionals.  Clinical Diagnostics: Johnson & 
Johnson Company; 2010. 
 
477. Nerenz DR, Neil N. Performance Measures for Health Care Systems: Center for Health 
Management Research; 2001. 
 
478. Australian Institute Of Health and Welfare. A guide to data development. Australian 
Institute of Health and Welfare (AIHW)2007. Report No.: AIHW Cat. no. HWI 94. 
 
479. Health Information and Quality Authority. Guidance on Developing Key Performance 
Indicators and Minimum Data Sets to Monitor Healthcare Quality Health Information 
and Quality Authority2013. 
 
480. Commission TJ. Attributes of Core Performance Measures And Associated Evaluation 
Criteria.  The Joint Commission2010. 
 
481. Organization WH. Mental Health Information Systems. World Health Organization2005. 
 
482. Council NHaMR. A guide to the development, implementation, and evaluation of clinical 
practice guidelines. Australia: National Health and Medical Research Council 1999. 
 
257 
 
483. HR R, Pronovost P, Diette G. From a process of care to a measure: thedevelopment and 
testing of a quality indicator.  International Journal for Quality inHealth Care. 
International Journal for Quality inHealth Care2001:489-96. 
 
484. Trochim WM. Types of Reliability. Research Method Knowledge Base2006. 
 
485. Mainz J. Developing evidence-based clinical indicators: a state of the art methods primer.  
International Journal for Quality in Health Care. International Journal for Quality in 
Health Care2003. 
 
486. Campbell S, Braspenning J, Hutchinson A, Marshall M. Research methods used in 
developing and applying quality indicators in primary care. .  Quality and Safety. Quality 
and Safety2002:358-64. 
 
487. Ezekwe N. Petroleum Reservoir Engineering Practice: Pearson Education Inc.; 2011. 
 
488. Commission. A. On Target: the practice of performance indicators.  Commission for 
Local Authorities and the National Health Service in England andWales. Commission for 
Local Authorities and the National Health Service in England andWales2000. 
 
489. AuBuchon JP, Puca K, Saxena S, Shulman IA, Waters JH. Getting Started in Patient 
Blood Management. Bethesda, MD: Advancing Transfusion and Cellular Therapies 
Worldwide (AABB),; 2011. 
 
490. Brockopp D, Schreiber J, Hill K, Altpeter T, Moe K, Merritt S. A successful evidence-
based practice model in an acute care setting. Oncol Nurs Forum 2011;38:509-11. 
 
491. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to 
teaching the practice of medicine. JAMA 1992;268:2420-5. 
 
492. Kitson A, Harvey G, McCormack B. Enabling the implementation of evidence based 
practice: a conceptual framework. Qual Health Care 1998;7:149-58. 
 
493. McInerney P, Suleman F. Exploring knowledge, attitudes, and barriers toward the use of 
evidence-based practice amongst academic health care practitioners in their teaching in a 
South African university: a pilot study. Worldviews Evid Based Nurs 2010;7:90-7. 
 
494. White B. Making evidence-based medicine doable in everyday practice. Fam Pract 
Manag 2004;11:51-8. 
 
495. Shorr AF, Duh MS, Kelly KM, Kollef MH, Group CS. Red blood cell transfusion and 
ventilator-associated pneumonia: A potential link? Crit Care Med 2004;32:666-74. 
 
258 
 
496. Taylor RW, Manganaro L, O'Brien J, Trottier SJ, Parkar N, Veremakis C. Impact of 
allogenic packed red blood cell transfusion on nosocomial infection rates in the critically 
ill patient. Crit Care Med 2002;30:2249-54. 
 
497. Shorr AF, Jackson WL. Transfusion practice and nosocomial infection: assessing the 
evidence. Curr Opin Crit Care 2005;11:468-72. 
 
498. Hannon T. The bloody truth: 10 facts about blood transfusions everyone should know.  
MLO: Medical Laboratory Observer 2010. 
 
 
 
 
 
 
 
 
 
259 
 
 
 
 
 
 
 
 
Appendices 
 
  
260 
 
 
 
 
Appendix A: Bloodcenter of Wisconsin 2011 Adult Blood Utilization Review Guidelines 
 
 
 
 
 
261 
 
 
 
262 
 
 
 
 
Appendix B: Patient Blood Management Newsletters 
263 
 
 
264 
 
 265 
 
Curriculum Vitae 
 
Nazanin Tabesh 
College of Engineering and Applied Science  
University of Wisconsin-Milwaukee, Milwaukee, WI 
 
 
 
Education 
 
2011 – 2015 Ph.D. in Biomedical and Health Informatics, College of Engineering and 
Applied Science, University of Wisconsin-Milwaukee, Milwaukee, WI.  
Emphasis in Health Information Systems  
 
Advisors:  
Timothy Patrick, Ph.D., Sandra Butschli, B.Sc., Gary Ross, Ph.D., Priya 
Nambisan, Ph.D., Zhihui Luo, Ph.D., Brian Wroblewski, MBA, M.S., Aaron 
Buseh, Ph.D., MPH, MSN 
 
Ph.D. Dissertation Research – From Data to Decision:  An Implementation 
Model for the Use of Evidence-Based Medicine, Data Analytics, and Education in 
Transfusion Medicine Practice. 
 
 
2008 – 2010 M.Sc. in Clinical Laboratory Science, College of Health Sciences University of 
Wisconsin-Milwaukee, Milwaukee, WI. 
Emphasis in Microbiology and Immunology  
 
Advisors:  
Marcia A. Firmani Ph.D., MSPH, Jerri-Anne Lyons Ph.D., Anthony A. Azenabor, 
Ph.D., C.S. (ASCP),  
 
M.S. Thesis Research – Comparison of Fitness among Drug-Resistant and Drug-
Susceptible Mycobacterium tuberculosis Clinical Isolates from Wisconsin: 
Survival and Cytokine Production in Human Macrophages.  
 
 
2002 – 2006 B.Sc. in Biological Sciences, College of Art and Sciences, Marquette University, 
Milwaukee, WI.  
Minor in Chemistry  
 
 
 
 266 
 
Professional Experience 
 
Application 
 
2013 - Present Systems Analyst, Dept. of Information Services, BloodCenter of Wisconsin, 
Milwaukee, WI.  
 
Define, design, implement, and support information technology and informatics 
solutions that meet the information and data management needs of clinical and 
research stakeholders. 
 
2011 – 2013 EMR Implementation Analyst, Norris Health Center, University of Wisconsin-
Milwaukee, Milwaukee, WI 
 
Defined, designed, and implemented processes to facilitate the transition of Norris 
Health Center from a paper-based clinic to an electronic medical record clinic. 
 
Research 
 
2012 – 2015 Research Associate, Dept. of Biomedical and Health Informatics, College of 
Engineering and Applied Sciences and College of Health Sciences, University of 
Wisconsin – Milwaukee, Milwaukee, WI; and Dept. of Information Services, 
BloodCenter of Wisconsin, Milwaukee, WI.   
 
Ph.D. Dissertation Research – From Data to Decision:  An Implementation 
Model for the Use of Evidence-Based Medicine, Data Analytics, and Education in 
Transfusion Medicine Practice. 
 
Other Research – Development and use of an analytics framework in Patient 
Blood Management as a feedback mechanism to evaluate changes and assess the 
sustainability of the changes in physicians‘ practice. 
 
2011 – 2012 Research Associate, Dept. of Human Molecular Genetic Center and Dept. of 
Biotechnology Bioengineering, Center for Computational Medicine, Medical 
College of Wisconsin, Milwaukee, WI. 
 
 Research – Multiscale Modeling and Data Integration in the Virtual Physiological 
Rat Project.  
 
2009 – 2010 Research Assistant, Dept. of Clinical Laboratory Science, College of Health 
Sciences, University of Wisconsin – Milwaukee, Milwaukee, WI. 
 
M.S. Thesis Research – Comparison of Fitness among Drug-Resistant and Drug-
Susceptible Mycobacterium tuberculosis Clinical Isolates from Wisconsin: 
Survival and Cytokine Production in Human Macrophages.  
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Other Research – A 10-year retrospective analysis of tuberculosis in the greater 
Milwaukee area.  
 
2007 – 2009 Research Technologist, Dept. of Human Molecular Genetics Center and Dept. of 
Biotechnology Bioengineering, Medical College of Wisconsin, Milwaukee, WI.   
 
Research – Multifunctional and High-Throughput Physiological Profiling of 
Engineered Heart Tissue for Drug Development.  
 
Teaching 
 
2010 Teaching Assistant, Dept. of Clinical Laboratory Science, College of Health 
Sciences, University of Wisconsin – Milwaukee, Milwaukee, WI 
 
Molecular and Genetic Diagnostics Laboratory Course (Winterim Session).  
 
2008   Instructor, Dept. of Clinical Laboratory Science, College of Health Sciences, 
University of Wisconsin – Milwaukee, Milwaukee, WI  
 
Course Titled: Techniques in Biomedical Sciences Laboratory (Summer Session).  
Coordinated and taught techniques in biomedical sciences laboratory course to 
high school students‘ in junior/senior level standing.  Duties included: preparing 
lectures and discussions, demonstrations, and practical‘s; lecturing and answering 
questions; correcting and grading homework and lab reports. 
 
2003 – 2004 Academic Tutor, Marquette University, Milwaukee, WI.  
Courses included: biology, general chemistry, general chemistry lab, and 
biochemistry. 
Duties included teaching lecture and reviewing homework materials, answering 
questions.  
 
 
Membership 
 
 
2013 - Present AABB (American Association of Blood Banks) 
Student Member  
 
2013 - Present MBAA (Midwest Business Administration Association) 
Student Member 
 
2012 - Present HIMMS (Healthcare Information and Management Systems Society) 
Student Member 
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2011 - Present AMIA (American Medical Informatics Association)  
Student Member 
 
201l - Present Healthcare Leadership Forum  
Student Member 
 
 
Conference Attendance 
 
2015 AMIA 2015 Annual Symposium, San Francisco, CA.  
(Student stipend award winner) 
 
2015 AABB 2015 Annual Meeting, Anaheim, CA.   
 
2015 HIMMS Wisconsin Dairyland Chapter 2015 Annual Spring Leadership 
Conference, Waukesha, Wisconsin.   
 
2015  Healthcare Leadership Forum: What Are Employers Considering to Address 
Healthcare Costs Over the Next Five Years? Milwaukee, WI. 
 
2014 AMIA 2014 Annual Symposium, Washington, DC.  
 (Student stipend award winner) 
 
2014 2014 MBAA International Conference, Chicago, IL. 
 
2014 2014 Leadership Healthcare Forum: Leveraging Evidence Across the Care 
Continuum! Chicago, IL. 
 
2013 AMIA 2013 Annual Symposium, Washington, DC.  
 (Student stipend award winner) 
 
2013 2013 Leadership Healthcare Forum: Healthcare Reform: What the healthcare 
industry should be doing now? Milwaukee, WI. 
 
2012 AMIA 2012 Annual Symposium, Washington, DC.  
 (Student stipend award winner) 
 
2011 AMIA 2011 Annual Symposium, Chicago, IL.  
 (Student stipend award winner) 
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Publications and Poster Presentations 
 
Publications: 
 
Daniel A. Beard, Maxwell L. Neal, Nazanin Tabesh-Saleki, Christopher T. Thompson, Mary 
Shimoyama and Brian E. Carlson. Multi-scale Modeling and Data Integration in the Virtual 
Physiological Rat Project. Annals of Biomedical Engineering  2012 (DOI: 10.1007/s10439-012-
0611-7). 
 
Conference Proceedings:  
 
Nazanin Tabesh, Mary E. Herwig, Julie F. DeLisle, Sandra J. Butschli. Analytics Framework: 
The Missing Piece to Patient Blood Management. (Oral Presentation). In: AABB 2015 Annual 
Meeting, Anaheim, CA. October 2015.  
 
Nazanin Tabesh, Julie F. DeLisle, Jean Shelby, Debora Oseland, Daniel B. Ross, Kathleen E. 
Puca. Impact of Individual Physician Blood Reports and ―1 vs. 2 unit‖ Metric to Lower RBC 
Transfusions. (Oral Presentation, Abstract # P31) In: Proceeding of the  NATA 16
th
 Annual 
Symposium, Prague, Czech Republic. April 2015. 
 
Nazanin Tabesh-Saleki, Mary E. Herwig, Julie F. DeLisle, Nanci L. Fredrich, Sandra J. 
Butschli, Timothy B. Patrick, and Kathleen E. Puca. Bridging the Gap in Knowledge and 
Practice: from Data to Decision. (Poster Presentation) In: Proceeding of the American Medical 
Informatics Association 2014 Annual Symposium, Washington, DC. November 2014.  
 
Nazanin Tabesh-Saleki, Brian E. Carlson, Christopher T. Thompson, Maxwell Neal, Daniel L. 
Cook, and Mary Shimoyama. Innovative Use of Ontologies: Association of Physiological 
Pathways to Corresponding Computational Models and Disparate Data Types. (Poster 
Presentation) In: Proceeding of the American Medical Informatics Association 2013 Annual 
Symposium, Washington, DC. November 2013. 
 
Nazanin Tabesh-Saleki, Mary Anne Wawrzyn, and Timothy Patrick. Managing Ambiguity and 
Continuity:  A Two-Year Summary of the UWM EMR Practicum. (Poster Presentation) In: 
Proceeding of the American Medical Informatics Association 2013 Annual Symposium, 
Washington, DC. November 2013. 
 
Nazanin Tabesh-Saleki, Brian E. Carlson, Christopher T. Thompson, Daniel A. Beard, and 
Mary Shimoyama. Making Computational Models Accessible through Ontologies and 
Visualization Tools. (Poster Presentation) In: Proceeding of the American Medical Informatics 
Association 2012 Annual Symposium, Washington, DC. November 2012. 
 
Nazanin Tabesh-Saleki, Rami W. Owais, Zubair Dhala, Maryanne Wawrzyn, and Timothy 
Patrick, 2012. EMR Practicum-II at University of Wisconsin-Milwaukee: Transition of Norris 
Health Center from Paper Forms to EMR. (Poster Presentation) In: Proceeding of the American 
Medical Informatics Association 2013 Annual Symposium, Washington, DC. November 2012. 
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Eric Dohman, Nazanin Tabesh-Saleki, Natalie Rahming, Colleen Lindell, and Timothy Patrick. 
EMR Practicum I at University of Wisconsin-Milwaukee. (Poster Presentation) In: Proceeding 
of the American Medical Informatics Association 2013 Annual Symposium, Chicago, IL. 
November 2011. 
 
Nazanin Tabesh-Saleki, Bryan Mounce, and Marcia Firmani. Comparison of fitness among 
drug-resistant and drug-susceptible Mycobacterium tuberculosis clinical isolates. (Poster 
Presentation) 110
th
 General Meeting of the American Society of Microbiology, San Diego, CA 
2010.  
 
Vy Lam, Nazanin Tabesh, Anesa Badic, Matthew Staniszewski, and Tetsuro Wakatsuki*. 2009. 
Multifunctional and High-Throughput Physiological Profiling of Engineered Heart Tissue for 
Drug Development. In: Proceeding of XXXVI International Congress of Physiological Sciences 
(IUPS2009) Function of Life: Elements and Integration, Kyoto, Japan. August – 2009. Poster # 
P1PM-4-3. 
 
 
Grants and Funding 
 
NIH/NHLBI      R15-HL092628-01A1        
Academic Research Enhancement Award for project titled, ―Mycobacterium tuberculosis: 
reactive oxygen and nitrogen intermediate resistance.‖  Firmani (PI) Tabesh-Saleki (Research 
Assistant) 
 
University of Wisconsin-Milwaukee College of Health Sciences Student Research Grant 
Award 
CHS Student Research Grant Award project titled, ―A comparison of survival among drug-
resistant and drug-susceptible Mycobacterium tuberculosis within activated macrophages.‖ 
Nazanin Tabesh-Saleki. 
 
 
Honors and Awards  
 
2014 College of Engineering and Applied Science Dean‘s Scholarship Award. 
University of Wisconsin-Milwaukee, Milwaukee, WI. 
 
2013 College of Engineering and Applied Science Dean‘s Scholarship Award. 
University of Wisconsin-Milwaukee, Milwaukee, WI.  
 
2011 The Chancellor's Golda Meir Library Scholar Award. College of Engineering and 
Applied Science, University of Wisconsin – Milwaukee, Milwaukee, WI. 
 
2010 Scientific Research Symposium 3
rd
 Place Award. College of Health Sciences, 
University of Wisconsin-Milwaukee, Milwaukee, WI.   
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Volunteer Experience 
 
2012 - Present Clinical and Translational Science Institute (CTSI) Southeastern Wisconsin 
Regional Collaboration. Milwaukee, WI. 
 
Regional biomedical collaboration involving clinical and translational science 
between Marquette University, the Medical College of Wisconsin, UW-
Milwaukee, the Milwaukee School of Engineering, the BloodCenter of 
Wisconsin, Children's Hospital, and Froedtert Hospital. 
The CTSI collaboration will advocate, facilitate, and foster the continuum of 
research from bench to bedside to community practice.  
 
2011 – 2013  Non-Academic Misconduct Committee, University of Wisconsin – Milwaukee. 
Milwaukee, WI. 
 
2010 Student representative on a new faculty Search and Screen Committee, College of 
Health Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI.  
